Stem Cells and their Potential for Clinical Application
NATO Science for Peace and Security Series This Series presents the results of scientific meetings supported under the NATO Programme: Science for Peace and Security (SPS). The NATO SPS Programme supports meetings in the following Key Priority areas: (1) Defence Against Terrorism; (2) Countering other Threats to Security and (3) NATO, Partner and Mediterranean Dialogue Country Priorities. The types of meeting supported are generally "Advanced Study Institutes" and "Advanced Research Workshops". The NATO SPS Series collects together the results of these meetings. The meetings are coorganized by scientists from NATO countries and scientists from NATO's "Partner" or "Mediterranean Dialogue" countries. The observations and recommendations made at the meetings, as well as the contents of the volumes in the Series, reflect those of participants and contributors only; they should not necessarily be regarded as reflecting NATO views or policy. Advanced Study Institutes (ASI) are high-level tutorial courses intended to convey the latest developments in a subject to an advanced-level audience Advanced Research Workshops (ARW) are expert meetings where an intense but informal exchange of views at the frontiers of a subject aims at identifying directions for future action Following a transformation of the programme in 2006 the Series has been re-named and re-organised. Recent volumes on topics not related to security, which result from meetings supported under the programme earlier, may be found in the NATO Science Series. The Series is published by IOS Press, Amsterdam, and Springer, Dordrecht, in conjunction with the NATO Public Diplomacy Division. Sub-Series A. B. C. D. E.
Chemistry and Biology Physics and Biophysics Environmental Security Information and Communication Security Human and Societal Dynamics
http://www.nato.int/science http://www.springer.com http://www.iospress.nl
Series A: Chemistry and Biology
Springer Springer Springer IOS Press IOS Press
Stem Cells and their Potential for Clinical Application
edited by
Nadja M. Bilko National University “Kyiv-Mohyla Academy”, Kyiv, Ukraine
Boris Fehse University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Wolfram Ostertag Medical School Hannover, Germany
Carol Stocking Heinrich-Pette-Institute for Experimental Virology and Immunology, Hamburg, Germany and
Axel R. Zander University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Published in cooperation with NATO Public Diplomacy Division
Proceedings of the NATO Advanced Research Workshop on Stem Cells and their Potential for Clinical Application Kiev and Simeiz, Ukraine August 23– 31, 2006
A C.I.P. Catalogue record for this book is available from the Library of Congress.
ISBN 978-1-4020-6468- 5 (PB) ISBN 978-1-4020-6467-8 (HB) ISBN 978-1-4020-6469-2 (e-book)
Published by Springer, P.O. Box 17, 3300 AA Dordrecht, The Netherlands. www.springer.com
Printed on acid-free paper
All Rights Reserved © 2008 Springer No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.
TABLE OF CONTENTS Preface ..................................................................................................... ix Acknowledgement ................................................................................... xi List of Participants................................................................................. xiii I HAEMATOPOIETIC STEM CELLS AND HAEMATOPOIESIS Clonal Dominance after Reconstitution of the Haematopoietic System with Bone Marrow Cells Retrovirally Transduced with Murine CD34 Variants Gottfried von Keudell, Kerstin Cornils, Anita Badbaran, Claudia Lange, Boris Fehse ..................................................................... 1 Function of the Membrane-Bound Isoform Ligands of the Receptor Tyrosine Kinase Subclass III in Inducing Self-Renewal of Early Hematopoietic Progenitor Cells Jutta Friel, Christoph Heberlein, Maren Geldmacher, Wolfram Ostertag ................................................................................... 17 Functional and Phenotypic Heterogeneity of the Human Hematopoietic Stem Cell (HSC) Compartment Olga I. Gan, Joby L. Mckenzie, Monica Doedens, John E. Dick ........... 45 Alterations of Frequency of Hematopoietic Precursors in Mice Subjected to Multiple Courses of Low-Dose G-CSF Injections Irina N. Nifontova, Daria A. Svinareva, Joseph L. Chertkov, Valerii G. Savchenko, Nina J. Drize ...................................................... 55
v
vi
TABLE OF CONTENTS
Regulation of Hematopoiesis by Growth Factors E. Richard Stanley .................................................................................. 63 II BIOLOGY OF NON-HAEMATOPOIETIC STEM CELLS Stem Cell Technologies in Gerontological Research Gennadij M. Butenko.............................................................................. 77 Osteopetrotic Models for Identifying Genes that Control Bone Resorption Wieslaw Wiktor-Jedrzejczak .................................................................. 83 Non-Hematopoietic Bone Marrow Cells for Regenerative Medicine Claudia Lange, Florian Tögel, Kai Jaquet, Harald Ittrich, Christoph Westenfelder, Axel Zander .................................................. 105 Epithelial Plasticity of Hepatocytes During Liver Tumor Progression Mario Mikula, Christian Lahsnig, Alexandra N. M. Fischer, Verena Proell, Heidemarie Huber, Eva Fuchs, Andreas Eger, Hartmut Beug, Wolfgang Mikulits ....................................................... 123 Blood Vessels as a Source of Progenitor Cells in Human Embryonic and Adult Life Mihaela Crisan, Bo Zheng, Elias T. Zambidis, Solomon Yap, Manuela Tavian, Bin Sun, Jean-Paul Giacobino, Louis Casteilla, Johnny Huard, Bruno Péault .............................................................. 137
TABLE OF CONTENTS
vii
III STEM CELLS AND MALIGNANCY Stem Cells and Leukaemia Volodymyr Bebeshko, Dimitry Bazyka ................................................. 149 Telomere and Stem Cell Biology in Chronic Myeloid Leukemia Stefan Balabanov, Ute Brassat, Mirja Bernhard, Viola Kob, Artur Gontarewicz, Tim H. Brümmendorf............................................ 163 Potential Immune Escape Mechanisms of Tumors: MHC Class I Molecules – Enemies or Friends Barbara Seliger .................................................................................... 171 The RUNX1 Transcription Factor: A Gatekeeper in Acute Leukemia Carol Stocking, Birte Niebuhr, Meike Fischer, Maike Täger, Jörg Cammenga.................................................................................... 183 IV CELL PROCESSING, EXPANSION AND GENETIC MODIFICATION Novel Methodological Approaches in Assessment and Enrichment of Stem Cell Population Nadja M. Bilko, Dennis I. Bilko ........................................................... 201 Animal Hybrids and Stem Cells: Their Use in Biotechnology and Clinical Practice Lev P. Djakonov ................................................................................... 211
viii
TABLE OF CONTENTS
Cryopreservation of Stem Cells Valentin I. Grischenko, Lubov A. Babiychik, Alexander Yu. Petrenko ........................................................................ 223 The M813 Retrovirus belongs to a Unique Interference Group and is Highly Fusogenic Vladimir Prassolov, Sibyll Hein, Dmitry Ivanov, Jürgen Löhler, Pavel Spirin, Carol Stocking ................................................................ 233 Reconstructing an Anti-Tumor Immune Repertoire for Targeted AML Therapy Matthias Theobald ............................................................................... 245 V CLINICAL HAEMATOPOIETIC STEM CELL TRANSPLANTATION Experience of Kyiv Center of Stem Cell Transplantation Viktor I. Khomenko............................................................................... 252 Anti Thymocyte Globuline Allows for Successful Transplantation from HLA Mismatched Unrelated Donors Axel R Zander, Tatjana Zabelina, Francis Ayuk, Christine Wolschke, Olga Waschke, Gitta Amtsfeld, Thomas Eiermann, Hartmut Kabisch, Boris Fehse, Jürgen Berger, Rudolf Erttmann, Nicolaus M Kröger.... 263
PREFACE This publication was initiated on the occasion of the NATO-Advanced Study Institute (ASI) meeting “Stem Cells and their potential for clinical application” which took place from August 23 – 25, 2006 in Kyiv and from August 26 – 31, 2006 in Simeiz, Ukraine. The meeting was devoted to “hot topics” in Stem cell research such as Regulation of Haematopoietic and Non-haematopoietic Stem Cells, Clinical Application of Stem Cells, Preclinical Models and Gene Therapy. The editors are pleased that the original idea of a book could eventually be realised. This was made possible because of the willingness of many meeting participants to saddle themselves with the additional work of compiling their data and thoughts in form of an article for this edition. We are thus foremost grateful to all contributors for their valuable input. In accordance with the conference’s main topics, the book is divided into five chapters - “Haematopoietic stem cells and haematopoiesis”, “Biology of nonhaematopoietic stem cells”, “Stem cells and malignancy”, “Cell processing; expansion and genetic modification” and “Clinical haematopoietic stem cell transplantation”. In the first part, various aspects of the regulation of haematopoiesis and haematopoietic stem cells (HSC) are described by such pioneers in the field as John Dick, Wolfram Ostertag and Richard Stanley. Olga Gan, John Dick and co-workers give an excellent overview on the heterogeneity of human HSC compartments. Jutta Friel et al. (from Wolfram Ostertag’s laboratory) deal with the role of membrane-bound isoform ligands in inducing HSC self-renewal and Richard Stanley reviews the role of growth factors in haematopoiesis. The effects of multiple injections of one particular growth factor, G-CSF, are described in a research article by Irina Nifontova, Nina Drize and colleagues, whereas Gottfried von Keudell, Boris Fehse and co-workers report their data on the impact of retroviral insertions on the clonal behaviour in murine HSC transplantation models. The second chapter of the book starts with a contribution of Gennadij Butenko on the use of stem cell technologies in gerontological research. Wieslav Wiktor-Jedrzejczak describes an interesting approach for the identification of genes involved in bone resorption control. An overview on the use of nonhaematopoietic bone marrow-derived stem cells for regenerative medicine is given by Claudia Lange, Axel Zander and co-workers. The topic of “plasticity” is covered by two groups: Mario Mikula, Wolfgang Mikulits and colleagues have investigated epithelial plasticity of hepatocytes during liver tumour ix
x
PREFACE
progression and Mihaela Crisan et al. from Bruno Peault’s lab introduce an innovative concept utilising blood vessels as a source of progenitor cells. The third chapter is mainly devoted to leukaemia research. Volodymyr Bebeshko and Dimitry Bazyka present an important insight into the changes of HSC due to irradiation after the Chernobyl accident. An outstanding review on the (stem cell) biology of chronic myeloid leukaemia with particular focus on the role of telomers is given by Stefan Balabanov, Tim Brümmendorf and colleagues. Barbara Seliger focuses on immune escape mechanisms of tumours, while Carol Stocking and her group present their data on the important role of RUNX1in the pathogenesis of acute leukaemia. Chapter 4 contains several contributions in the areas of cell processing, expansion and genetic modification. Nadja Bilko and Dennis Bilko propose novel methodological approaches to assess and enrich stem cells. L.P. Djakonov discusses the possibility of using animal hybrids in biotechnology. Valentin Grischenko, Lubov Babiychik and Alexander Petrenko have thorougly analysed the impact of various cryopreservation regimens on different HSC – a highly relevant question in transplantation medicine. During their search for novel gene analysis and therapy tools Vladimir Prassolov, Carol Stocking et al. have identified a novel retrovirus M813 which is described in their report. Concluding this chapter, Matthias Theobald presents his efforts on reprogramming T cells for targeted AML therapy. The final chapter comprises two reports on clinical haematopoietic stem cell transplantation (HSCT). Viktor Khomenko shares the experience of the Kiev center for stem cell transplantation. The final article in this book by Axel Zander and colleagues summarises data with the use of Antithymocyte globuline (ATG) in (HLA-mismatched) allogeneic transplantation, an approach which was promoted in the Hamburg Clinic for HSCT. The editors hope that this book reflects the spirited interaction and interesting scientific discussions which characterised the NATO-ASI meeting “Stem Cells and their potential for clinical application”. As the conference the book is not only intended to provide state-of-the-art articles in this field, but also to give insights into some of the highly interesting projects ongoing in Clinical Haematology and Stem cell research in Eastern Europe. Hamburg, Kyiv, St. Petersburg. Nadja N. Bilko, Boris Fehse, Wolfram Ostertag, Carol Stocking, Axel Zander.
ACKNOWLEDGEMENT The organisers as well as the participants of the “Stem Cells and their potential for clinical application”-meeting are most grateful to the NATO-Advanced Study Institute for the generous support which made this conference possible. Thanks are also due to the Ukrainian Ministry for Education and Science, the Ministry of Public Health and the National University “Kyiv-Mohyla Academy” for their support in executing the meeting. Special thanks go to the local teams for the excellent organisation at both locations. Finally, the editors are indebted to the team at Springer for the support during compilation of this book. Hamburg, Kyiv, St. Petersburg. Nadja N. Bilko, Boris Fehse, Wolfram Ostertag, Carol Stocking, Axel Zander.
xi
LIST OF PARTICIPANTS Prof. Dr. Dimitry Bazyka Dept. of Clinical Immunology Research Centre for Radiation Medicine Melnikova 53 Kyiv, 04050 Ukraine
[email protected]
Prof. Dr. John E. Dick Div. of Cell and Molecular Biology University Health Network Toronto Medical Discovery Tower, Rm 8-301 101 College Street Toronto, ON, M5G 1L7, Canada
[email protected]
Prof. Dr. Nadija Bilko National University “Kiev-MohylaAcademy” Centre of molecular and cell investigations 2, Skovoroda Kiev 04070 / Ukraine
[email protected]
Prof. L. P. Djakonov All-Russian scientific research institute of veterinary medicine Russian academy of agricultural sciences Moscow, Russia
[email protected]
PD Dr. Tim H. Brümmendorf Dept. of Hematology and Oncology with Sections BMT and Pneumology University Medical Center HamburgEppendorf Martinistraße 52 20246 Hamburg, Germany
[email protected]
PD Dr. Boris Fehse Universitätsklinikum HamburgEppendorf Onkologisches Zentrum Klinik für Stammzelltransplantation Martinistr. 52 20251 Hamburg, Germany
[email protected]
Prof. Dr. Gennadij M. Butenko Institute of Gerontology AMS of Ukraine Vyshgorodskaya st. 67 Kyiv04114, Ukraine
[email protected]
Prof. Dr. Valentin I. Grischenko Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine 23 Pereyaslavskaya Str. 61015, Kharkov, Ukraine
[email protected]
xiii
xiv
LIST OF PARTICIPANTS
Prof. Dr. Wiesław Wiktor-Jędrzejczak Department of Hematology, Oncology, and Internal Diseases Medical University of Warsaw Banacha 1a 02-097 Warsaw, Poland,
[email protected] Viktor I. Khomenko Kiev City BMT Center BMT Department Pobeda Str. 119-121 Kiev, Ukraine Dr. Claudia Lange Universitätsklinikum HamburgEppendorf Onkologisches Zentrum Klinik für Stammzelltransplantation Martinistr. 52 20251 Hamburg, Germany
[email protected] Prof. Dr. Wolfgang Mikulits Department of Medicine I, Institute of Cancer Research Medical University of Vienna Borschke-Gasse 8° 1090 Vienna, Austria
[email protected] Dr. Irina Nifontova National Hematology Research Center Russian Academy of Medical Sciences Novozykovsky 4a 125167 Moscow, Russia
[email protected]
Prof. Dr. Wolfram Ostertag Hannover Medical School Carl-Neuberg-Str. 1 D-30625 Hannover, Germany
[email protected] Prof. Bruno Péault, Ph.D. Children’s Hospital of Pittsburgh Rangos Research Center Pittsburgh, USA
[email protected] Prof. Dr. Vladimir Prassolov Engelhardt Institute of Molecular Biology Russian Academy of Science Vavilov Str. 32 Moscow 117984 / Russia
[email protected] Prof. Dr. Barbara Seliger Martin Luther University HalleWittenberg Institute of Medical Immunology Magdeburger Straße 2 06112 Halle, Germany
[email protected] Prof. Dr. E. Richard Stanley Albert Einstein College of Medicine 1300 Morris Park Avenue, Bronx New York 10461, USA
[email protected]
LIST OF PARTICIPANTS
Dr. Carol Stocking Heinrich-Pette-Institut Martinistr. 52 20251 Hamburg / Germany e-mail:
[email protected] Prof. Dr. Matthias Theobald Johannes Gutenberg-University Department of Hematology & Oncology Langenbeckstrasse 1 55101 Mainz, Germany
[email protected]
Prof. Dr. Dr. h.c. Axel R Zander Universitätsklinikum HamburgEppendorf Onkologisches Zentrum Klinik für Stammzelltransplantation Direktor Martinistr. 52 20251 Hamburg
[email protected]
xv
I HAEMATOPOIETIC STEM CELLS AND HAEMATOPOIESIS
CLONAL DOMINANCE AFTER RECONSTITUTION OF THE HAEMATOPOIETIC SYSTEM WITH BONE MARROW CELLS RETROVIRALLY TRANSDUCED WITH MURINE CD34 VARIANTS GOTTFRIED VON KEUDELL, KERSTIN CORNILS, ANITA BADBARAN, CLAUDIA LANGE, BORIS FEHSE* Clinic for Stem Cell Transplantation, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
Keywords: CD34; bone marrow transplantation; retroviral vector; insertional mutagenesis
Abstract. Using a long-term serial bone marrow transplantation assay we have recently observed that retroviral gene marking may result in both benign clonal dominance as well as malignant transformation of single cell clones. The growth advantage of dominant clones has been attributed to insertional mutagenesis, i.e. transcriptional dys-regulation of key growth-regulatory genes due to near-by vector insertions. In order to investigate the physiological role of the CD34 antigen we have of recent performed an analogous serial bone marrow transplantation assay with retroviral vectors encoding murine fulllength or truncated CD34 or, as control, eGFP followed by BM transplantation with long-term follow-up. Therefore, 6 animals were serially transplanted for each of the three transgene groups according to our previously published protocol. Similarly to our earlier results, in long-term repopulating bone marrow stem cells we found insertions into genes shown to be involved in cell cycle regulation and stem cell self-renewal such as a Core-binding factor α group member (Cbfα2t3h), runt-related Runx3, Ras p21 protein activator 4 (RasA4), Hematopoietically expressed homeobox (Hhex) or FBJ Osteosarcoma Oncogene B (Fosb). We detected common insertion sites (CIS) within the three groups, but also within the much larger insertional dominance database (IDDb). However, despite the small group size some differences in insertion site
______ * To whom correspondence should be addressed. PD Dr. Boris Fehse, Clinic for Stem Cell Transplantation, University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany, E-mail:
[email protected]
1 N. M. Bilko et al. (eds.), Stem Cells and their Potential for Clinical Application, 1–15. © 2008 Springer.
2
G. VON KEUDELL ET AL.
patterns were noted for the different transgenes requiring further investigation. It is therefore tempting to speculate that common features as well as differences in insertion pattern of retroviral vectors expressing different transgenes may allow investigating the mutual influence of retroviral vector insertion sites (RVIS), transgenes and host factors during insertional mutagenesis. 1. Introduction Stable integration into the host genome is an important feature of retroviral (RV) vectors making them an interesting tool for gene transfer experiments as well as gene therapy applications which require long-term transgene expression. Integration of RV vectors occurs, as earlier shown for their replicationcompetent ancestors in a semi-random fashion, preferentially in the vicinity of transcribed genes.1-4 Importantly, any integration into (or in the neighbourhood of) a gene locus represents a genetic lesion and may impact (e.g. disrupt, activate) the expression of the respective “targeted” gene thus fulfilling the criteria of “insertional mutagenesis”. In a more restricted sense, only those events which lead to changes in a cell’s phenotype are referred to as insertional mutagenesis. Those alterations may become particularly significant, if the retroviral (vector) insertion leads to the up-regulation of cellular protooncogenes (POG) or the disruption of tumour suppressor genes.5-9 In a worst-case-scenario, insertional mutagenesis may thus lead to oncogenic transformation of normal cells.5-9 Malignant transformation as a consequence of retroviral vector-mediated gene transfer has therefore always represented a safety concern in the development of human gene therapy, although earlier theoretical considerations estimated this risk to be very low.10 In line, initial gene therapy trials did not reveal major consequences of random vector insertions.10,11 However, in 2002 we first reported acute myeloid leukaemia (AML) development in a murine marking study with a γ-retroviral vector expressing the marker gene ∆LNGFR (truncated low-affinity nerve growth factor receptor).5 Molecular analysis of the leukaemic clone revealed that an insertion of the RV vector in front (5’) of the second exon of the Evi1 protooncogene had led to a strong (more than 1000 fold) transcriptional upregulation of this gene.5,12 Several lines of evidence indicated that the used transgene, a signalling molecule, played a supportive role during leukaemia establishment.5 Unfortunately, only a few months later one of the boys treated for X-linked severe combined immune-deficiency (SCID-X1) in the worldwide very first successful gene therapy trial developed a lymphoproliferative disease.6 Subsequently, another two out of the meanwhile 10 patients in that
CLONALITY AFTER RETROVIRAL CD34 TRANSDUCTION
3
trial have developed similar diseases resembling acute lymphoid leukaemia (ALL).6 In all those cases, insertion into one and the same proto-oncogene, LMO-2, has apparently played a crucial role.5 Moreover, in striking similarity with our murine study there is evidence12, although conflicting13, suggesting a leukaemia-promoting role of the therapeutic transgene, the common γ-chain of the IL-2 (IL-2R γc) and other interleukin receptors. In fact, in a parallel gene therapy study with the same transgene there has not been any sign of lymphoproliferative disease so far, although both studies differ only very slightly.14 Therefore, the subsequent events promoting leukaemia development after LMO-2 activation still remain to be elucidated. Recently we have shown that insertional mutagenesis may not only result in malignant transformation, but also lead to benign clonal dominance.15 We found that benign clonal dominance represents one possible consequence of the transcriptional dysregulation of various genes, in particular proto-oncogenes in the absence of additional tumour-promoting events. This data has been confirmed in various in vitro studies and in a non-human primate model.16-18 Eventually, very similar observations were again made in a clinical gene therapy study, this time on the treatment of Chronic granulomatous disease (CGD). In that study, RV vector-mediated insertional mutagenesis led to the dominance of haematopoietic clones almost all bearing vector insertion sites in one of the three gene loci MDS1-EVI1, PRDM16 or SETBP1.19 Since transcription of the respective targeted gene was strongly up-regulated in each (analysed) case and the distribution of insertion sites immediately after transduction was, as expected, semirandom without any preference for one of the three genes, it is safe to suggest that insertional mutagenesis was critical for the establishment of clonal dominance. Moreover the authors even concluded that the significant clinical benefit seen in their study was augmented by insertional activation of the three genes.19 Taken together the above data indicates that RV vector-mediated insertional mutagenesis is an efficient tool to identify genes involved in (benign as well as malignant) clonal dominance. Those genes obviously play a crucial role in the regulation of (stem cell) self renewal as well as proliferation and are therefore of great interest for a better understanding of stem cell biology. Moreover, potential stem cell growth factors identified by this approach may be of great interest for the expansion of stem cells, e.g. in the frame of cell therapy strategies. At the same time efficient (even large scale) identification of vector insertion sites in mixed samples has become possible based on sensitive new technologies20-21 and the completion of the murine and human genome projects22. Therefore we have aimed at the establishment of a database that contains retroviral vector insertion sites (RVIS) in long-term reconstituting
4
G. VON KEUDELL ET AL.
haematopoietic stem and progenitor cells (Insertional dominance database, IDDb)23. The present work summarises our efforts to identify insertion sites in clones which have reconstituted murine haematopoiesis after retroviral gene transfer. We transduced bone marrow (stem) cells with retroviral vectors expressing one of the following three different transgenes: murine full-length CD34, murine (naturally occurring) truncated CD34 and enhanced Green fluorescent protein (eGFP). Gene-modified BM cells were transplanted into lethally irradiated recipient mice which were followed up for more than 6 months before their BM was serially transplanted into secondary recipients.24 RVIS in long-term repopulating cells of both primary and secondary cohorts were identified by LM-PCR. 2. Material and Methods 2.1. MURINE STUDY
Design of the mouse experiments has been described elsewhere in detail.24,25 In short, a sex-mismatched (male into female) diallelic (CD45.2/Ly5.2 into CD45.1/Ly5.1) C56Bl/6J mouse model was used. After 48 and 72 hours prestimulation of bone marrow stem cells in cytokine-containing medium,24 two rounds of retroviral transduction were carried with spleen focus-forming virus (SFFV)-derived vectors24,26 in Retronectin®-coated (Takara Shuzo, Otsu, Japan) vector-preloaded plates.25,27
Figure 1. Experimental Set-up. Irradiated female mice were transplanted with retrovirally transduced BM cells from male donors (6 mice per vector). After 6 months of monitoring a secondary BMT took place. Spleen cells were used for the analysis of retroviral vector insertion sites (RVIS) by means of Ligation-Mediated PCR (LM-PCR)20,21. After another 6 months followup spleen cells of the secondary recipients were again analysed for RVIS via LM-PCR.
CLONALITY AFTER RETROVIRAL CD34 TRANSDUCTION
5
Three vector groups (murine full-length CD34, mfCD34; murine truncated CD34, mtCD34; enhanced Green fluorescent protein, eGFP) and one control group were included. Transduced cells (1 x 106) were transplanted into lethally (10 Gy) irradiated recipient mice (6 per group). After six months, mice were humanely killed and haematopoietic organs were isolated. Serial BMT was performed into 6 (per group) lethally (10 Gy) irradiated recipient mice. An overview of the experimental design is given in Fig. 1. 2.2. ISOLATION OF DNA
DNA was isolated from 5 x 106 spleen cells using QIAamp spin columns (QIAGEN Blood Mini Kit, Hilden, Germany) according to the manufacturer’s instructions. DNA concentrations were determined on a spectrophotometer. 2.3. LIGATION-MEDIATED PCR (LM-PCR) AND SPECIFIC PCR
LM-PCR was performed as described to retrieve sequences adjacent to the 5’ LTR of the SF91 vector.7,15,21 In short, genomic DNA obtained from spleen cells of transplanted animals was digested with 5 U of the Tsp509 I restriction enzyme (New England BioLabs, UK) per 200ng DNA for 15 minutes at 37° and subsequently for 2h at 65° C. For primer extension (PE) (95° for 5 min; 64° for 30 min; 72° for 15 min) 0.25 pmol/µl of biotinylated retroviral primer A1RV (5’ Biotin CTGGGGACCATCTGTTCTTGGCCTC 3’) was used. The PE product was purified using QIAquick PCR kit (QIAGEN) and enriched with streptavidin-labeled Dynabeads. An asymmetric polylinker cassette (linker oligo 1: 5‘-GACCCGGGAGATCTGAATTCAGTGGCACAGCAGTTAGG3‘; linker oligo 2: 5‘-CCTAACTGCTGTGCCACTGAATTCAGATCTCCCG3‘) was attached to those fragments by blunt-end ligation to allow directed PCR amplification. Both first and nested PCR (94°C for 2 min; 94°C for 15 sec, 60°C for 30 sec, 68°C for 2 min for 30 cycles; 68°C for 10 min) were performed using Extensor Hi-Fidelity PCR Master Mix (ABgene, Hamburg, Germany) with LTR-specific primers A2RV (5’ GCCCTTGATCTGAACTTCTC 3’), A3RV (5’ CCATGCCTTGCAAAATGGC 3’) and linker-specific primers OC1 (5’ GACCCGGGAGATCTGAATTC 3’) and OC2 (5’ AGTGGCACAGCAGTTAGG 3’), respectively.15,21 PCR products were isolated after gel electrophoresis using QIAquick Gel Extraction Kit (QIAGEN) and subjected to directly sequencing using the primer RAseq (5’ CTTGCAAAATGGC 3’) and Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City , CA, USA). A detailed description of all LMPCR procedures is given in Kustikova et al.21
6
G. VON KEUDELL ET AL.
Correct identification of insertion sites was proven by specific PCR reactions. Therefore, locus-specific primers were designed based on sequences obtained as described above. PCR was carried out using the LTR-specific primers A2RV and the respective locus-specific primer using Extensor HiFidelity PCR Master Mix and the same conditions as described above. 2.4. INSERTION SITE ANALYSIS
Sequences recovered as detailed above were screened using the NCBI mouse genome database (http://www.ncbi.nlm.nih.gov/BLAST). In case of unclear results (such as hits in BAC clones), the UCSC database was used (http://www.ensembl.org). Gene classification followed database records and PubMed literature. Further analysis of verified insertion sites was per formed by screening the Retrovirus tagged cancer gene databases (RTCGD) at http://rtcgd.ncifcrf.gov and the Stem cell database (SCDb) at http://stemcell.princeton.edu. 3. Results 3.1. RETRIEVAL OF RV INSERTION SITES
In this study we analysed haematopoietic cells from 13 primary (3 eGFP [11,13,14], 5 mfCD34 [22-26], 5 mtCD34 [27,28,30-32]) and 18 secondary (6 for each group) transplanted animals. Numbers of primary animals were lower because a few mice died or showed low haematopoietic chimaerism and were therefore excluded from secondary BMT. DNA probes isolated from spleen cells from all those animals underwent LM-PCR. Dominant PCR signals representing abundant clones21 were isolated from the agarose gel and directly sequenced (Fig. 2). In total, 238 distinct signals were analysed. To identify unequivocal RV insertion sites the presence of LTR (and LM-PCR polylinker) sequences was always required. If LTR sequences could not be found in the sequence, a PCR with insertion-specific primers (one located in the LTR and one in the putative integration site) was performed to verify the exact RV vector LTR/genome transition point. For 166 (70%) of the isolated PCR fragments, the obtained sequences could be unambiguously located on the mouse genome. For the other PCR signals, sequences were either too short to be assigned to a given locus or integration had occurred in a repetitive sequence. Some isolated PCR fragments did not allow sequencing, probably due to high GC content and/or low DNA quantity. Unexpectedly, some sequences were not locatable despite high
CLONALITY AFTER RETROVIRAL CD34 TRANSDUCTION
7
Figure 2. Typical LM-PCR gel showing RVIS after secondary transplantation. Common RVIS in different animals are indicated by stars (e.g.: *1: RasA4; *2: Cbfa2t3h; *4: Hic; compare Table 1).
quality. The latter observation obviously reflects remaining gaps of the mouse genome project. In many cases, identical insertions were found in more than one animal of the same group (Fig. 2). Since pooled bone marrow was used in each case for transplantation (Fig. 1), those identical insertions reflect the dominant growth features of the identified clone. Overall, a total of 43 different insertion sites from all three groups were identified in the first cohort, 34 in the second cohort. 3.2. RV VECTOR INSERTIONS IN RECONSTITUTING CELLS ARE PREDOMINANTLY LOCATED IN LOCI OF SIGNALLING GENES AND PROTO-ONCOGENES
As reported previously, insertion sites of RV vectors in reconstituting cells showed a non-random distribution. In fact, if considering a locus of ±100kb susceptible to transcriptional dysregulation28, already insertions in the first cohorts of mice showed a clear preference for proto-oncogene (>20%) and signalling gene (>50%) loci (Fig. 3). The obvious selective advantage of clones with insertions in those genes resulted in even higher proto-oncogene insertion prevalence (almost 40%) in secondary BMT recipients. Together, more than 80% of all insertions retrieved from secondary recipients had occurred in loci containing signalling genes or proto-oncogenes. The list of insertions contains a number of genes which had been initially detected by insertional mutagenesis or are listed as common insertion sites (CIS) in the Retrovirus Tagged Cancer
G. VON KEUDELL ET AL.
8
Gene Database (RTCGD)29, a database summarising insertion sites obtained with replication-competent retroviruses (RCR). In addition, several genes were also detected in various recent studies using RV vector gene transfer thus representing common retroviral vector insertion sites (CRVIS) in the Insertional Dominance Database (IDDb).23 All RVIS identified in our study and their putative functions are summarised in Table 1. 3.3. DIFFERENCES WITH DIFFERENT TRANSGENE
Rel. numbers of insertions into… [%]
Although the groups used in this study were relatively small, we subsequently analysed distribution of insertion sites for the three different transgene groups. Combining all integration data from primary and secondary recipients we thus compared 18 RVIS for the eGFP vector, 30 RVIS for mtCD34 and 35 RVIS for mfCD34. As could be seen from Fig. 3, no significant differences were seen with regard to the distribution of RVIS in different types of genes, although the tCD34 vector revealed less insertions into gene loci of groups 1 and 2 (protooncogenes and signalling genes) and more insertions into gene groups 3 and 4 (other and unknown genes). 60 Oncogenes Signalling Other Unknown
50 40 30 20 10 0 First Cohort (n=43)
Second Cohort (n=34)
Figure 3. Distribution of RVIS in different types of genes in repopulating hematopoietic cells of 1st and 2nd cohort animals. RVIS were classified as in Table 1. Note the strong overrepresentation of RVIS into oncogenes already in the first cohort, which even further increases after serial transplantation.
4. Discussion Retroviral insertional mutagenesis has been used for more than 2 decades to identify proto-oncogenes. More recently, a causal role of retroviral
CLONALITY AFTER RETROVIRAL CD34 TRANSDUCTION
9
vector-mediated insertional mutagenesis in the development of clonal dominance in long-term haematopoiesis has been established in preclinical models and clinical trials.5-9,15-18 In those studies it has been shown that RV vector insertions into gene loci of key regulatory factors may increase self-renewal and/or initiate malignant transformation. Following this path we here used a gene marking/bone marrow transplantation model established in our laboratory to assess possible side effects of retroviral gene transfer.5,15,25 In particular we were interested in a possible role of different transgenes on insertion site distribution in long-term reconstituting haematopoietic cell clones. Therefore we comparatively analysed the impact of three retroviral vectors expressing different transgenes (murine full-length CD34, mfCD34; murine truncated CD34, mtCD34; eGFP) from identical viral backbones (SF91)26. We have recently described physiological consequences of ectopic expression of the two murine CD34 variants in murine haematopoietic cells.24 In this report we have focussed on the analysis of a possible impact of RV vector insertion sites on long-term haematopoiesis. In cell clones reconstituting long-term hematopoiesis we found a strong overrepresentation of RVIS in proto-oncogenes and signalling genes. After primary BMT, more than 70% of all insertions were detected in gene loci of proto-oncogenes (>20%) or signalling genes (>50%). This frequency was even higher (>80%, almost 40% in POG) in secondary recipients. This data is in full agreement with our previous findings obtained with other RV vectors.15 Moreover, our results have contributed to a large Insertional Dominance Database (IDDb) comprising at the time being 280 insertion sites retrieved from long-term reconstituting hematopoietic cell clones.23 Establishment of the latter has been the result of common efforts of different laboratories in Europe and the US. The use of different transgenes and retroviral vectors by the contributing laboratories mainly excludes effects attributable to certain vector or gene types. In fact, a thorough analysis of the IDDb showed no effect of vector backbone or transgene type on insertion site distribution so far. We therefore concluded that in the majority of cases the retroviral vector insertion site in dominant (stem cell) clones has had directly affected the cells’ phenotype leading to clonal dominance.23 Based thereon, the IDDb may become an important tool for the identification of genes encoding key regulators of the stem cell phenotype (self renewal, unlimited proliferation), so-called stemness genes.30 It is not surprising that many of the genes found in our study as well as in the IDDb represent well-known proto-oncogenes involved in the regulation of cell proliferation. However, there is a number of other genes which so far were not known as regulators of stem cell growth (Table 1). Those genes may be very interesting novel candidate stemness genes, in particular if the insertions
G. VON KEUDELL ET AL.
10
represent common insertion sites (CIS) in the RTCGD29 or CRVIS within the IDDb23. From the given study, a number of genes may be added to the list of putative stemness genes, as for example: (i) known proto-oncogenes (Fosb, Hhex, Hic1, Rhof), (ii) transcription factors (Cbfα2t3h , Runx3, Utf1), (iii) genes involved in apoptosis signalling (FasL, Tnfsf10), (iv) receptor molecules (Edg1, Ly78) or (v) other signalling genes (Dirc, Rab3gap2, RasA4, Sesn2, Tbc1d5, Terf2) most of them being listed in the RTCGD or IDDb as CIS or CRVIS. TABLE 1. Summary of RVIS detected in repopulating haematopoietic cells of primary and secondary mice. Mouse numbers (second cohort mice are labelled with II) and transgenes (t = mtCD34, f = mfCD34, g = eGFP) are indicated. Gene classes are defined as follows: class 1 = common insertion sites, proto-oncogenes and self-renewal genes, class 2 = signalling genes and classes 3&4 = other and unknown genes.23 Mice Locus
From/to TSS Chromo- Hits in Name, (proposed ) function RTCGD Orientation some /IDDb
11GI Akt2
+3 kb (i2)
13g
Class
Akt1: 3/2
Thymoma viral oncogene homolog 1 2, kinase
+100 kb(i11) 17A3.3 R
0
Ankyrin Repeat and SAM Domain 2 Containing 1 (Odin)
27t Arid1b II.1t
+330 kb (i15) 17A1 F
0
AT Rich Interactive Domain 1B (Swi1 like)
3
II.2,3f Atf7ip
-46 kb R
6G1
2/1
Activating TF 7 interacting protein, transcription co-repressor activity
1
8E1
7/1
Core-binding factor, runt domain, a subunit 2, translocated 2, 3 1 homolog
+19 kb R
15E1
0
Cdc42 Effector Protein 1, Rho GTPase binding
2 3
Anks1
31t Cbfα2t3h -15kb F II.2t 13g
Cdc42ep1
7A3
24
Dhrs3
+56 kb F
4E1
0
Dehydrogenase reductase SDR Family3
26f
Dirc2
+13 kb (3.I) F
16B3
0
Disrupted in renal cell carcinoma 2 2, peptidase activity
23f 31t
Edg1 (Dph5)
-100 kb F -102 kb F
3G1
0/2
Endothelial differentiation, sphingolipid G-protein-coupled receptor 1, endothelial differentiation
1
32t
FasL
-8.5 kb R
1H2.1
0/2
Fas ligand (TNF superfamily, member 6), apoptosis induction
1
CLONALITY AFTER RETROVIRAL CD34 TRANSDUCTION Mice Locus
From/to TSS Chromo- Hits in Name, (proposed ) function RTCGD Orientation some /IDDb
11 Class
11 II.1
Fosb
-24 kb F
7A2
0/1 (Fos: 5/0)
FBJ osteosarcoma oncogene B, DNA binding
1
II.1f II.6f
Frmd6
+62 kb (6.I) R
12C2
0
FERM domain containing 6, function: protein-binding?
2
II.2f
Ggta1
-45kb R
2B
0
GlycoproteinGalactosyltransferase alpha 1.3
2
28t
Gtf2i
+28 kb (i9)
5G2
0/2
General Transcription Factor 2, transcriptional activation of growth- 2 regulated genes
25f
H3f3a
+36 kb F
1H4
0
H3 histone, family 3A, DNA binding
3
II.6t
Hhex
+2.5 kb (i2) R
19C1
26/1
Hematopoietically expressed homeobox gene, T-cell oncogene
1
24f
Hic1
-39 kb R +86 kb F
11B5
3/3
Hypermethylated in cancer 1, 1 transcription factor, Wnt antagonism
32t
Insm1
-8,5 kb R
2G2
0
13g
LOC
+45kb R
2E4
0
LOC 624373, hypothetical protein
4
24f
LOC
-4 kb R
7E3
0
LOC 626307, hypothetical protein
4
24
LOC
+28kb R
3F2.2
0
14g
LOC
>350 kb(I?) F 10D1
0
II.4f
LOC
-9 kb F
8B3.3
0
15D1
0/2
28t 30t
Lrrc6
-2.8 kb R +23 kb (i3) R
Insulinoma associated 1, nucleic acid binding
LOC195514, similar to glyceraldehyde3-phosphate dehydrogenase LOC629040, similar To Neuron Navigator 2 LOC621377, similar to Adenine phosphoribosyltransferase (APRT) Leucin repeat containing 6
3
4 4 4 1
Latent transforming growth factor 23f
Ltbp1
+33 kb (2.I) F 17E
0
binding protein 1,TGF-β receptor
2
pathway II.5g
Ly78
-26 kb R
13D1
0/2
31t
Nr1d1
-11kb R
11D
0
Odc1
-151 kb R
12A1.1
0
II.1, 5,6f
lymphocyte antigen 78 (CD180), receptor, signalling Nuclear Receptor Subunit1 group D member 1 Ornithin-Decarboxylase 1, checkpoint that guards against tumourogenesis
1 2 2
G. VON KEUDELL ET AL.
12
Mice Locus
Hits in From/to TSS ChromoRTCGD Name, (proposed ) function Orientation some /IDDb
22f
Ogfr11
+10 kb (1.I) F
28t
Pef1
+0.5 kb (1.I) 4D2.2 F
Phlpp
+103 kb (i1) 1E2.1 R
Ppfia4
+33 kb (i26) 1E4 F
II.2f
30t
1A4
Class
0
Opioid growth factor receptor like 2 1, receptor activity
0
Penta EF-hand domain containing 2 1, signalling, apoptosis
0
PH domain and leucin rich repeat protein phosphatase, dephos2 phorylates Akt, promotes apoptosis, and suppresses tumour growth
0
Protein Tyrosine Phosphatase, Receptor Type, f polypeptide (PTPRF) interacting protein (liprin), alpha 4
2
14g, Rab3ga -37 kb F II.4g p2
1H5
0
similar to Rab3 GTPase activating protein, regulation of GTPase 2 activity
27t
Rapgef2 -34 kb F
3E3
0
Rap guanine nucleotide exchange 2 factor 2, intracellular signalling
28t
Rapgef3 +40 kb R
15F1
0
Rap guanine nucleotide exchange 2 factor 3, intracellular signalling
27t, II.1t
RasA4
+8,5 kb (i3) F
5G2
0
RAS p21 protein activator 4, intracellular signalling
II.3g Rhof
-4.4 kb R
5F
4/1
Ras homolog gene family member, 1 small GTPase mediated signalling
27t II.1t
Rik
+15 kb (i2) R 4D1
0
RIKEN cDNA 4931406I20 gene, ubiquitin cycle
4
30t
Rnpc1
+19 kb R
2H3
0
RNA-binding Region (RNP1, RRM) containing 1 (Seb4)
3
II.2f
Runx3
-80 kb F
4D2.3
5/1
Runt related 3, myeloid development
1
24f II.2f
Sesn2
+6 kb (i1) F
4D2.3
0/3
Sestrin 2, induction in response to DNA damage
1
28t
Synj2
+30,5 kb (6.I) F
17A1
0
Synaptojanin 2, IP signalling
2
22f/ II.3f
Tbc1d5
+150 kb(i3) F
17C
1/1
TBC domain family member 5, GTPase activator activity
1
+47 kb F
8D3
0
Telomeric Repeat binding factor 2, telomere length regulation
2
25f Terf2 II.2,4f
2
CLONALITY AFTER RETROVIRAL CD34 TRANSDUCTION
Mice Locus
Hits in From/to TSS ChromoRTCGD Name, (proposed ) function Orientation some /IDDb
Class
19C1
0
Transmembran Protein 23, kinase2 transferase activity
+13 kb (3.I) II.6g Tnfsf10 F 32t +200 kb F
3A3
2/2
Tumour necrosis factor (ligand) superfamily, member 10, apoptosis induction
1
25f Terf2 II.2,4f
+47 kb F
8D3
0
Telomeric Repeat binding factor 2, telomere length regulation
2
II.1t
Treml2 +24 kb F
17C
0
Triggering receptor expressed on 2 myeloid cells like 2, signalling
11g
Trp53i1 -25 kb R 1
2E1
0
Trp53 inducible Protein 11, Tumour-Protein p53 inducible
2
II.3f II.4f
Utf1
+29 kb F
7F4
0
Undifferentiated embryonic cell transcription factor 1, ES-cell oncogene
1
22f
Usp36
+43 kb (3') F 11E2
3/1
Ubiquitin specific peptidase 36; guanyl-nucleotide release factor activity/ tumour suppressor gene?
1
14f
Tmem2 +19 kb R 3
13
We also assessed a possible influence of the expressed transgene on the RVIS distribution. In our relatively small study, some tendency towards decreased frequencies of RVIS in POG and signalling gene loci might be seen for the mtCD34 vector. However, within the much larger IDDb23 there was no difference in the distribution of insertion sites between vectors encoding fluorescent vs. cell surface marker genes. In conclusion the present report confirms the significant impact of γretroviral vector insertion sites on the establishment of clonal dominance in hematopoiesis after (serial) bone marrow transplantation. The identification of a number of putative stemness genes may contribute not only to a better understanding of stem cell biology but, in the long run also to the development of novel approaches for stem cell based therapeutic regimens, e.g. in regenerative medicine. Acknowledgements
This work was kindly supported by the Deutsche Forschungsgemeinschaft (FE568/5-2) and the Erich und Gertrud Roggenbuck-Stiftung.
14
G. VON KEUDELL ET AL.
References 1. Rohdewohld H., Weiher H., Reik W., Jaenisch R. and Breindl M. (1987) Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites. Journal of Virology 61, 336-343. 2. Mooslehner K., Karls U. and Harbers K. (1990) Retroviral integration sites in transgenic Mov mice frequently map in the vicinity of transcribed DNA regions. Journal of Virology 64, 3056-3058. 3. Wu X., Li Y., Crise B. and Burgess S.M. (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751. 4. Mitchell R.S., Beitzel B.F., Schroder A.R., Shinn P., Chen H., Berry C.C., Ecker J.R. and Bushman F.D. (2004) Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. Aug; 2(8):E234. 5. Li Z., Düllmann J., Schiedlmeier B., Schmidt M., von Kalle C., Meyer J., Forster M., Stocking C., Wahlers A., Frank O., Ostertag W., Kühlcke K., Eckert H.-G., Fehse B. and Baum C. (2002) Murine Leukemia Induced by Retroviral Gene Marking. Science 296, 497. 6. Hacein-Bey-Abina S., von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorensen R., Forster A., Fraser P., Cohen J.I., de Saint-Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonnet D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E. et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419. 7. Modlich U., Kustikova O.S., Schmidt M., Rudolph C., Meyer J., Li Z., Kamino K., von Neuhoff N., Schlegelberger B., Kuehlcke K., Bunting K.D., Schmidt S., Deichmann A., von Kalle C., Fehse B., Baum C. (2005) Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 105, 42354246. 8. Du Y., Spence S.E., Jenkins N.A. and Copeland N.G. (2005) Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood 106, 2498-2505. 9. Seggewiss R., Pittaluga S., Adler R.L., Guenaga F.J., Ferguson C., Pilz I.H., Ryu B., Sorrentino B.P., Young W.S. 3rd, Donahue R.E., von Kalle C., Nienhuis A.W. and Dunbar C.E. (2006) Acute myeloid leukemia associated with retroviral gene transfer to hematopoietic progenitor cells of a rhesus macaque. Blood 107, 3865-3867. 10. Cornetta K., Morgan R.A. and Anderson W.F. (1991) Safety issues related to retroviralmediated gene transfer in humans. Human Gene Therapy 2, 5-14. 11. Anderson W.F. (2000) Gene therapy. The best of times, the worst of times. Science 288, 627629. 12. Woods N.B., Bottero V., Schmidt M., von Kalle C., Verma I.M. (2006) Gene therapy: therapeutic gene causing lymphoma. Nature 440, 1123. 13. Thrasher A.J., Gaspar H.B., Baum C., Modlich U., Schambach A., Candotti F., Otsu M., Sorrentino B., Scobie L., Cameron E., Blyth K., Neil J., Abina S.H., Cavazzana-Calvo M. and Fischer A. (2006) Gene therapy: X-SCID transgene leukaemogenicity. Nature 443, 7109. 14. Gaspar H.B., Parsley K.L., Howe S., King D., Gilmour K.C., Sinclair J., Brouns G., Schmidt M., von Kalle C., Barington T., Jakobsen M.A., Christensen H.O., Al Ghonaium A., White H.N., Smith J.L., Levinsky R.J., Ali R.R., Kinnon C. and Thrasher A.J. (2004) Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181-2187.
CLONALITY AFTER RETROVIRAL CD34 TRANSDUCTION
15
15. Kustikova O., Fehse B., Modlich U., Yang M., Düllmann J., Kamino K., von Neuhoff N., Schlegelberger B., Li Z. and Baum C. (2005) Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308, 1171-1174. 16. Du Y., Jenkins N.A. and Copeland N.G. (2005) Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 106, 39323939. 17. Modlich U., Bohne J., Schmidt M., von Kalle C., Knöss S., Schambach A. and Baum C. (2006) Cell culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108, 2545-2553. 18. Calmels B., Ferguson C., Laukkanen M.O., Adler R., Faulhaber M., Kim H.-J., Sellers S., Hematti P., Schmidt M., von Kalle C., Akagi K., Donahue R.E. and Dunbar C.E. (2005) Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood 106, 2530-2533. 19. Ott M.G., Schmidt M., Schwarzwaelder K., Stein S., Siler U., Koehl U., Glimm H., Kühlcke K., Schilz A., Kunkel H., Naundorf S., Brinkmann A., Deichmann A., Fischer M., Ball C., Pilz I., Dunbar C., Du Y., Jenkins N.A., Copeland N.G., Luthi U., Hassan M., Thrasher A.J., Hoelzer D., von Kalle C., Seger R. and Grez M. (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nature Medicine 12, 401-409. 20. Schmidt M., Hoffmann G., Wissler M., Lemke N., Mussig A., Glimm H., Williams D.A., Ragg S., Hesemann C.U. and von Kalle C. (2001) Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Human Gene Therapy 12, 743-749. 21. Kustikova O.S., Baum C. and Fehse B. (2007) Retroviral integration site analysis in hematopoietic stem cells. Methods in Molecular Medicine, in press 22. Mouse Genome Sequencing Consortium; Waterston RH, et al. (2002) Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520-562. 23. Kustikova O., Geiger H., Li Z., Brugman M.H., Chambers S.M., Shaw C.A., Pike-Overzet K., de Ridder D., Staal F.J..T, von Keudell G., Cornils K., Nattamai K.J., Modlich U., Wagemaker G., Goodell M.A.., Fehse B. and Baum C. (2006) Retroviral vector insertion sites associated with dominant hematopoietic clones mark “stemness” pathways. Blood, in press 24. Lange C., Li Z., Fang L., Baum C. and Fehse B. (2007) CD34 modulates the trafficking behavior of hematopoietic cells in vivo. Stem cells and Development, in press 25. Li Z., Fehse B., Schiedlmeier B., Düllmann J., Frank O., Zander A.R., Ostertag W. and Baum C. (2002) Persisting multilineage transgene expression in the clonal progeny of a hematopoietic stem cell. Leukemia 16, 1655-1663. 26. Hildinger M., Abel K.L., Ostertag W., and Baum C. (1999) Design of 5' untranslated sequences in retroviral vectors developed for medical use. Journal of Virology 73, 4083-4089. 27. Kühlcke K., Fehse B., Schilz A., Loges S., Lindemann C., Ayuk F., Lehmann F., Stute N., Fauser A.A., Zander A.R. and Eckert H.-G. (2002) Highly efficient retroviral gene transfer based on centrifugation-mediated vector pre-loading of tissue culture vessels. Molecular Therapy 5, 473-478. 28. Bartholomew C. and Ihle J.N. (1991) Retroviral insertions 90 kilobases proximal to the Evi-1 myeloid transforming gene activate transcription from the normal promoter. Molecular and Cellular Biology 11, 1820-1828. 29. Akagi K., Suzuki T., Stephens R.M., Jenkins N.A. and Copeland N.G. (2004) RTCGD: retroviral tagged cancer gene database. Nucleic Acids Research 32, D523-527. 30. Ivanova N.B., Dimos J..T, Schaniel C., Hackney J.A., Moore K.A. and Lemischka I.R. (2002) A stem cell molecular signature. Science 298, 601-604.
FUNCTION OF THE MEMBRANE-BOUND ISOFORM LIGANDS OF THE RECEPTOR TYROSINE KINASE SUBCLASS III IN INDUCING SELF-RENEWAL OF EARLY HEMATOPOIETIC PROGENITOR CELLS
JUTTA FRIEL1 , CHRISTOPH HEBERLEIN 2, MAREN * GELDMACHER 3 AND WOLFRAM OSTERTAG 3 1Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie an der Universität Hamburg, Hamburg, Germany 2CellTec GmbH, Hamburg, Germany 3Hannover Medical School, Hannover, Germany
Keywords: Stroma-hematopietic cell interaction; Stroma-encoded membrane-bound and soluble ligands; Stroma-independent mutants
Abstract. Maintenance and differentiation of hematopoietic stem and progenitor cells are controlled by complex interactions with the stroma microenvironment. Stroma-cell interactions can be supported by locally expressed membranespanning cell-surface growth factors. Ligands of the tyrosine receptor kinases subclass III like SCF or CSF-1 are expressed by stroma as soluble glycoproteins, proteoglycans or membrane-bound glycoproteins. SCF synergizes with other growth factors in enhancing growth of early progenitor cells whereas CSF-1 is known to regulate the survival, proliferation and differentiation of mononuclear phagocytes. Whereas the biological role of the soluble isoforms of SCF and CSF1 are well characterized, the function of the membrane-bound ligands remain unclear. To analyze the biological significance of membrane-bound SCF and -CSF-1 in vitro we used an epithelial cell line to ectopically express the different isoforms. In cocultures of SCF- or CSF-1 transduced epithelial cells with primary early hematopoietic progenitor cells we examined whether interaction between
______ * To whom correspondence should be addressed. Wolfram Ostertag, Hannover Medical School, CarlNeuberg-Str. 1, D-30625 Hannover, Germany
17 N. M. Bilko et al. (eds.), Stem Cells and their Potential for Clinical Application, 17–44. © 2008 Springer.
18
J. FRIEL ET AL.
the membrane-bound isoforms of SCF and CSF-1 and their receptors mediate cell proliferation, self-renewal or differentiation. We show here that the membranebound isoforms of SCF and CSF-1 both have functions in inducing self-renewal of early hematopoietic cells. In contrast, soluble SCF and CSF-1 exert specific functions: SCF by itself causes clonal extinction whereas CSF-1 is involved in the macrophage differentiation. In context with the stroma-hematopoietic cell interaction we also show that CSF-1 can sustain the self-renewal of a murine stem cell line Myl-D7. 1. Introduction Hematopoietic stem cell development is governed by a complex interplay between signals from stem cells and those emanating from the bone marrow stroma. In stroma, stem cells must periodically activate to produce progenitoror transient amplifying cells that are committed to produce mature hematopoietic lineages. Stromal cells form a hematopoietic microenvironment by expressing growth factors, adhesion molecules and matrix proteins, all of which regulate the homing, growth, survival and differentiation of stem cells. Growth factors produced by stroma include cytokines such as IL-1 and IL6, ligands of receptor tyrosine kinase like SCF, CSF-1 and Flt-3 ligand; Notch ligands, bone morphogenetic protein 4 and sonic hedgehog. Hematopoietic stem cells interact with their microenvironment differently, involving cellcell interactions, association to extracellular matrix proteins and binding to membrane-bound- and soluble growth factors. Growth factors, which are produced both as soluble and membrane-bound isotype proteins include members of the receptor tyrosine kinase subclass III, such as stem cell factor (SCF) (Anderson et al., 1990; Huang et al., 1990), colony stimulating factor-1 (CSF-1, M-CSF) (Ladner et al., 1988; Ceretti et al., 1988) and Flt 3 ligand (Hannum et al., 1994; McClanahan et al., 1996). SCF is encoded by the mouse Steel (Sl) loci (Zsebo et al., 1990). The SlDickie allele of mutant mice (Sld) encodes a smaller protein due to deletions of the transmembrane and intracellular domains. Sld cells exclusively express a secreted form of SCF (Flanagan et al., 1991). Another mutation of the Steel locus, Sl/Sl, results in complete loss of SCF production (Zsebo et al., 1990). Mutations of both the Steel and Sld loci result in similar phenotypic disorders of hematopoiesis characterized by reduction in stem cell numbers, anemia, mast cell- and repair deficiencies (Nocka et al., 1989; McCulloch et al., 1965). Phenotypes of Sld mice show that the membrane inserted SCF must have an
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
19
essential function that differs from that of soluble SCF (Dexter and Moore, 1977; Fujita et al., 1988). The kit receptor is expressed on hematopoietic stem cells implying a function of SCF in the regulation of self renewal and/or adhesion of cells to stroma (Ogawa et al., 1991; Ikuta and Weissman,1992; Kodoma et al., 1994). Soluble SCF synergizes with early and late acting cytokines including the Flt3 ligand, Thrombopoietin (TPO), IL-3, GM-CSF and erythropoietin (Epo) to enhance the growth of primitive cells (McNiece et al., 1991; Lemoli et al., 1993; Ramsfjell et al., 1997). Other studies indicate that hematopoiesis, controlled by stroma cell interaction, also functions with stroma deficient in the synthesis of SCF (Ikuta and Weissman, 1992; Sutherland et al., 1993; Itoh et al., 1989). CSF-1 and SCF are evolutionary related and show genetic and structural homologies: the gene structure, the sequence of the extracellular domains, the proteolytic maturation and the tertiary folds of the proteins are very similar. Additionally, the receptors for CSF-1 and SCF appear to have diverged from an ancestor molecule of the PDGF receptor (Yarden et al., 1986,1987). The CSF-1 receptor (c-fms) is expressed on primitive multipotent hematopoietic cells (Bartelmez and Stanley, 1985), phagocyte progenitor cells (Tushinski et al., 1982), monoblasts, promonocytes, monocytes (Byrne et al., 1981) and tissue macrophages (Stanley et al., 1983). Several studies suggest that the CSF-1 receptor could be also involved in the regulation of more early cells: primitive hematopoietic cells express the CSF-1 receptor and CSF-1 synergize with IL-1, IL-3, IL-6, G-CSF and GM-CSF to induce the formation of multipotential colonies (Broxmeyer et al., 1988; Bartelmez et al., 1989; Friel et al., 2005). Furthermore, the progenitor activity of day 12 spleen colony-forming cells can be blocked by neutralizing antibodies against the CSF-1 receptor (Gilmore and Shadduck, 1995). Whatever the nature of the receptor tyrosine kinase subclass III ligand isoforms involved, it is presently unclear whether they induce different signaling effects in early hematopoietic cells upon binding to its receptor. To determine the function of the SCF/CSF-1 isoforms we used an embryonic epithelial cell line to express ectopically each membrane-bound and soluble ligand. In cocultures with human and murine early progenitor cells we determined their proliferative and developmental responses. The murine hematopoietic stem cell line Myl-D7 spontaneously differentiate along the lymphoid, myeloid and erythroid lineages. Myl-7 cells shows a strict stromal dependence for growth of self-renewing stem cells and express high levels of CSF-1 receptor (Itoh et al., 1996). We used this cell line to analyze the function of CSF-1 in maintaining multipotent cells. In an other attempt to characterize unknown factors that could sustain stem cells we
J. FRIEL ET AL.
20
generated stroma-independent Myl-D7 mutants. The autostimulatory activity of these mutants was examined. 2. Results To verify the different functions of the isoforms of SCF and CSF-1 in promoting stroma-dependent growth a non-stromal cell system was used to express the soluble and membrane-bound cDNA isoforms. TABLE 1. Cell lines used and expression of SCF/CSF-1 ligands Feeder cell cDNA used for line transduction
-
MS5 MMCE MMCE MMCE
Sld m2 SCF
UNC Sl/Sl
-
SCF expression
CSF-1 expression
membranebound
soluble
membranebound
soluble
+
+
+
+
+
+
-
-
+
-
-
-
-
UNC Sl/Sl Sld
-
+
+
+
UNC Sl/Sl m2 SCF
+
-
-
+ +
+ + +
+ + +
MS Sl-2 MS Sl-2
m2 SCF
+
+
Described as
MS5 MMCE MMCE MMCE Sl/Sl stroma Sl/Sl stroma Sl/Sl stroma Sld stroma Sld stroma
To exclude synergistic effects between stroma encoded factors and the ectopically expressed SCF/CSF-1 isoforms we used as a coculture system the murine embryonic epithelial cell line MMCE (Rapp et al., 1979). MMCE does not produce any isoform of SCF or CSF-1 and does not express genes for those growth factors like IL-1α, IL-6, IL-11, Flt 3 ligand, G-CSF, Epo or TPO that are known to synergize with SCF or CSF-1 in augmenting growth of hematopoietic cells (McNiece et al., 1991; Lemoli et al., 1993: Ramsfjell et al., 1997). MMCE cells also do not express genes for MIP-1α or TGF-β that could inhibit the maintentance of hematopoietic progenitors on stroma (Mayami et al.,
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
21
1995). The only growth factor mRNA detected of the large number tested was PDGF-A (data not shown, Friel et al., 2002). Untransduced MMCE cells failed to support short or long term proliferation of hematopoietic progenitors. The untransduced murine stromal cell line MS5 (Itoh et al., 1989) expressing wildtype SCF and CSF-1 was used as a control. For SCF/CSF-1 expression of different cell lines used see Table 1. 2.1. MEMBRANE-BOUND SCF ON ITS OWN IS BIOLOGICALLY ACTIVE AND INDUCES LONG TERM GROWTH OF TF1 CELLS IN COCULTURE ON EPITHELIAL CELLS
To determine the function of the SCF isoforms in inducing long-term growth of hematopoietic cells we used the human CD34+ progenitor cell line TF1 (Kitamura et al., 1989). Ectopic secretion of soluble Sld SCF by MMCE could not stimulate long term proliferation of TF1 in coculture. Conditioned medium of MMCE cells synthesizing soluble Sld SCF stimulated only a short term response of TF1 cells (Fig. 1).
Figure 1. Long term growth of TF1 induced by epithelial MMCE cells expressing membranebound SCF. Long term growth of TF1 cells was determined by serial clone transfer experiments. 48 clones from several independent experiments with cell numbers >5·10² cells were transferred on new feeders during the first and second transfer. Each point represents the mean (±SD) of five independent experiments. The results are calculated as % of TF1/Sl+ MS5 control cocultures. C.E.s at the first clonal transfer of TF1 cells were set to 100%. t MMCE transduced with cDNA for mb SCF, s MMCE transduced with cDNA for soluble Sld SCF, C parental MMCE, I Sl+MS5.
22
J. FRIEL ET AL.
Ectopic expression of membrane-bound (mb) SCF, however, confered stroma like growth promoting activity to epithelial MMCE cells (Fig. 1). The initial cloning efficiency of TF1 on transduced MMCE expressing mb SCF was about one third compared to cocultures on murine Sl+MS5 stroma. On repeated serial transfer the proliferation of TF1 clones on MMCE ectopically expressing mb SCF was as high as that on Sl+MS5 stroma (data not shown). This reflects the selection of adapted TF1 clones in coculture on transduced competent MMCE cells. Thus, mb SCF on its own can mediate long term growth promoting signals to hematopoietic precursor cells. MMCE cells express PDGF-A which is not a specific hematopoietic cytokine but shows potential mitogenic effects on hematopoietic cells in presence of other primary factors (Michalevicz et al., 1986; Delwiche et al., 1985). Its effects are presumably indirectly mediated, for example by upregulation of IL-1 (Yan et al., 1993) in stromal macrophages, CSF-1 or IL-6 from mesenchymal cells (Hall et al., 1989). From our RT-PCR analysis no upregulation of any one of the tested factors could be observed in MMCE cells expressing the PDGF-A gene, regardless whether transduced with SCF encoding retroviral vectors or not (Friel et al., 2002). However, we cannot exclude some synergistic action between membrane-bound SCF and PDGF in cocultures on modified MMCE. Certainly, parental MMCE could not support proliferation of TF1 (cf. Fig. 1). 2.2. EXOGENOUSLY ADDED SOLUBLE SCF CAN NOT IMPAIR OR MIMIC THE EFFECT OF MEMBRANE-BOUND SCF
Two reasons could explain the failure of soluble Sld SCF to induce long term growth of hematopoietic cells on stroma. One might be the production of inadequate levels of protein by Sld stroma and by Sl/Sl and MMCE cells ectopically expressing Sld SCF. The other could be an antagonistic function of the mutated Sld SCF compared to the membrane-bound isoform. To test for these possibilities we added recombinant soluble SCF, that is produced as a cleavage product of mb SCF, to TF1 feeder cocultures. Addition of exogenous recombinant SCF even in excess of 100ng/ml to TF1 on Sl+MS5 cells had little or no effect on cloning efficiencies (Fig. 2a). In contrast, supplementation of Sld stroma cocultures with recombinant SCF further reduced the growth promoting potential about 2.5-fold (Fig. 2b). Functional neutralization of the added recombinant SCF by anti SCF antibodies surprisingly increased the cloning efficiency 2-fold beyond that seen without adding recombinant SCF. In contrast, addition of recombinant SCF to Sld stroma cocultures ectopically expressing mb SCF did not influence the proliferation rate of TF1 (Fig. 2b). Addition of recombinant SCF to cocultures of TF1 on Sl/Sl
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
23
stroma not expressing any isoform of SCF showed an even more dramatic effect. The growth promoting potential is reduced 4-fold. Neutralization of the exogenously supplied SCF by anti SCF antibodies restored the original growth inducing activity of the parental Sl/Sl stroma (Fig. 2c). Supplementation of recombinant SCF to cocultures of TF1 on Sl/Sl stroma already ectopically expressing soluble Sld SCF showed only a slight effect. This most likely is caused by the already synthesized SCF. Again, addition of recombinant SCF to Sl/Sl cocultures ectopically expressing mb SCF did not impair the proliferation rate of TF1 (Fig. 2c).
Figure 2. Soluble SCF reduces the cloning efficiency of TF1 cells. TF1 cells were cultured on feeders in presence of various amounts of reombinant mouse SCF. Neutralizing anti-SCF antibody was added as indicated from day 10 to day 16. Viable clones were counted following the second transfer. Each column represents the mean±SD of four independent experiments calculated as % of CEs of control cocultures. Titration of recombinant SCF on: a) Sl+MS5 cocultures expressing wildtype SCF. C.E. of control coculture on Sl+MS5 without addition of recombinant SCF was set to 100%. b) Stroma cocultures producing Sld or Sld plus mb SCF. C.E.s of control cocultures without addition of recombinant SCF on Sld stroma (white columns), or Sld stroma transduced to express mb SCF (dark grey) were set to 100%. c) Sl/Sl cocultures expressing no SCF, soluble Sld SCF or mb SCF. C.E.s of control cocultures without addition of recombinant SCF on Sl/Sl UNC (white columns), or Sl/Sl UNC transduced to express Sld SCF (grey columns) or mb SCF (dark grey) were set to 100%. d) MMCE cocultures producing mb SCF. C.E. of control coculture on MMCE transduced to express mb SCF without addition of recombinant SCF was set to 100%. Dark grey columns: cell lines presenting mb SCF.
24
J. FRIEL ET AL.
Not unexpectedly, addition of large quantities of recombinant SCF to TF1 cocultures on parental MMCE synthesizing no SCF or transduced Sld SCF did not increase the cloning efficiencies of TF1 cells. Addition of recombinant SCF, even in excess of 100 ng/ml to cocultures of TF1 on MMCE cells transduced to present mb SCF could not impair the growth promoting potential of these feeder cells (Fig. 2d). Taken together, supplementation of stromal or epithelial cocultures with recombinant SCF in absence of membrane-bound SCF suppresses the cloning efficiency of TF1 cells. Neutralization of the effect of soluble SCF by anti-bodies abolishes the negative effect and restored the original growth promoting activity of the stroma. Thus, soluble SCF, either as recombinant protein or as mutated Sld SCF, on its own induces the growth abrogating effect in TF1 feeder cocultures. Even high concentrations (100 ng/ml) of recombinant SCF can not mimic the effect of membrane SCF in providing growth support for TF1. 2.3. NEUTRALIZATION OF THE SCF/C-KIT INTERACTION CAN INCREASE OR INHIBIT PROLIFERATION OF TF1 ON FEEDER CELLS
To verify that the SCF c-kit interaction plays the essential role in stimulating TF1 in our coculture system, neutralization experiments were set up using the anti c-kit monoclonal antibody YB5.B8 (Lerner et al., 1991). Data presented in Fig. 3a show that addition of α-c-kit drastically inhibited growth of TF1 on wildtype Sl+MS5 stroma in a concentration dependent manner. Application of α-c-kit to cocultures of TF1 on parental Sld stroma confirmed the importance of the SCF/c-kit interaction (Fig. 3b). Preventing binding of SCF to c-kit by adding α-c-kit antibodies increased the cloning efficiency of TF1 on Sld stroma up to 2-fold (Fig. 3b). Thus, addition of SCF antibodies (cf. Fig. 2b) as well as α-c-kit antibodies to cocultures results in a beneficial effect on the growth promoting potential of Sld cells. Hence, Sld stroma can promote long term growth of TF1 cells only by mechanisms independent of the SCF-c-kit complex when the effect of soluble SCF is neutralized. Addition of α-c-kit to cocultures of TF1 on transduced Sld stroma producing mbSCF reduced the cloning efficiency about 2-fold. Even high amounts of antibodies (5.6 µg/ml) could not completely inhibit the proliferation of TF1 cells (Fig. 3b). One explanation could be that addition of neutralizing α-c-kit prevented the interaction of Sld SCF with c-kit, thereby promoting an SCF/c-kit independent growth stimulatory pathway. α-c-kit antibodies if added to cocultures of TF1 on transduced MMCE expressing mbSCF causes complete inhibition of growth as expected (Fig. 3d). These inhibition experiments thus confirmed the essential role of the SCF/c-kit interaction in supporting long term stroma dependent growth of TF1.
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
25
Figure 3. Neutralizing anti c-kit moAb inhibits proliferation of TF1 on feeder cells expressing membrane-bound SCF. TF1 cells were cocultured in presence of serial dilutions of YB5.B8 moAb on stromal or epithelial cell lines expressing either endogenous and/or transduced SCF genes. Viable clones were counted after the second serial transfer. Data are mean±SD values of three to five independent experiments calculated as % of control Sl+MS5 cocultures which was not supplemented with α-c-kit Ab. Neutralizing anti-c-kit antibody was added as indicated from day 10 to day 16. Potential nonspecific inhibiting effects of the antibody preparation were excluded by culturing TF1 cells in suspension with 100 U/mL rGM-CSF in presence of various amounts of YB5.B8 moAb and counting proliferating cells after 72 hours. Addition of α-c-kit Ab to: a) P Sl+MS5 cocultures expressing wild type SCF; ! TF1 cells grown in suspension with 100 U/ml r GM-CSF. b) P Sld cocultures producing Sld or I Sld and ectopically mb SCF. c) 1 Sl/Sl cocultures producing no SCF, ectopically p soluble Sld SCF or i mb SCF. d) s epithelial MMCE cocultures expressing transduced mb SCF.
2.4. MEMBRANE-BOUND SCF IS SUPERIOR TO SOLUBLE SLD SCF IN SUPPORTING GROWTH OF PRIMARY HEMOPOIETIC CELL GROWTH
A number of reports have shown that CD34+ cells obtained from umbilical cord blood (CB) are quiescent (Mayani and Lansdorp, 1998). We therefore extended our system for SCF induced proliferation to the CB CD34+
26
J. FRIEL ET AL.
population to evaluate which isoform of SCF could more efficient induce proliferation. CD34+ cells were cocultured on MMCE cells expressing mb or soluble Sld SCF and as controls on untransduced MMCE and on Sl+MS5 stroma.
Figure 4. Membrane-bound SCF stimulates clonogenic CD34+ CB progenitors stronger than soluble SCF. Cord blood CD34+ cells were seeded on feeders. Each point represents the mean ±SD of six independent experiments. A) net increase of total cord blood cells; B) Colony forming units (CFU) are calculated as CFU per 100 cells plated in methylcellulose. Cloning efficiencies were recorded after coculturing for 7, 14, 21, and 28 days. Data are mean(±SD) of several independent experiments as indicated. p CD34+ cells cocultured on Sl+ MS5 stroma; P CD34+ cells cocultured on untransduced MMCE cells; i CD34+ cells cocultured on MMCE cells expressing membrane-bound SCF; I CD34+ cells cocultured on MMCE cells expressing soluble Sld SCF.
Within one week the total number of hematopoietic cells increased on stimulation with Sl+MS5 stroma 5-fold (Fig. 4a). Membrane-bound SCF was slightly more effective (3.5-fold) than soluble Sld SCF (2.8-fold) in enhancing the total number of hematopoietic cells at this time point. A proliferating cell population was also initially detected in coculture with untransduced epithelial cells, although the proliferation capacity declined within two weeks (Fig. 4a). After four weeks in coculture the proliferation potential of Sld SCF induced CB cells was 6-fold decreased, that of mb SCF stimulated cells 1.5-fold. Thus, proliferating cells were maintained significantly longer in cultures supported by membrane-bound SCF than by Sld SCF. To investigate the cloning efficiency of the progenitor cells in these cocultures we analyzed their colony formation ability in methylcellulose supplemented with recombinant growth factors. The results indicate that within the first two weeks mb SCF as well as Sld SCF or Sl+MS5 stroma induced
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
27
comparable cloning efficiencies of primary hematopoietic cells (Fig. 4b). After four weeks the cloning efficiency of soluble Sld SCF stimulated hematopoietic progenitors declined 3-fold as opposed to cells driven by mb SCF. MMCE feeder by itself was unable to stimulate progenitors longer than one week (Fig. 4b). These results clearly show that membrane-bound SCF was superior to soluble Sld SCF in stimulating clonogenic progenitors throughout the culture period of four weeks. Furthermore, membrane-bound SCF induces comparable proliferation rates of clonogenic precursors as Sl+MS5 stroma. The conditioning of the CD34+ cells as analyzed by colony assays in methylcellulose revealed that membrane-bound SCF mainly supports the maintenance of multipotent and bipotent progenitors. The number of CFU-GM and CFU-GEMM constituted 32% of total colony-forming cells after one week and 52% after two weeks in coculture. In contrast, the proportion of multipotent progenitors in cocultures induced by Sld SCF are 4-fold lower after three weeks in culture (Table 2), but the contents of erythroid colonies (BFU-e’s) increased 1.5-fold at the same time point. The results indicate that soluble Sld SCF promotes more committed cells than membrane-bound SCF. Mature myeloid colonies increased about 1.5-fold in contrast to CFU-C derived from membrane-bound SCF expressing cultures (Friel et al., 2002). The effect of soluble Sld SCF on the stimulation of erythroid precursors is at the first glance unexpected, since Sld mice bear erythroid deficiencies (McCulloch et al., 1965). The simplest explanation is, that the increased appearance of BFU-e’s is correlated with the increased number of macrophage colonies. It is known that macrophage colonies in vitro cultures have supporting effects on erythroid colonies, perhaps by secreting Epo. Nevertheless, we could not exclude that due to a synergistic effect of an uncharacterized factor produced by epithelial MMCE cells the number of erythroid progenitors in Sld conditioned hematopoietic cells is promoted. TABLE 2. Membrane-bound isoforms of SCF and CSF-1 show comparabel effects in inducing proliferation of primary CD34+ cells but membrane-bound SCF has a stronger effect on the selfrenewing potential. 250 cord blood cells cocultured on MMCE feeders expressing different CSF-1 isoforms were weekly plated in methylcellulose supplemented with hematopoietic growth factors. On day 14 colonies were examined. CFU-values were calculated as % of total CFU. Data are mean±SD of five experiments. *) After three weeks in coculture 500 cells were plated in methylcellulose. a) Cloning efficieny of CD34+ cells stimulated by different SCF- or CSF-1 isoforms as indicated. **) mb CSF-1 and soluble SCF yielded significant differences (P<.02). ***) mb CSF-1 significantly enhanced the outcome of clonogenic cells compared to soluble CSF-1 (P<.02). b) Distribution of clonogenic CD34+ progenitors stimulated by SCF- or CSF-1 isoforms to myeloid lineages. Stastic calculations refer to mean values after 3 weeks in coculture. Induction of G+M colonies: a) mb SCF and soluble SCF showed comparable effects (P>.05); b)
28
J. FRIEL ET AL.
soluble CSF-1 stimulated significant more lineage-specific cells than mb CSF-1 (P<.05). Induction of GM colonies: c) mb SCF was more efficient than soluble SCF (P<.05); d) difference between mb CSF-1 and soluble CSF-1 was not apparent (P>.05). Induction of BFU-e colonies: e) a higher production of colonies was achieved by mb SCF as compared to soluble SCF (P<.01); f) mb CSF-1 increased the output of erythroid progenitors when compared to soluble CSF-1 (P<.01). Induction of GEMM colonies: g) mb SCF enhanced the frequency of multipotential cells in contrast to soluble SCF (P<.02); h) mb CSF-1 induced higher expansion of multipotential cells than soluble CSF-1 (P<.05).
MMCE untransduced cells support mainly the survival of committed myeloid (CFU-G and CFU-M) and erythroid (BFU-e) progenitors for at least up to two weeks. The cocultivation experiments using CB CD34+ cells thus confirmed our results obtained with the cell line TF1: ectopic expression of membrane-bound SCF can substitute for stroma functions like long term maintenance and expansion of multipotent progenitors. 2.5. MEMBRANE-BOUND CSF-1, BUT NOT SECRETED CSF-1 GLYCOPROTEIN STIMULATES SELF-RENEWAL OF PRIMARY CD34+ CELLS
Up to 5% of unstimulated CB mononuclear cells are CSF-1-receptor positive as measured by flow cytometry (data not shown). In the first week of coculture on transduced MMCE cells all CSF-1 isoforms promoted proliferation of CB CD34+ cells with comparable rates (Fig. 5a). However, within four weeks the stimulatory activity of wildtype CSF-1 declined dramatically. Obviously, the soluble isoform provided only a limited expansion of CB CD34+ cells.
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
b)
CD34 expression of CB cell stimulated by wildtype CSF-1
10
10
1
10
2
PE
10
3
10
4
10
Counts
69.6%
0
10
1
10
2
PE
10
3
10
4
M1
10
20 40 60 80 100
Counts
M1
20 40 60 80 100
49.5%
17.03% M1
0
0
M1 0
soluble CSF-1
membrane-bound CSF-1
0
Counts
74.3%
0 20 40 60 80 100
40 80 120 160 200
MS5 stroma
Counts
29
0
10
1
10
2
PE
10
3
10
4
10
0
10
1
10
2
103 104
PE
CD34 PE
Figure 5. A) Membrane-bound CSF-1 stimulates amplification of CD34+ progenitors. 2·104 cord blood CD34+ cells were cocultivated on feeders in 24-well plates. Increase of total cells was weekly determined and cells were transferred to new feeders. The results are calculated as % of CD34+/MS5 control cocultures. Amplification rates of CB CD34+ cells on MS5 stroma were set to 100% at each time point. Each point represents the mean±SD of five independent experiments. Membrane-bound isoforms of SCF or CSF-1 induced longer-lasting self-renewal of primary CD34+ cells. a) After 3 weeks in coculture a highly significant difference between populations supported by mb SCF and soluble SCF was found (P<.01); b) Growth rate of population sustained by mb CSF-1 was significantly different from cells stimulated by soluble CSF-1 (P<.002). B) Membrane-bound CSF-1 induces self-renewal of CD34+ progenitors. Expression of the CD34 antigen of cord blood cells cocultured for 14 days on MMCE cells expressing ectopically the different CSF-1 isoforms. Cells were stained with PE-conjugated anti-human CD34 anibodies. High expression of the CD34 antigen reflects the self-renewing potential of CB cells stimulated by mb CSF-1.
30
J. FRIEL ET AL.
Membrane-bound CSF-1 (mb CSF-1) in contrast induced high amplifications of CB CD34+ cells even on day 28 (Fig. 5a). Remarkably, the proliferation inducing signals of mb CSF-1 remained constant and were similar throughout the culture (Fig. 5a). The self-renewal inducing activity of the mb CSF-1 isoform and the differentiation promoting effect of the soluble form was indicated by CD34 antigene expression of the cocultured cells. Cultures induced by mb CSF-1 showed no decrease in the pool size of CD34+ progenitors compared to CD34+/MS5 stroma control cultures (Fig. 5b). In contrast, stimulation by soluble CSF-1 resulted in a marked (4-fold) reduction of CD34+ progenitors (Fig. 5b). These results suggest that mb CSF-1 can sustain self-renewal of early progenitors whereas soluble CSF-1 induces differentiation of stimulated cells. The phenotype of clonogenic precursors was assessed by colony assays to compare the differentiation-inducing effects of either mb- or soluble CSF-1. Membrane-bound CSF-1 sustained early cell subpopulations stronger than wildtype- or soluble CSF-1 (4- to 6-fold, respectively; Table 2) as evidenced by the higher proportion of colonies derived from early progenitor cells (BFU-e, CFU-GEMM). Stimulation of CB CD34+ cells by soluble CSF-1 thus may lead to myeloid differentiation of committed progenitors. The mb isoform of SCF stimulated a higher proportion of CFU-GEMM than the corresponding CSF-1 isoform. This may be a consequence of the higher potential of SCF in supporting self renewal of early progenitors (Table 2; Friel et al., 2005). 2.6. MEMBRANE-BOUND- AND SOLUBLE CSF-1 OVEREXPRESSED BY MMCE CELLS CAUSE DIFFERENTIAL RESPONSES OF MYL-D7 CELLS IN COCULTURES
We next analyzed the effects of the CSF-1 isoforms on the development of Myl-D7, a strictly stroma-dependent stem cell line (Itoh et al., 1996). At least 51% of Myl-D7 cells express among other multilineage markers high levels of CSF-1 receptors (data not shown). A strong proliferation response of Myl-D7 cells was only obtained on MMCE feeders expressing mb CSF-1 as is clearly shown in Fig. 6. Although the proliferation stimulated by mb CSF-1 declined slightly during the cultivation period it was still 4-fold stronger than that of wildtype- or soluble CSF-1 at 3 weeks of culture (Fig. 6).
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
31
Figure 6. Proliferation of the murine Myl-D7 stem cell line is stimulated efficiently only by membrane-bound CSF-1. 2·103 Myl-D7 cells were cultured on MMCE cells expressing the different CSF-1 isoforms in 48-well plates. Cloning efficiencies were determined weekly and Myl-D7 clones (>102 cells) were transferred onto new MMCE cells. Values of Myl-D7/MS5 cocultures were set to 100% at each time point (data not shown). Results are expresses as percentage of control Myl-D7/MS5 cultures and are mean values ±SD (four experiments). After 3 weeks in coculture a) no difference was found in the proliferation rates of cells stimulated by either wildtype- or soluble CSF-1 (P>.05); b) mean values for populations stimulated by membrane-bound- or soluble CSF-1 were significantly different (P<.001).
To characterize the development of Myl-D7 cells induced by soluble- or mb CSF-1 we examined the surface-marker phenotype of cocultured Myl-D7 cells by FACS analyses. Cells stimulated by mb CSF-1 showed only a slight trend towards differentiation into the macrophage lineage. Only a small subfraction of cells expressed the mononuclear-phagocyte-specific marker F4-80 (Hume et al., 1984). In contrast, cells induced by wildtype- or soluble CSF-1 expressed 12-fold and 23-fold higher amounts of the F4-80 antigen. The multipotential phenotype of Myl-D7 cells, as indicated by the unchanged expression of the CD90 (Thy-1) and F4-80 antigens, was thus maintained in cocultures sustained by mb CSF-1. Soluble CSF-1, as expected, induced an apparent shift toward differentiation into the macrophage-lineage (data not shown; Friel et al., 2005).
32
J. FRIEL ET AL.
2.7. A STRONG SUSTAINED MITOGENIC SIGNAL IS INDUCED BY MEMBRANE-BOUND CSF-1 IN SCA-1+ LIN- PRIMITIVE QUIESCENT STEM CELLS
We next tried to determine whether membrane-bound CSF-1 could stimulate a subpopulation of very primitive cells. Lineage marker negative mouse Lin-Sca1+ cells were cocultured on MMCE cells expressing either the cDNA for wildtype, soluble or membrane-bound CSF-1. Untransduced CSF-1+MS5 stroma was used as a control. From two weeks on a continuous decrease in the proliferation of hematopoietic cells supported by wildtype- or soluble CSF-1 was seen. The better growth response of cells exposed to mb CSF-1 was again seen by higher (3-fold and 10-fold) levels of proliferating cells over four weeks of cocultivation (Fig. 7).
Figure 7. Membrane-bound CSF-1 on its own induces high self-renewal response of primitive Lin-Sca+ cells. Membrane-bound CSF-1 can stimulate very early cells. Lin-Sca-1+ cells were cocultivated on MMCE cells ectopically expressing different CSF-1 isoforms as indicated. Increase of Lin-Sca-1+ cells on MS5 stromal cells was set to 100% at each time point. Proliferation of Lin-Sca-1+ cells on MMCE feeders was shown as % of Lin-Sca-1+/MS5 controls. Each point represents the mean±SD (three separate experiments). After 3 weeks in coculture a) growth rate of cells stimulated by soluble CSF-1 was profoundly lower than that of cells stimulated by membrane-bound CSF-1 (P<.05).
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
33
The number of colonies obtained in the CFC assay of Lin-Sca-1+ cells that had been stimulated with each of the CSF-1 isoforms corresponded to the resultant amplification (Fig. 7). The cloning potential of cells after three weeks in culture maintained by mb CSF-1 was about 4-fold higher than in cultures stimulated by soluble- or wildtype CSF-1. The qualitative differences between these CSF-1 forms in sustaining primitive hematopoietic progenitors were again obvious. The number of colonies produced by early progenitors (CFU-GEMM) in the population stimulated by mb CSF-1 was 4-fold higher as in the parallel culture promoted by wildtype CSF-1 and even 13-fold higher than in cultures sustained by soluble CSF-1. Conversely, soluble CSF-1 apparently induced differentiation into mature cells. Following two weeks coculturing, 87% of all colonies were derived from macrophage precursors, whereas only 30% of the colonies induced by mb CSF-1 was of that type (Table 2). 2.8. FRACTIONATION AND ANALYSIS OF MS5 SUPERNATANT IDENTIFIES CSF-1 AS A MAJOR GROWTH FACTOR COMPONENT FOR MYL-D7 STEM CELLS
The stem cell line Myl-D7 not only expresses differentiation markers of all lineages but is dependent for growth on self-renewing stem cells within the Myl-D7 clone which spontaneously differentiates along the lymphoid, myeloid, or erythroid direction (Itoh et al., 1996). Supernatant of MS5 induces short term growth of Myl-D7 cells. This may indicate that at least soluble stem cell growth factors are secreted by MS5 cells. MS5 conditioned medium (CM) was fractionated using a Q sepharose column. Twenty-nine fractions were pooled into 2-3 fraction pools which were bioassayed for activity on lineage negative Myl-D7 cells, activity on cells of the CSF-1 responsive BAC1.2F5 macophage cell line (Morgan et al., 1987), and tested for the presence of CSF-1 by SDS-PAGE and Western blotting. The majority of bioactivity on lineage negative Myl-D7 cells was present in fractions 13-24 of the Q Sepharose column (Fig. 8a). Bioactivity on BAC1.2F5 cells, which are specifically responsive to CSF-1 or GM-CSF, was detected in column fractions 10-21 in an overlapping region (Fig. 8b). Finally, by Western blotting, CSF-1 was detected as a 24Kd reduced and deglycosylated monomer in overlapping column fractions 13-21 (Fig. 8c).
34
J. FRIEL ET AL.
Figure 8. CSF-1 supports for a limited period the proliferation of Myl-D7 stem cells. a) Fractions that contain a growth promoting activity can be separated by HiTrap Q sepharose column fractionation of MS5 CM. Short-term growth assay of lineage negative Myl-D7 cells stimulated with total MS5 CM as a control or pools of fractions (FXN) from a HiTrap Q sepharose column (3-11). 10% v/v of each pool was used per sample. Results for the following pools are shown: 4, FXN 4-6; 5, FXN 7-9; 6, FXN 10-12; 7, FXN 13-15; 8, FXN 16-18; 9, FXN 19-21; 10, FXN 2224; 11, FXN 26-29. The positions of the flow through fractions as well as NaCl gradient are also shown. b) Growth stimulation of BAC1.2F5 cells by HiTrap Q sepharose column fractions is consistent with the presence of CSF-1. BAC1.2F5 cell growth assay to determine units of CSF-1 in MS5 CM and fractions (FXN) from the HiTrap Q sepharose column. Units are defined arbitray (personal communication Dr. Medlock). (3-11): Fraction pools 3, FXN 3-5; 4, FXN 6+7; 5, FXN 8+9; 6, FXN 10+11; 7, FXN 12+13; 8, FXN 14+15; 9, FXN 16+17; 10, FXN 18+19; 11, FXN 20+21. MS5 CM was generated from cells grown in 10% FBS. The positions of the flow through fractions as well as NaCl gradient are also shown. c) Identification of CSF-1 protein in pools of fractions with short-term Myl-D7 growth stimulating activity. Western blot analysis of pools of fractions from the HiTrap Q sepharose column: 1, FXN 1-3; 2, FXN 4-6; 3, FXN 7-9; 4, FXN 1012; 5, FXN 13-15; 6, FXN 16-18; 7, FXN 19-21; 8, FXN 22-24; 9, FXN 26-29; 10, FXN 30-33; 11, FXN 34+35. High molecular weight bands probably result from incomplete deglycosylation of CSF-1 in some fractions.
We could also inhibit the bioactivity in fractions 13-24 using the neutralizing anti-CSF-1 antibody, demonstrating that CSF-1 in these fractions
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
35
was involved in stimulating Myl-D7 proliferation (data not shown; Heberlein et al., 2006). CSF-1 is thus one major bioactive factor released by MS5 cells which can stimulate Myl-D7. However, it should be noted that stimulation of lineage negative Myl-D7 cells by E.coli-derived recombinant-CSF-1 at equivalent CSF-1 concentrations was by far less efficient than CM from MS5 cells. Furthermore, the stimulation of lineage negative cells by MS5 supernatants was far better than that of L929 supernatants having similar concentrations of CSF-1 (data not shown). Thus it is likely that MS5 stromal cells produce additional factors that are required for Myl-D7 cell maintenance. 2.9. STROMA-INDEPENDENT MUTANTS CAN BE ISOLATED FROM MYL-D7
For the isolation of stroma-independent mutants, Myl-D7 cells were separated from MS5 and plated in 24-well or 96-well plates (105cells/well) without stroma. The overall frequency of stroma-independent mutants was very low (1.6x10-8). 89 stroma-independent mutants were obtained. The stroma-independent mutants belong to two different classes: secretors and non secretors. The supernatants of the 89 mutants were tested for their ability to support stroma-independent growth of Myl-D7. Myl-D7 cells were plated at two concentrations (2.0x105 cells/mL and 5x105 cells/mL) in triplicate in 24-well plates containing CM from confluent mutant cultures. For most of the supernatants tested the number of wild type Myl-D7 indicator cells decreased rapidly to less than 10% within the first 10 days. These mutants were classified as non secretors. Only 26 of the total 89 mutants secreted an activity stimulating the survival/proliferation of Myl-D7 for at least two weeks. Furthermore, only ten of these secretor mutants (e.g. #6i-4, #6i-22) stimulated the growth of Myl-D7 for longer than 6 weeks (data not shown; Heberlein et al., 2006). 2.10. CSF-1 IS ECTOPICALLY EXPRESSED IN SOME STROMA-INDEPENDENT MUTANTS
Ectopic expression of growth factors and autostimulation are often responsible for factor independence. As shown above, CSF-1 secreted by MS5 cells may be a potent stimulator of at least short-term proliferation of Myl-D7 cells. We therefore compared the steady-state CSF-1 mRNA levels of uncloned Myl-D7 cells, of several stroma-dependent clones and of many stroma-independent clones by Northern analysis (Fig. 9), to analyze if CSF-1 is expressed in stroma-independent Myl-D7 mutants.
36
J. FRIEL ET AL.
Figure 9. Some factor secreting mutants expresses CSF-1 transcripts. Northern blot analysis. 12mg of total RNA/lane were analyzed. The major transcript was a 4.0 kb CSF-1 message. Results for parental Myl-D7 cells, stroma-dependent subclones derived and stroma-independent mutants are shown: 1, #3i-1; 2, #5i-1; 3, #6i-4; 4, #6i-5; 5, #3i-2; 6, #4i-1; 7, #5i-3; 8, #6i-2; 9, #6i-3; 10, #6i-17; 11, #6i-18; 12, #6i-19; 13, #6i-20; 14, #6i-21; 15, #6i-22; 16, #6i-23; 17, #6i26. Those stroma-independent mutants that are secretors are also indicated. Although additional CSF-1 specific splice variants could be detected at low levels in MS-5 and Myl-D7 mutants with high CSF-1 expression, no mutant/cell line specific splice product could be shown. However, the size of the splice product detected depended on the probe that was used for hybridization. Two additional messages (3.2 kb and 2.3 kb) were detected by hybridization with a full length CSF-1 cDNA and only one additional message (2.3kb) was detected by hybridization with a 3’ fragment of the cDNA.
Low expression of a 4kb transcript was detected in uncloned cells of MylD7 and in all stroma-dependent subclones. Two types of secreting mutants were identified. About half of the secretors (7/16), expresses ectopically high levels of CSF-1 transcripts (e.g. #5i-1, #5i-3, #6i-2, #6i-3, #6i-4). The remainder of the secretors expressed low levels of CSF-1 transcripts, comparable to the very low level of CSF-1 message in wild type Myl-D7 (e.g. #6i-5, #6i-21, #6i-22, #6i-26). Interestingly, highly elevated CSF-1 mRNA levels were also found in some of the non-secreting mutants (e.g. #4i-2, #5i-2) (Fig. 9). In these mutants, CSF-1 may be acting internally within the CSF-1 receptor expressing cells as previously shown in rat myoblasts (Borycki et al., 1995). This specific form of
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
37
factor/receptor interaction has also been described for IL-3 (Dührsen et al., 1988; Dunbar et al., 1989). In summary, we show that the secretory mutants can be divided into two types, mutants expressing ectopically high levels of CSF-1 mRNA that probably secrete CSF-1 and other mutants that express low levels of CSF-1 mRNA that may not release CSF-1 but instead other factors that stimulate MylD7 proliferation (Heberlein et al., 2006). 3. Discussion Stromal cells not only mediate the homing of primitive cells but also produce stimulatory and inhibitory acting molecules that control maintenance of stem cells in the hematopoietic microenvironment. A shift in the balance between such opposing factors may determine the proliferation of hematopoietic cells on stroma (Dorshkind, 1990; Kim and Broxmeyer, 1998; Eaves et al., 1991). An important stromal derived growth factor, SCF, appears to play a major role in mechanisms like this. SCF can be expressed as a membrane-bound molecule that can be subsequently cleaved to soluble protein. The physiological functions of these isoforms are not well known. The deficiencies in mature eythroid precursors and in pluripotent hematopoietic stem cells in Sld mutant mice (McCulloch et al., 1965) indicated that the membrane-bound SCF isoform has an essential function in hematopoiesis. Our study using TF1 cells strongly suggest that the membrane presentation of SCF induces significantly higher proliferation signals compared to soluble Sld SCF. In contrast, soluble Sld SCF stimulates short term proliferation only and prevents long term growth of TF1. This was shown both by Sld SCF stroma or by adding recombinant SCF to cocultures (Fig. 2) The importance of the interaction between mb SCF and c-kit is also demonstrated by the finding that SCF deficient Sl/Sl stroma is less efficient than stroma expressing wildtype + + SCF Sl MS5 in inducing long term growth of CD34 hematopoietic cells. This deficiency could be rescued by ectopic expression of membrane-bound SCF resulting in significant higher proliferation of cocultured TF1 cells. Conversely, expression of soluble Sld SCF in transduced Sl/Sl stroma leads to growth abrogation of TF1. Blocking the c-kit receptor by neutralizing antibodies to avoid binding of mb SCF resulted in reduced clonability of TF1 cells on stroma. Preventing binding of secreted SCF to the c-kit receptor resulted in significantly higher growth rates of TF1 on Sld stroma. These results indicate that the membrane-bound SCF/c-kit receptor complex is responsible for inducing long term proliferation of hematopoietic cells on stroma. Furthermore, the two isoforms of SCF have antagonistic functions in promoting growth of
38
J. FRIEL ET AL.
hematopoietic precursors. Soluble Sld SCF is “recessive” to its membrane counterpart but epistatic to other stroma derived factor-receptor interactions. We have evaluated this assumption by utilizing CB CD34+ cells in coculture experiments with epithelial cells expressing either membrane-bound or Sld SCF. Cycling of primary stem cells have been reported to be correlated with a sequential loss of the proliferation capacity. Our results have shown that the reduction of proliferation is less when membrane-bound SCF stimulates the CD34+ cells as opposed to soluble Sld SCF (Fig. 4). Consequently, membranebound SCF stimulated CB cells show higher proliferation potential than cells stimulated by soluble SCF. Thus, the overall effect of the SCF isoforms is similar on primary as well as on immortalized TF1 cells. Membrane-bound SCF supports the survival and proliferation of hematopoietic colony forming cells with a predominantly bi- or multipotent character, whereas soluble Sld SCF promotes mainly the maintenance of unipotent precursors. Furthermore, the phenotype of CFC induced by membrane-bound SCF resembles that of cells supported by Sl+MS5 stroma. Thus, membranebound SCF ectopically expressed in epithelial MMCE cells can function as a surrogate stroma system for CD34+ cells. Our data could possibly suggest that the antagonism of the SCF isoforms may be simply caused by different kinetics of c-kit activation. Inefficient c-kit activation by soluble SCF could thus be the consequence of suboptimal amounts of Sld SCF produced either by parental Sld stromal cells or by the transduced retroviral vectors. High concentrations of soluble SCF should then be able to imitate the effect of the membrane-bound isoform or to compete with membrane-bound SCF for c-kit activation. However, in our test system recombinant SCF even when exogenously applied in high concentrations (100 ng/mL) is neither able to replace the membrane-bound SCF/c-kit interaction nor to increase the growth rate of CD34+ TF1 on stroma or epithelial cells secreting Sld SCF (Fig. 2). These data clearly argue against the possibility that different levels of expression of the SCF isoforms simply induced the observed antagonistic effects (Friel et al., 2002). The difference between the interaction of soluble and membrane-bound SCF with the c-kit receptor seems to be qualitative and not quantitative. Kapur et al. have demonstrated qualitatively different functions of both SCF isoforms in vivo. They have shown that transgene expression of membrane-bound SCF but not of soluble SCF in Sld mice significantly compensates SCF related hematological deficiencies (Kapur et al., 1998). Although structurally related, CSF-1 was first shown to be a proliferation factor in early hematopoiesis almost 20 years ago (Bartelmez and Stanley, 1985; Stanley et al., 1986; Bartelmez et al., 1989) by the group that first defined CSF-1 (Stanley and Heard, 1977). These studies indicated that CSF-1 acted on
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
39
primitive cells by synergizing with other growth factors. Furthermore, CSF-1 was also active in an in vitro clonogenic assay for stem cells (CFU-S) (Pragnell et al., 1988). However, subsequent work has mainly focused on its role in regulating the proliferation, differentiation and function of macrophages (reviewed in Pixley and Stanley, 2004). The data presented here indicate the dual potential of the CSF-1 isoforms in inducing proliferation and development. Binding of the membrane-bound isoform to the CSF-1 receptor induces long-term high proliferation rates of early human and murine progenitor cells. In contrast, activation of the soluble CSF-1/CSF-1 receptor complex resulted in short-term proliferation. Activation of the CSF-1 receptor by membrane-bound CSF-1 resulted in maintenance of progenitors characterized by the unaltered expression of either the CD34 antigen in human- or the B220-, CD34- and Thy-1 markers in murine Myl-D7 cells. BFU-e- and CFU-GEMM levels were substantially higher in membranebound CSF-1 stimulated cultures compared to those cultured with soluble- or wildtype CSF-1. The growth inducing effects of the membrane-bound forms of CSF-1 and SCF were comparable. However, aspects of the phenotype of stimulated cells show qualitative differences. Membrane-bound SCF stimulated more the primitive colony-forming precursors (BFU-e, CFU-GEMM) of human CD34+ cells than the corresponding isoform of CSF-1, demonstrating the stronger effect of membrane-bound SCF in inducing self-renewal of early progenitors (Table 2). The results suggest that the cell-surface isoform of CSF-1 can replace the membrane-bound isoform of SCF in supporting long-term proliferation but not for stimulation of self-renewal (Friel et al., 2005). Growth abrogation of human- and murine hematopoietic cells caused by soluble- or wildtype CSF-1 could be, in contrast to the effects of membranebound CSF-1, a consequence of the induction of differentiation into the monocytic lineage. The lack in supporting progenitor subpopulations was not unexpected since macrophage precursors are known to be the major targets of soluble CSF-1 (Stanley et al., 1983). Soluble SCF is active only in cooperation with other cytokines (Lemoli et al., 1993; Ramsfjell et al., 1997). Therefore growth abrogation induced by soluble SCF was not accompanied by significant differentiation of stimulated cells. Instead SCF leads to clonal extinction (Itoh et al., 1997; Friel et al., 2002). Differential effects of the isoforms of a particular factor could be the consequence of receptor-mediated signaling. Proliferation leading to selfrenewal could depend on the signaling intensity through the factor/receptor complex (Zandstra et al., 2000). In this context, membrane-bound factors mediating cell-cell interactions may substitute for high local concentrations of a soluble factor resulting in delayed internalization of the factor/receptor complex
40
J. FRIEL ET AL.
that normally takes place immediately after soluble factor/receptor interaction. Indeed, it was reported, that membrane-bound SCF is more persistent in inducing phosphorylation of the SCF receptor than soluble SCF (Miyazawa et al., 1995). The molecular mechanisms by which the CSF-1/CSF-1 receptor complex causes different biological effects are not known. We infer that membrane-bound CSF-1 in analogy to SCF may induce a strong receptor activation thereby favoring self-renewal of early cells whereas soluble CSF-1 provides only a short receptor activation resulting in monocytic differentiation of CSF-1 receptor presenting cells. We used the stroma dependent Myl-D7 cell line to define unknown stem cell factors secreted by MS5 stromal cells. CSF-1 was identified as a major growth factor component of the MS5 supernatant by biochemical analysis. Recombinant CSF-1 induced short-term growth (3 days) of Myl-D7 to a similar extent as MS5 CM. Furthermore, growth of the parental Myl-D7 clone in MS5 CM could be inhibited by addition of an α-CSF-1 antibody, indicating that at least one of the active molecules is CSF-1. Thus we conclude that CSF-1 is a potent stimulator of the limited proliferation of the Myl-D7 stem cell line (Heberlein et al., 2006). In an another approach to identify unknown stroma-mediated functions we screened stroma-independent mutants of the multipotent stem cell line Myl-D7 in order to isolate mutants that secrete a factor maintaining wild type cells. At least two different components stimulating the survival/proliferation of the parental Myl-D7 clone were detected in the CM of different secreting mutants. Consistent with the results obtained with the biochemical approach, one of these activities was CSF-1. Factor secreting mutants express CSF-1 with a high incidence (Fig. 9). Interestingly, uncloned Myl-D7 and all stroma-dependent subclones also express very low levels of CSF-1. This result is not unexpected. The murine FDC-Pmix stem cells also had been shown by us to express low levels of CSF-1 upon differentiation (Just et al., 1993). Others suggest that CSF-1 is expressed at early stages (CFU-GEMM) during the development of myeloid progenitors to osteoclasts (Lacey et al., 1998). An other growthinducing factor is secreted by one stroma-independent Myl-D7 mutant. This has been so far not characterized by our group. This growth factor can stimulate alone or in combination with CSF-1 self-renewal of parental Myl-D7 stem cells. In contrast to MS5 stromal cells or MS5 CM, recombinant CSF-1 did not stimulate long-term survival/proliferation of Myl-D7. This may reflect the requirement of other growth factors expressed by MS5 cells that synergize with CSF-1 as indicated by early studies (Bartelmez and Stanley, 1985; Bartelmez et al., 1989). Consistent with early observations we show here that CSF-1 can replace SCF as a stem cell factor in sustaining early cells and that CSF-1 is involved in
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
41
the induction of proliferation of a stem cell line (Friel et al., 2005; Heberlein et al., 2006).
References Anderson DM, Lyman SD, Bird A, Wignall JM, Eisenman J, March CJ, Boswell HS, Gimpel SD, Cosman D, Williams DA, 1990. Molecular cloning of mast cell growth factor, that is active in both membrane bound and soluble forms. Cell 63: 235 Bartelmez SH, Stanley ER, 1985. Synergism between hemopoietic growth factors (HGFs) detected by their effects on cells bearing receptors for a lineage-specific HGF: assay of hemopietin-1. J Cell Physiol 122: 370 Bartelmez SH, Bradley TR, Bertoncello I, Mochizuki DY, Tushinski RJ, Stanley ER, Hapel AJ, Young IG, Kriegler AB, Hodgson GS, 1989. Interleukin-1 plus interleukin-3 plus colony stimulating factor-1 are essential for clonal proliferation of primitive myeloid bone marrow cells. Exp Hematol 17: 240 Borycki A-G, Smadja F, Stanley ER, Leibovitch SA, 1995. Colony-Stimulating Factor 1 (CSF-1) is involved in an autocrine growth control of rat myogenic cells. Exp Cell Res 218: 213 Broxmeyer HE, Williams DE, Cooper S, Hangoc G, Ralph P, 1988. Recombinant human granulocyte colony-stimulating factor and recombinant human macrophage colonystimulating factor synergize in vivo to enhance proliferation of granulocyte-macrophage, erythroid, and multipotential progenitor cells in mice. J Cell Biochem 38: 127 Byrne PV, Guilbert LJ, Stanley ER, 1981. Distribution of cells bearing receptors for a colonystimulating factor (CSF-1) in murine tissues. J Cell Biol 91: 848 Ceretti DP, Wignall J, Anderson D, Tushinski RJ, Gallis BM, Stya M, Gillis S, Urdal DL, Cosman D, 1988. Human macrophage-colony stimulating factor: alternative RNA and protein processing from a single gene. Mol Immunol 25: 761 Delwiche F, Raines E, Powell J, Ross R, Adamson J, 1985. Platelet-derived growth factor enhances in vitro erythropoiesis via stimulation of mesenchymal cells. J Clin Invest 76: 137 Dexter TM, Moore MAS, 1977. In vitro duplication and cure of hematopoietic defects in genetically anemic mice. Nature 269: 412 Dorshkind K, 1990. Regulation of hemopoiesis by bone marrow stromal cells and their products. Ann Rev Immunol 8: 111 Dührsen U, 1988. In vitro growth patterns and autocrine production of hemopoietic colony stimulating factors: analysis of leukemic populations arising in irradiated mice from cells of an injected factor-dependent continous cell line. Leukemia 2: 334 Dunbar CE, Browder TM, Abrams JS, Nienhuis AW, 1989. COOH-terminal modified interleukin-3 is retained intracellularly and stimulates autocrine growth. Science 245: 1493 Eaves CJ, Cashman JD, Kay RT, Dougherty GJ, Otsuka T, Gaboury LA, Hogge DE, Lansdorp PM, Eaves AE, Humphries RK, 1991. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. Blood 78: 110 Flanagan JG, Chan DC, Leder P, 1991. Transmembrane form of the kit ligand growth factor is determined by alternative splicing and is missing in the Sld mutant. Cell 64: 1025 Friel J, Itoh K, Bergholz U, Jücker M, Stocking C, Harrison P, Ostertag W, 2002. Hierarchy of stroma-derived factors in supporting growth of stroma-dependent hemopoietic cells:
42
J. FRIEL ET AL.
membrane-bound SCF is sufficient to confer stroma competence to epithelial cells. Growth Factors 20: 35 Friel J, Heberlein C, Geldmacher M, Ostertag W, 2005. Diverse isoforms of colony-stimulating factor-1 have different effects on the development of stroma-dependent hematopoietic cells. J Cell Physiol 204: 247 Fujita J, Onoue H, Nakamaya H, Kanakura Y, 1988. In vitro duplication and in vivo cure of mastcell deficiency of Sl/Sld mutant mice by cloned 3T3 fibroblasts. Proc Natl Acad Sci USA 86: 2888 Gilmore GL, Shadduck RK, 1995. Inhibition of day-12 spleen colony-forming units by a monoclonal antibody to the murine macrophage/monocyte colony-stimulating factor receptor. Blood 85: 2731 Hall DJ, Jones SD, Kaplan DR, Whitman M, Rollins BJ, Stiles CD, 1989. Evidence for a novel signal transduction pathway activated by platelet-derived growth factor and by doublestranded RNA. Mol Cell Biol 9: 1705 Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J, Luh J, Duda G, Martina N, Peterson D, Menon S, Shanafelt A, Muench M, Kelner G, Namikawa R, Rennick D, Roncarolo MG, Zlotnick A, Rosnet O, Dubreuil P, Birnbaum D, Lee F, 1994. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of hemopoietic stem cells and is encoded by variants RNAs. Nature 368: 643 Heberlein C, Friel J, Itoh K, Medlock E, Li L, Nakayama N, Stocking C, Geldmacher M, Ostertag W, 2006. Involvement of CSF-1 in generating a stroma-independent hematopoietic stem cell line. J Cell Physiol: 206: 556 Huang E, Nocka K, Beier DR, Chu T-Y, Buck J, Lahm H-W, Wellner D, Leder P, Besmer P, 1990. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of ckit receptor, the gene product of the W locus. Cell 63: 225 Kim CH, Broxmeyer HE, 1998. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, Steel factor, and the bone marrow environment. Blood 91: 100 Ladner MB, Martin GA, Noble JA, Wittman VP, Warren MP, McGrogan M, Stanley ER, 1988. cDNA cloning and expression of murine macrophage colony-stimulating factor from L929 cells. Proc Natl Sci USA 85: 6706 Lerner NB, Nocka KH, Cole SR, Qiu F, Strife A, Ashman LK, Besmer P, 1991. Monoclonal antibody YB5.B8 identifies the human c-kit protein product. Blood 77: 1876 Ikuta K, Weissman IL, 1992. Evidence that hematopoietic stem cells express mouse c-kit but do not depend on Steel factor for their generation. Proc Natl Acad Sci USA 89: 1502 Itoh K, Tezuka H, Sakoda H, Konno M, Nagata K, Uchiyama T, Uchino H, Mori KJ, 1989. Reproducible establishment of hemopoietic supportive stromal cell lines from murine bone marrow. Exp Hematol 17: 145 Itoh K, Friel J, Kluge N, Kina T, Kondo-Takaori A, Kawamata S, Uchiyama T, Ostertag W, 1996. A novel hemopoietic multi-lineage clone, Myl-D-7, is stromal cell dependent and supported by an alternative mechanism(s) independent of stem cell factor/c-kit interaction. Blood 87: 3218 Itoh K, Friel J, Laker C, Zeller W, Just U, Bittner S, Nibbs RJ, Harrison P, Nishikawa S-I, Mori KJ, Ostertag W, 1997. The role of soluble growth factors and of stroma cells in inducing transient growth and clonal extinction of stroma cell dependent erythroblastic leukemia cells. Leukemia 11: 1753
STROMA CELL SIGNALLING FOR HSC SELF RENEWAL
43
Just U, Friel J, Heberlein C, Tamura T, Baccarini M, Tessmer U, Klingler K, Ostertag W, 1993. Upregulation of lineage specific receptors and ligands in multipotential progenitor cells is part of an endogenous program of differentiation. Growth Factors 9: 291 Kapur R, Majumdar M, Xiao X, McAndrews-Hill M, Schindler K, Williams DA, 1998. Signaling through the interaction of membrane-restricted stem cell factor and c-kit receptor tyrosine kinase: genetic evidence for a differential role in erythropoiesis. Blood 91: 879 Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, Piao YF, Miyazono K, Urabe A, Takaku F, 1989. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or Erythropoietin. J Cell Physiol 140: 323 Lacey DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliot R, Colombero A, Elliot G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ, 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165 Lemoli RM, Fogli M, Fortuna A, Motta MR, Rizzi S, Benini C, Tura S, 1993. Interleukin-11 stimulates the proliferation of human hematopoietic CD34+CD33-DR- cells and synergizes with stem cell factor, interleukin-3 and granulocyte-macrophage colony-stimulating factor. Exp Hematol 21: 1668 Mayami H, Little M-T, Dragowska W, Thornbury G, Lansdorp PM, 1995. Differential effects of the hematopoietic inhibitors MIP-1α, TGF-β, and TNF-α on cytokine-induced proliferation of subpopulations of CD34+ cells purified from cord blood and fetal liver. Exp Hematol 23: 422 Mayani H, Lansdorp PM, 1998. Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells. Stem Cells 16: 153 McClanahan T, Culpepper J, Campbell D, Wagner J, Franz-Bacon K, Mattson J, Tsai S, Luh J, Guimaraes MJ, Mattei MG, Rosnet O, Birnbaum D, Hannum CH, 1996. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand. Blood 88: 3371 McCulloch EA, Siminovitch L, Till JE, Russel ES, Bernstein SE, 1965. The cellular basis of the genetically determined hemopoietic defect in anemia mice of genotype Sl/Sld. Blood 26: 399 McNiece IK, Langley KE, Zsebo KM, 1991. Recombinant human stem cell factor synergizes with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and the eythroid lineages. Exp Hematol 19: 226 Michalevicz R, Katz F, Stroobant P, Janossy G, Tindle RW, Hoffbrand AV, 1986. Plateletderived growth factor stimulates growth of highly enriched multipotent haematopoietic progenitors. Br J Haematol 63: 591 Miyazawa K, Williams DA, Gotoh A, Nuishimaki J, Broxmeyer HE, Toyama. K, 1995. Membrane-bound steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood 85: 641 Morgan CJ, Pollard JW, Stanley ER, 1987. Isolation and characterization of a cloned growth factor dependent macrophage cell line, BAC12F5. J Cell Physiol 130:420-427 Nocka K, Majumder S, Chabot B, Ray P, Cervone M, Bernstein A, Besmer P. 1989. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice - evidence for an impaired c-kit kinase in mutant mice. Genes and Dev 3: 816 Ogawa M, Matsuzaki Y, Nishikawa S, Hayashi S, Kunisada T, Sudo T, Kina T, Nakauchi H, Nishikawa S, 1991. Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med 174: 63 Pixley FJ, Stanley ER, 2004. Regulation of Macrophages by CSF-1. Trends in Cell Biol 14: 628 Ramsfjell V, Borge OJ, Cui L, Jacobson SEW, 1997. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+CD38-)
44
J. FRIEL ET AL.
human bone marrow progenitor cells: Distinct and key interactions with the ligands for c-kit and flt 3, and inhibitory effects of TGF-β and TNF-α. J Immunol 158: 5169 Rapp UR, Jorma K-O, Heine UI, 1979. Establishment and characterization of the epithelial mouse embryo cell line MMC-E. Cancer Res 39: 4111 Stanley ER, Heard PM, 1977. Factors regulating macrophage production and growth. Purification and some properties of the colony stimulating factor from medium conditioned by mouse L cells. J Biol Chem 252: 4305 Stanley ER, Guilbert LJ, Tushinski RJ, Bartelmez SH, 1983. CSF-1: a mononuclear phagocyte lineage-specific growth factor. J Cell Biochem 21: 151-159 Stanley ER, Bartocci A, Patinkin D, Rosendaal M, Bradley TR, 1986. Regulation of very primitive, multipotent, hemopoietic cells by hemopoietin-1. Cell 45: 667 Sutherland HJ, Hogge DE, Cook D, Eaves CJ, 1993. Alternative mechanisms with and without steel factor support primitive human hematopoiesis. Blood 81: 1465 Tushinski RJ, Oliver IT, Guilbert LJ, Tynan PW, Warner JR, Stanley ER, 1982. Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. Cell 28: 71 Yan XQ, Brady G, Iscove NN, 1993. Platelet-derived growth factor (PDGF) activates primitive hematopoietic precursors (pre-CFCmulti) by upregulating IL-1 in PDGF receptor-expressing macrophages. J Immunol 150: 1 Yarden, Y, Escobedo JA, Knang WJ, Yang-Feng TL, Daniel TO, Tremble PM, Chen EY, Ando ME, Harkins RN, Francke U, Fried VA, Ullrich A, Williams LT, 1986. Structure of the receptor for platelet-derived growth factor helps define a familiy of closely related growth factor receptors. Nature 323: 226 Yarden Y, Kuang W-J, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A, 1987. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6: 3341 Zandstra PW, Lauffenburger DA, Eaves CJ, 2000. A ligand-receptor signaling threshold model of stem cell differentiation control: a biologically conserved mechanism applicable to hematopoiesis. Blood 96: 1215 Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, Hsu R-Y, Birkett NC, Okino KH, Murdock DC, Jacobsen FW, Langley KE, Smith KA, Takeishi T, Cattanach BM, Galli SJ, Suggs SV, 1990. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63: 213
FUNCTIONAL AND PHENOTYPIC HETEROGENEITY OF THE HUMAN HEMATOPOIETIC STEM CELL (HSC) COMPARTMENT OLGA I. GAN, JOBY L. McKENZIE, MONICA DOEDENS, JOHN E. DICK* Division of Cell and Molecular Biology, University Health Network; Department of Molecular and Medical Genetics, University of Toronto, Toronto, Canada
1. Introduction The hematopoietic system in mammals is comprised of a heterogeneous population of cells which range in function from mature cells of different lineages with limited proliferative potential to multipotent stem cells with extensive proliferative, differentiative and self-renewal capacities. Over a lifetime, the human body produces a trillion blood cells per day. To sustain that enormous cell output, functionally mature cells are generated from highly proliferative, but short-lived progenitors, which in turn arise from a rare population of quiescent hematopoietic stem cells (HSC) that sustain the entire hematopoietic hierarchy. Understanding the composition of HSC compartment is critical for clinical applications such as gene therapy or ex vivo expansion of small hematopoietic samples, for example umbilical cord blood (CB). The only conclusive method to assay stem cells is to follow their ability to repopulate conditioned recipients. Remarkable progress had been achieved in transplantation studies of murine HSC. It was shown that the murine HSC compartment is sustained by long-term repopulating cells that are phenotypically distinct from short-term repopulating cells and multi- and oligolineage progenitors1,2. In order to study the human HSC compartment, we and others have developed in vivo models of human hematopoiesis by transplanting immune-deficient mice with human cells3. Initially, severe combined immunedeficient (SCID) mice were used as recipients for studying human
______ * To whom correspondence should be addressed. John E. Dick, Division of Cell and Molecular Biology, University Health Network, Toronto Medical Discovery Tower, Rm 8-301, 101 College Street, Toronto, ON, M5G 1L7, Canada; email:
[email protected]
45 N. M. Bilko et al. (eds.), Stem Cells and their Potential for Clinical Application, 45–53. © 2008 Springer.
46
O.I. GAN ET AL.
hematopoiesis, however, later it was shown that non-obese diabetic (NOD)SCID mice provided improved engraftment by human cells of different cell lineages4. The primitive hematopoietic cells able to repopulate immunedeficient mice were operationally defined as SCID-repopulating cells (SRC). A detailed view of the developmental, proliferative, differentiation and selfrenewal potentials requires long-term analysis of uniquely marked SRC, as purification of homogeneous populations of human HSC is not yet possible. To carry out such a detailed clonal analysis, we employed retroviral transduction where SRC are uniquely marked based on semi-random integration of the virus into the genome. Thus, each SRC and its progeny have a unique tag that is used to retrospectively follow the clones after transplantation5,6. 2. Functional Heterogeneity of Human SRC Several years ago we used an optimized Moloney-based retroviral gene transfer protocol for the detailed examination of the clonal composition of the transduced cells that comprised the human graft in NOD/SCID recipients7. The key feature of this assay was the sequential bone marrow aspirations that allowed temporal changes in the clonal make-up of the graft to be evaluated. These studies enabled identification of SRC with differing potentials for repopulation. Kinetic analysis of repopulation showed significant variability in the proportion of gene-marked cells. Analysis of the fate of individual SRC and their progeny demonstrated that some clones appeared early and were lost, whereas other new clones appeared later. Some of the clones supported hematopoiesis over the entire time of analysis. These data clearly identify shortterm repopulating cells but the designation of long-term SRC was limited by the relatively brief duration of observation permitted by the NOD/SCID model (the life span of NOD/SCID mouse is short due to the development of endogenous lymphomas). The cardinal property of HSC is its ability to self-renew. However, in order to strictly satisfy self-renewal requirements, a clone must be present in both the primary and secondary recipients and this was not evaluated in these series of experiments due to low levels of engraftment in secondary recipients. Although this study provided insight into the clonal composition of human HSC hierarchy, it was unknown if the ex vivo manipulations required for retroviral marking had quantitative or qualitative effects on SRC fates. The developments in lentivector transduction protocols enabled efficient transduction of SRC in the absence of cytokine and serum stimulation8. Using minimal ex vivo manipulation to mark hematopoietic cells with lentiviral integration, the fates of SRC were evaluated9. As reported previously using retroviral-marking, lentivector transduced short-term SRC contributed rapidly
HETEROGENEITY OF HUMAN HSC
47
to the graft, but disappeared at later time points. By contrast, cells designated as long-term SRC either appeared at the end of the experiment or persisted over the entire duration of analysis. Therefore, the human HSC pool is functionally heterogeneous and comprised of individual stem cells with differing life spans and proliferative potentials. 3. Improved Xenotransplantation Models and Phenotypic Heterogeneity of Human SRC Aforementioned studies were based on the repopulation capacities of hematopoietic cells following intravenous (IV) injection. IV injection requires effective homing of stem cells to the bone marrow. This requirement might exclude classes of cells with defective homing and/or repopulating cells that are more sensitive to the residual immunity of immune-deficient mice. In order to investigate this possibility, we developed a novel transplant assay in which human cells were injected into the bone marrow cavity of NOD/SCID mice10. By direct intra-femoral (IF) transplantation we showed that there was rapid and substantial human engraftment following 2-3 weeks after IF transplantation which differed from routine IV graft kinetics. We showed that cells responsible for this rapid engraftment belonged to the lineage-negative (Lin ) + +/low + subpopulation, whereas cells expressing high CD38 did not CD34 CD38 engraft. Of note, previous IV transplantation studies demonstrated that almost + all SRC belong to Lin CD34 subpopulation; with only minimal SRC activity + found in the Lin CD34 population11. Among CD34 cells, cells belonging + to CD34 CD38 subpopulation were solely responsible for the engraftment upon IV transplantation in NOD/SCID mice12. However, using improved xenotransplantation models, such as NOD/SCID/β2microglobulin-deficient mice or NOD/SCID mice depleted of CD122-positive cells (i.e., cells expressing IL2Rβ - natural killers and macrophages), it was shown that the + + CD34 CD38 subpopulation also contains repopulating cells13,14. We demonstrated that IF injection and eradication of CD122-positive cells + +/low SRC15. represents the most sensitive assay for CD34 CD38 Previously, using limiting dilution analysis, Bhatia et al.12 showed that the + frequency of SRC (upon IV injection) in the CD34 CD38 subpopulation was 1 in 617 cells. Using the novel IF model and limiting dilution approach we showed that this frequency was 1 in 121 cells (McKenzie et al, Blood in press). To further purify this subpopulation we exploited rhodamine (Rho), a fluorescent dye that binds to active mitochondria in cells, thus reflecting the metabolic state of the cell16,17,18. Rho efflux is mediated by P-glycoprotein, encoded by multidrug resistance gene-119. Murine long-term HSC were + enriched based on low retention of Rho1. We sorted Lin CD34 CD38 cells into
48
O.I. GAN ET AL.
two subpopulations: 20% of cells with the lowest Rho retention and 20% with the highest (McKenzie et al., Blood in press) and injected equivalent numbers + of cells into recipient mice. At seven weeks post-transplantation, CD34 CD38 + Rholow cells established significantly higher grafts than CD34 CD38 Rhohigh + cells (75 ± 11% versus 24 ± 12%, respectively), suggesting that CD34 CD38 Rholow phenotype may enrich for HSC. Limiting dilution analysis was performed to quantify SRC enrichment. The frequency of SRC was estimated at + 1 in 30 CD34 CD38 Rholow cells, which represents a 4-fold enrichment in + comparison to the CD34 CD38 population. Therefore, this improved protocol is a step towards achieving a homogeneous population of HSC. Interestingly, despite the big differences in frequencies of SRC in + + CD34 CD38+/low and in CD34 CD38 subpopulations (namely 1 in 500010 and 1 in 121, respectively), the overall content of repopulating cells in both populations is comparable because the former represents about 40% of all Lin + CD34 cells, and the latter is about 2-5%. However, the question regarding + + +/low cells in comparison to CD34 CD38 cells longevity of CD34 CD38 remained unanswered. 4. Self-Renewal Properties of Human HSC Self-renewal, the distinguishing property of HSC, was previously not evaluated due to the limitation of engraftment in secondary recipients7. To circumvent this limitation, we employed the new NOD/SCID model (IF injection combined with anti-CD122 treatment) coupled with lentiviral marking to address possible differences in longevity and self-renewal between the different populations of + + Lin CD34 cord blood cells. Upon injection of CD34 CD38+/low cells, as previously shown, a substantial myelo-erythroid engraftment was observed at 3 weeks following transplantation. These cells were also able to provide lymphomyeloid repopulation at 12 weeks post-transplantation15,20. Therefore, this cell subpopulation fulfilled both the long-term and multilineage requirement of stem cells. However, their self-renewal ability was not known. Thus, + CD34 CD38+/low cells were sorted, transduced with lentiviral vector and injected IF into pre-conditioned recipients20. Several weeks following transplantation, the primary recipients were sacrificed and cells from the injected femur as well as the cells from other bones (designated here as the remaining bone marrow [BM]) were analyzed for the presence of human cells, and an aliquot of cells were stored for Southern blot analysis. The remaining cells were injected into secondary recipients (cells from the right femur of the primary mouse were injected into one secondary recipient and cells from the BM of the primary mouse were injected into a separate secondary recipient) and sacrificed several weeks later. Two secondary recipients were transplanted from one
HETEROGENEITY OF HUMAN HSC
49
primary recipient in order to determine if there was a difference in the selfrenewing fate of daughter cells that remained at the site of injection versus those that migrated to other hematopoietic sites. Surprisingly, a robust human multilineage graft was observed in the secondary recipients of primary injected right femur cells as well as BM cells, establishing that CD34+CD38+/low population contains SRC with self-renewal potential. Southern blot analysis of the clonal composition of the grafts showed that self-renewal of SRC was highly heterogeneous. Thus, some SRC made major contributions to all hematopoietic territories of secondary mice, whereas others did not engraft secondary recipients. Interestingly, in some cases, clones that were undetected in primary recipients were now detected only in secondary mice, suggesting that upon transplantation into primary mice, SRC were in a (semi)-quiescent state and secondary transplantation provided a stimulus for their activation. Heterogeneity in self-renewal properties of SRC could be attributed to the nature of their cell source; indeed, it is possible that in a more + pure SRC subpopulation (namely Lin CD34 CD38 ) the self-renewal behavior may be more homogeneous and predictable. To test the repopulation properties of a more highly purified cell population, + we used IF injection of CD34 CD38 cells into pre-conditioned mice. This also resulted in rapid (2-3-weeks) erythromyeloid engraftment. The overall engraftment level increased over time and by 12 weeks post-transplantation the majority of the graft was comprised of human lymphoid cells. Similar to the + +/low cells, the injected right femur and BM experimental design of CD34 CD38 + cells from the primary recipient of CD34 CD38 cells were transplanted into separate secondary recipients. Both cells sources established significant human grafts in secondary recipients. The clonal composition of the grafts was similar + +//low cells. There were many SRC detected to that described for CD34 CD38 only in primary recipients that extinguished in secondary recipients. There were also clones that were activated upon secondary transplantation from a quiescent state in primary recipients. Finally, in recipients of both injected femur and the rest of the BM there were self-renewing SRC. Therefore, both + +/low + and CD34 CD38 subpopulations contains SRC with heteroCD34 CD38 geneous self-renewal potential. To assess the clonal behavior of SRC in the entire human HSC compartment, we used Lin CB cells transduced with a lentiviral vector encoding EGFP. Recently, concerns have been raised regarding clonal selection following retroviral marking21. In our lentiviral marking experiments there was no significant increase in the proportion of marked EGFP-positive cells in 72 mice analyzed over 30 weeks, a finding consistent with the absence of clonal dominance of marked human HSC with a third-generation lentiviral vector20. To study the clonal dynamics of SRC we monitored more than 400 clones in 44
50
O.I. GAN ET AL.
primary and secondary recipients over 7 months and found the same three basic patterns of self-renewal seen after transplantation of purified cells: some clones were present only in primary recipients; some were activated in secondary mice; and some self-renewed. The long-term analysis of the clonal composition of primary and secondary mice provided insight into HSC dynamics following transplantation. In the field of hematopoiesis, two general ideas exist about the fate of HSC following transplantation and during steady-state hematopoiesis 22. The first model, clonal succession, postulates that a small subset of stem cells provides blood reconstitution after irradiation, with consequent exhaustion due to differentiation and subsequent replacement by other activated stem cells23,24. However, several studies in mice, cats and nonhuman primates were incompatible with the clonal succession model5,25,26. According to the second model, clonal maintenance, there is a period of clonal instability during early reconstitution followed by maintenance of the blood production by a subset of cells. Our clonal studies over 7 months following blood reconstitution were inconsistent with the clonal succession model and supported the clonal maintenance model, in which long-term hematopoiesis in maintained by stable clones after an initial period of clonal flux20. The extensive analysis of the fate of many clones in primary and secondary recipients allowed us to approach another long-standing question in the field of HSC biology. More than 40 years ago Till et al27 proposed that the selfrenewing fate of individual murine spleen colony-forming cells (CFU-S) is governed by stochastic processes; although the fate of any single CFU-S is uncertain, the population of HSC would appear to have predictable and ordered fates. Later, studies on cats demonstrated that the highly variable repopulation kinetics could also be replicated by computer simulation according to the stochastic model28. The alternative model of HSC control proposes that fate choices of any individual HSC are deterministic and can be predicted. In support of this hypothesis were studies in which long-term and short-term HCS were physically separated from progenitor cells based on their phenotypic profiles, indicating that an ordered developmental program is established in the downstream progeny of long-term HSC29-32. However, after the injection of single HSC there was broad heterogeneity in percent engraftment and wide variation in self-renewal potential1,33, suggesting the existence of stochastic elements in HSC fate. Our analysis of the fate of SRC clones provides several lines of evidence favoring the stochastic model of stem cell self-renewal mechanisms. The localized cell delivery through IF injection provided a unique opportunity to evaluate repopulation, and more important, self-renewal capacities of SRC daughter cells. For example, we observed cases where one daughter SRC resided in the injected femur of the primary mouse in a quiescent
HETEROGENEITY OF HUMAN HSC
51
or slowly dividing state, and thus was not detected. However, in the secondary recipient, this daughter SRC was activated to proliferate and produced a substantial clone of lympho-myeloid progeny. In contrast, the other daughter cell remained active in both the primary and secondary recipients, generating a large clone in both mice. Our data, taken together with the murine HSC purification experiments, allowed us to propose an integrated model20 in which regulation of self-renewal versus differentiation decisions of HSC is mostly stochastic, however, once a decision to commit to differentiation is made, immediate downstream progeny are funneled into a more rigid developmental program. In conclusion, the SRC assay provided us a unique opportunity to gain insights into the developmental program of human HSC biology. We revealed + phenotypic heterogeneity of human HSC where CD34 CD38 and + CD34 CD38+/low subpopulations extensively differ in the frequency of SRC, but possess the same ability for short- and long-term repopulation. We also showed the functional heterogeneity of all SRC as short-term and long-term repopulating cells, and their wide heterogeneity in self-renewal potential.
References 1. Benveniste P, Cantin C, Hyam D, Iscove NN. Hematopoietic stem cells engraft in mice with absolute efficiency. Nat Immunol. 2003;4:708-713. 2. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109-1121. 3. Dick JE, Guenechea G, Gan OI, Dorrell C. In vivo dynamics of human stem cell repopulation in NOD/SCID mice. Ann N Y Acad Sci. 2001;938:184-190. 4. Larochelle A, Vormoor J, Hanenberg H, et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med. 1996;2:1329-1337. 5. Jordan CT, Lemischka IR. Clonal and systemic analysis of long-term hematopoiesis in the mouse. Genes Dev. 1990;4:220-232. 6. Lemischka IR, Raulet DH, Mulligan RC. Developmental potential and dynamic behavior of hematopoietic stem cells. Cell. 1986;45:917-927. 7. Guenechea G, Gan OI, Dorrell C, Dick JE. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol. 2001;2:75-82. 8. Guenechea G, Gan OI, Inamitsu T, et al. Transduction of human CD34+ CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. Mol Ther. 2000;1:566-573. 9. Mazurier F, Gan O, McKenzie J, Doedens M, Dick J. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood. 2004;103:545-552.
52
O.I. GAN ET AL.
10. Mazurier F, Doedens M, Gan OI, Dick JE. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med. 2003;9:959-963. 11. Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID- repopulating activity. Nat Med. 1998;4:1038-1045. 12. Bhatia M, Wang JCY, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA. 1997;94:5320-5325. 13. Glimm H, Eisterer W, Lee K, et al. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice. J Clin Invest. 2001;107:199-206. 14. Hogan CJ, Shpall EJ, Keller G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci U S A. 2002;99:413-418. 15. McKenzie JL, Gan OI, Doedens M, Dick JE. Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells. Blood. 2005;106:1259-1261. 16. Johnson LV, Walsh ML, Chen LB. Localization of mitochondria in living cells with rhodamine 123. Proc Natl Acad Sci U S A. 1980;77:990-994. 17. Zijlmans JM, Visser JW, Kleiverda K, Kluin PM, Willemze R, Fibbe WE. Modification of rhodamine staining allows identification of hematopoietic stem cells with preferential shortterm or long-term bone marrow-repopulating ability. Proc Natl Acad Sci U S A. 1995;92:8901-8905. 18. Kim M, Cooper DD, Hayes SF, Spangrude GJ. Rhodamine-123 staining in hematopoietic stem cells of young mice indicates mitochondrial activation rather than dye efflux. Blood. 1998;91:4106-4117. 19. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 1991;66:85-94. 20. McKenzie JL, Gan OI, Doedens M, Wang JC, Dick JE. Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nat Immunol. 2006;7:1225-1233. 21. Kustikova O, Fehse B, Modlich U, et al. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science. 2005;308:1171-1174. 22. Crooks GM, Weinberg K. The unpredictable stem cell. Nat Immunol. 2006;7:1129-1130. 23. Kay HEM. How many cell-generations? (Hypothesis). Lancet. 1965;1:418-419. 24. Drize NJ, Keller JR, Chertkov JL. Local clonal analysis of the hematopoietic system shows that multiple small short-living clones maintain life-long hematopoiesis in reconstituted mice. Blood. 1996;88:2927-2938. 25. Abkowitz JL, Persik MT, Shelton GH, et al. Behavior of hematopoietic stem cells in a large animal. Proc Natl Acad Sci U S A. 1995;92:2031-2035. 26. Schmidt M, Zickler P, Hoffmann G, et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood. 2002;100:2737-2743. 27. Till JE, McCulloch EA, Siminovitch L. A Stochastic Model of Stem Cell Proliferation Based on the Growth of Spleen Colony-Forming Cells. Proc Natl Acad Sci USA. 1964;51:29-36. 28. Abkowitz JL, Catlin SN, Guttorp P. Evidence that hematopoiesis may be a stochastic process in vivo. Nat Med. 1996;2:190-197. 29. Jones R, Wagner J, Celano P, Zicha M, Sharkis S. Separation of pluripotent haematopoietic stem cells from spleen colony-forming cells. Nature. 1990;347:188-189.
HETEROGENEITY OF HUMAN HSC
53
30. Trevisan M, Iscove NN. Phenotypic analysis of murine long-term hemopoietic reconstituting cells quantitated competitively in vivo and comparison with more advanced colony-forming progeny. J Exp Med. 1995;181:93-103. 31. Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci U S A. 2001;98:1454114546. 32. Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity. 1994;1:661-673. 33. Ema H, Sudo K, Seita J, et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev Cell. 2005;8:907-914.
ALTERATIONS OF FREQUENCY OF HEMATOPOIETIC PRECURSORS IN MICE SUBJECTED TO MULTIPLE COURSES OF LOW-DOSE G-CSF INJECTIONS I.N. NIFONTOVA* , D.A. SVINAREVA, J.L. CHERTKOV, V.G. SAVCHENKO, N.J. DRIZE National Hematology Research Centre, Moscow, Russian Federation
Keywords: granulocyte colony-stimulating factor (G-CSF); LTC-IC; CFU-C; granulocytes
Abstract. G-CSF is a major extracellular regulator of hematopoiesis and the most used cytokine in clinical practice. Coherently with and for a long time after the repeated injections of low doses of G-CSF the study of alterations in hematopoietic precursor cells concentration in the bone marrow of mice was undertaken. G-CSF treatment did not affect the number of granulocytes and oligopotent precursor cells (CFU-C). However, frequency of early multipotent stem cells (LTC-IC) decreased one month after the last (7th) course of G-CSF injections, moreover it halved during the following year. The exhaustion of LTC-IC after G-CSF treatment is discussed.
1. Introduction Mobilised peripheral blood stem cells are used as the source of stem cells for transplantation, moreover most allogeneic transplants now utilize peripheral blood rather than bone marrow1. A variety of mobilisation regimes are used but granulocyte colony-stimulating factor (G-CSF) is the most frequently employed2,3. In some cases G-CSF treatment of volunteers is involved in experimental researches4,5,6. The main therapeutic G-CSF application is
______ * To whom correspondence should be addressed. Irina N. Nifontova, National Hematology Research Centre, Russian Academy of Medical Science, Novozikovskiy pr. 4a, Moscow 125167, Russian Federation. E-mail:
[email protected]
55 N. M. Bilko et al. (eds.), Stem Cells and their Potential for Clinical Application, 55–62. © 2008 Springer.
56
I.N. NIFONTOVA ET AL.
correction of neutropenia of various ethyology7,8,9. The remote consequences of G-CSF injections are not studied enough. Mobilization and homing of hematopoietic precursors are the mirror processes sharing the same mediators and analogous signaling pathways10,11. Despite increasing application of mobilized hematopoietic stem cells (HSC) the mechanism of their motion in and out of the bone marrow is not completely understood yet. The involvement of such adhesion molecules as integrins β1, β2 interacting with VLA-4, VLA-5, LFA-1, as well as L-selectin, stroma derived factor SDF-1 with it's receptor CXCR4 and some of the metalloproteases was previously shown12. The exact mechanism G-SCF influences target cells is not yet understood fully. Efficiency of HSC mobilization depends on longevity of G-SCF injections and the dosage used. In humans for supporting treatment after the chemotherapy as well as for the HSC mobilization 5-10 µg/kg for 7-14 days is used13. In some cases patients receive multiple repeated G-SCF courses. The mobilizing dose for murine HSC is considerably higher than for human ones: usually from 200 up to 300 µg/kg is injected for 5-17 days leading to more then 10-fold increase of the number of different hematopoietic precursors in the peripheral blood14,15. When 10 times lower dose is used CFU-S number in the peripheral blood experienced a 4-fold increase (versus 32-fold increase in case the mobilizing concentration is used) while in the bone marrow HSC frequency almost was halved 15. During the mobilization HSC are loosing the connection with the niche cells, though returning to their “places” later. Such a disturbance may cause an accelerating turnover of HSC. The alterations of concentration of hematopoietic precursors of different stages of maturation in the bone marrow of mice subjected to multiple G-CSF treatment were studied in the presented work. 2. Materials and Methods (CBA x C57Bl6)F1 3 months-old female mice were obtained from Stolbovaya Animal Centre, Moscow Region, Russian Federation. Weight in the beginning of the G-CSF courses varied between 24 and 26 grams. Granulocyte colony-stimulating factor (G-CSF) (Neupogen 48 Mio U, F.Hoffmann-La Roche, Switzerland) was dissolved in 0,85% NaCl with 0,1% bovine serum albumin (Sigma) and was injected subcutaneously (25 µg/kg in 0,2 ml of 0,85% NaCl) once a day for 4 days. White blood cells (WBC) count and the hemogram of the peripheral blood were analyzed before and one day after each course. Seven courses were performed during half-year. Concentration of early hematopoietic precursors was estimated through long-term culture initiating cells (LTC-IC) frequency. A day prior to the test the MS-5 cell line16 was seeded in 60 wells of 96-well cultivation plate. From 3 to 5
EFFECTS OF MULTIPLE G-CSF INJECTIONS IN MICE
57
thousands of MS-5 cells were seeded into each well. All of the margin wells were filled with 0,1M NaOH to prevent plate from drying. Bone marrow (BM) cells were taken from the femur of live mice under the light anesthesia through the knee joint. BM cells were suspended in the Fisher medium and plated onto MS-5 containing wells in four consecutive dilutions. Usually 60, 20, 6,7 and 2,25×103 cells were plated per well in each dilution. Cells were cultivated in nutrient medium adapted for long-term bone marrow cultures17 in 33°C humidified atmosphere with 5% CO2. A half of the medium was renewed once a week. After 6 weeks of cultivation the medium was replaced with semisolid medium containing methylcellulose 1,1% in αMEM, 30% fetal bovine serum, 2u/ml erythropoetin, and 10% conditioned medium (mixture of WEHI 3B18 2 parts and L92919 1 part) as a source of G-CSF, M-CSF, GM-CSF and Il-3. Two weeks later the wells with colonies formed were counted under the inverted microscope. LTC-IC frequency was calculated using Puasson’s statistics20. More mature hematopoietic progenitors (CFU-C) frequency was estimated using standard CFU-C assay 21. 3. Results Prolonged low-dose G-CSF treatment doesn’t lead to any significant alterations of WBC count in peripheral blood (Fig. 1).
Figure 1. WBC count of the periferal blood of the mice during and after the G-CSF courses.
58
I.N. NIFONTOVA ET AL.
Frequency of hematopoietic precursors of different stages of maturation (CFU-C and LTC-IC) was estimated during 2nd , 3rd and 5th course and 1, 4 and 12 months since the last G-CSF course. Cells, capable to generate colonies in the semisolid medium (CFU-C), differ by their maturation status, the earliest ones producing the detectable colonies after 21 days of cultivation22. The most mature progenitors, generating the colony after 7 days in culture, do not respond to G-CSF injections neither during the courses themselves (Fig. 2a), nor after the injections are done (Fig. 3а). The absence of effect is confirmed by unaffected hemogram of peripheral blood of treated animals (data not shown). Less differentiated precursors, capable to generate colonies in semisolid medium after 21 days of cultivation, do not respond to G-CSF injection either (Fig. 2b, Fig. 3b).
Figure 2. (A) CFU-C 7 frequency in bone marrow of mice during low-dose G-CSF treatment. (B) CFU-C 21 frequency in bone marrow of mice during low-dose G-CSF treatment. (C) LTC-IC frequency in bone marrow of mice during low-dose G-CSF treatment.
EFFECTS OF MULTIPLE G-CSF INJECTIONS IN MICE
59
Figure 3. (A) CFU-C 7 frequency in bone marrow of mice after low-dose G-CSF treatment. (B) CFU-C 21 frequency in bone marrow of mice after low-dose G-CSF treatment. (C) LTC-IC frequency in bone marrow of mice after low-dose G-CSF treatment.
It was previously shown that six-day course of both 25 and 250 µg/kg of GCSF injections had halved the concentration of preHSC (an early hematopoietic precursor detected like LTC-IC in culture after 5 weeks)23 but it normalized again during the following month15,24. In the set of experiments described above involving a non-mobilizing 10-fold lower dose course repeating seven times per half-year the significant (p< 0.01) increase of LTC-IC frequency was observed after the 4th course (Fig. 2с). One month since the last course LTC-IC frequency has been, on the contrary, 2-fold lower then the normal amount (p< 0.01) (Fig 3с). So unlike single course of high doses of G-CSF, repeated low-dose treatment leads to decrease in of early hematopoietic precursor frequency. During the following year it halved, decreasing even further. The data shows that the more mature progenitors are the least sensitive to repeated G-CSF injections. They generate normal amounts of mature granulocytes during the whole set of courses. The frequency of the early
60
I.N. NIFONTOVA ET AL.
hematopoietic precursors significantly decreases after long-term G-CSF treatment. 4. Discussion Multiple courses of low doses of G-CSF lead to decrease in frequency of early hematopoietic precursors (LTC-IC) in the bone marrow. The concentration of more differentiated progenitors CFU-C-7 and CFU-C-21 as well as mature granulocytes does not react to the dose of factor used in the described experiments. G-CSF is known to stimulate proliferation of early multipotent HCS in vitro (multipotential blast cell colonies)25. One might expect a continuous course of injections (even low-dose) should lead to the increase of concentration of HSC of various sets of hematopoietic hierarchy. However CFU-C frequency was not affected which could be explained by stable local regulation of these types of precursor by cells of endothelial niche where they are localized26. Less differentiated precursors are regulated by osteoblastic niche27 and are localized on the endosteal surface of the bone. G-CSF even in low doses activates osteoclasts that lead to osteopenia and decrease in the bone mass28,29. Activated osteoclasts not only take part in the mobilization of HSC process but change the endostal surface itself 30. Moreover G-CSF activates the secretion of metalloproteases by bone marrow cells and this is a key factor of dissociation of HSC from stromal cells during the mobilization process31. The whole data explains the decrease in early HSC frequency observed in the bone marrow of treated mice. Apparently, osteoclasts and G-CSF mobilize hematopoietic precursors from theirs niches, on the other hand, homing and adhesion of mobilized precursors are impaired by the same factors. So these precursors could irreversibly differentiate, begin to proliferate or undergo apoptosis. Therefore multiple treatments with G-CSF might exhaust HSC pool in the bone marrow. G-CSF application to the healthy donors should be performed with the most precaution possible, as its remote consequences are not scrutinized and need a further investigation.
References 1. Gratwohl A, Baldomero H, Schmid O et al. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplant. 2005;36:575-590. 2. Remberger M, Ringden O, Blau IW et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood. 2001;98:1739-1745.
EFFECTS OF MULTIPLE G-CSF INJECTIONS IN MICE
61
3. Korbling M, Anderlini P, Hematology TA. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood. 2001;98:29002908. 4. Angelopoulou M, Novelli E, Grove JE et al. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol. 2003;31:413-420. 5. Brenner S, Whiting-Theobald N, Kawai T et al. CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. Stem Cells. 2004;22:1128-1133. 6. Selleri C, Montuori N, Ricci P et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood. 2005;105:2198-2205. 7. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-170. 8. Trillet-Lenoir V, Green J, Manegold C et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319-324. 9. Blackwell S, Crawford J. Filgrastim (r-metHuG-CSF) in the chemotherapy setting. In: Morstyn G, Dexter TM, eds. Filgrastim (r-metHuG-CSF) in Clinical Practice.1994; New York: Marcel Dekker. 10. Kronenwett R, Graf T, Nedbal W et al. Inhibition of angiogenesis in vitro by alphav integrindirected antisense oligonucleotides. Cancer Gene Ther. 2002;9:587-596. 11. Cutler C, Antin JH. Peripheral blood stem cells for allogeneic transplantation: a review. Stem Cells. 2001;19:108-117. 12. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002;30:973-981. 13. Schwab G, Hecht T. Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): a new dimension in immunotherapy. Ann Hematol. 1994;69:1-9. 14. Molineux G, Pojda Z, Hampson IN et al. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood. 1990;76:2153-2158. 15. Drize N, Gan O, Zander A. Effect of recombinant human granulocyte colony-stimulating factor treatment of mice on spleen colony-forming unit number and self-renewal capacity. Exp Hematol. 1993;21:1289-1293. 16. Kobari L, Dubart A, Le Pesteur F et al. Hematopoietic-promoting activity of the murine stromal cell line MS-5 is not related to the expression of the major hematopoietic cytokines. J Cell Physiol. 1995;163:295-304. 17. Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol. 1977;91:335-344. 18. Prestidge RL, Watson JD, Urdal DL et al. Biochemical comparison of murine colonystimulating factors secreted by a T cell lymphoma and a myelomonocytic leukemia. J Immunol. 1984;133:293-298. 19. Mayer P. The growth of swine bone marrow cells in the presence of heterologous colony stimulating factor: characterization of the developing cell population. Comp Immunol Microbiol Infect Dis. 1983;6:171-187. 20. Nifontova IN, Ershler MA, Drize NI. Dynamics of precursor cell composition in bone marrow culture derived from mice deficient by tumor necrosis factor. Bull Exp Biol Med. 2003;135:285-288.
62
I.N. NIFONTOVA ET AL.
21. Drize NI, Drutskaya MS, Gerasimova LP et al. Changes in the hemopoietic system of mice deficient for tumor necrosis factor or lymphotoxin-alpha. Bull Exp Biol Med. 2000;130:676678. 22. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood. 1993;81:2844-2853. 23. Deriugina EI, Drize NI, Olovnikova NI et al. [The precursor hematopoietic cell: its origin in ontogeny, proliferative activity and proliferative potential]. Ontogenez. 1991;22:125-132. 24. Drize N, Chertkov J, Samoilina N et al. Effect of cytokine treatment (granulocyte colonystimulating factor and stem cell factor) on hematopoiesis and the circulating pool of hematopoietic stem cells in mice. Exp Hematol. 1996;24:816-822. 25. Ikebuchi K, Clark SC, Ihle JN et al. Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A. 1988;85:3445-3449. 26. Yin T, Li L. The stem cell niches in bone. J Clin Invest. 2006;116:1195-1201. 27. Taichman RS. Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood. 2005;105:2631-2639. 28. Takamatsu Y, Simmons PJ, Moore RJ et al. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood. 1998;92:3465-3473. 29. Kokai Y, Wada T, Oda T et al. Overexpression of granulocyte colony-stimulating factor induces severe osteopenia in developing mice that is partially prevented by a diet containing vitamin K2 (menatetrenone). Bone. 2002;30:880-885. 30. Kollet O, Dar A, Shivtiel S et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med. 2006;12:657-664. 31. Roberts AW. G-CSF: a key regulator of neutrophil production, but that’s not all! Growth Factors. 2005;23:33-41.
REGULATION OF HEMATOPOIESIS BY GROWTH FACTORS
E. RICHARD STANLEY* Albert Einstein College of Medicine, Bronx, New York, USA
Keywords: blood cells, macrophages, osteoclasts, review, CSF-1
Abstract. The history of the role of hematopoietic growth factors (HGFs) in the regulation of hematopoiesis is briefly reviewed, commencing with the studies that defined the hematopoietic stem cell and led to the development of in vitro assays for HGFs. The nature of HGF synergism and the underlying mechanisms, as well as the “permissive” versus “instructive” models of HGF action, are also discussed. In addition, work on one of the HGFs, colony stimulating factor-1 (CSF-1), is reviewed, including its function in development as revealed by studies of mouse mutants and its role in innate immunity, inflammatory disease and cancer. 1. Introduction Under the control of several cytokines, the proliferating and differentiating hematopoietic stem cell (HSC) gives rise to common myeloid and common lymphoid progenitor cells which, as they proliferate and differentiate, progressively develop a more restricted capacity for differentiation, eventually giving rise to progenitor cells that are capable of forming only one mature blood or lymphoid cell type. This process is regulated by hematopoietic growth factors (HGFs). The majority of HGFs were identified through the development of semisolid culture methods for bone marrow in which progenitor cells proliferate and differentiate to form macroscopic colonies of mature differentiated blood cells. Here the history of the development of our understanding of the HSC, the discovery of the HGFs and
______ *
To whom correspondence should be addressed. E. Richard Stanley, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461, USA
63 N. M. Bilko et al. (eds.), Stem Cells and their Potential for Clinical Application, 63–75. © 2008 Springer.
64
E. RICHARD STANLEY
the mechanisms by which they regulate HSC differentiation are briefly reviewed and followed by an outline of our own studies on the role of one HGF, colony stimulating factor-1 (CSF-1) in development and disease. 2. Hematopoietic Growth Factors 2.1. HEMATOPOIETIC STEM CELLS
The development of the spleen colony forming unit (CFU-s) assay of Till and McCulloch1 in which lethally irradiated mice intravenously injected with a single cell suspension of hematopoietic cells develop colonies containing red cells, granulocytes, macrophages and megakaryocytes in their spleens, paved the way to our current understanding of the pluripotent stem cell. Indeed, in subsequent studies this group presented criteria that defined stem cells as cells with the capacity to: a) self-replicate, b) proliferate extensively and c) to differentiate to all the mature blood and lymphoid cell types. While they showed that some CFU-s appeared to possess these characteristics, these workers were careful not to use the term “hematopoietic stem cell” to describe the entities in hematopoietic cell suspensions that gave rise to spleen colonies2. The heterogeneity of cell types within CFU-s colonies suggested that at best only some CFU-s were HSC. Subsequently, several experiments clearly established that the CFU-s assay does not measure HSC. First, most spleen colonies did not contain all the mature blood cell types. Second, colonies arising 7-10 days after cell transplantation were comprised of erythroid cells only and developed from different cells than 14-day colonies, which mostly contained cells of multiple lineage3. Third, the observed decline in CFU-s numbers upon repeated serial transplantation in lethally irradiated recipient mice was not expected of stem cells with the capacity to self-replicate4. Finally, in elegant experiments, it was shown that CFU-s content was not correlated with hematopoietic repopulating ability, by showing that bone marrow cells from mice treated previously with 5-fluorouracil were largely depleted of CFU-s, but strikingly enriched for hematopoietic repopulating activity5. These studies coupled with additional cell fractionation and transplantation studies have led to the following generally agreed upon characteristics of mouse hematopoietic cells: a) They are capable of long-term (> 6 months) repopulation of both myeloid and lymphoid systems, b) they represent 10-5 of the total bone marrow cells (by contrast, the frequency of CFU-s is 1 in 2,500) and c) they are not cycling or are very slowly cycling in the normal steady-state in vivo5,6.
REGULATION OF HEMATOPOIESIS BY GROWTH FACTORS
65
2.2. HGFS AND THEIR ACTIVITIES
Only one HGF, the red cell regulator, erythropoietin, had been discovered at the time the CFU-s assay was described7. The description of the CFU-s assay influenced the development of in vitro approaches to the culture of hematopoietic cells. The independent development, in 1966, of the semi-solid culture techniques for granulocyte/macrophage colony formation by hematopoietic cells by Pluznik and Sachs8 and Bradley and Metcalf 9, heralded a new era in which these and other in vitro culture systems were used to assay both the colony forming cells (CFU-c) giving rise to colonies and the colony stimulating factors (CSFs) regulating their development. Among the HGFs identified and/or studied using these approaches were “lineage-restricted” or “late-acting” HGFs that, in the absence of other cytokines, regulate primarily one cell lineage. 2.3. SYNERGISM BETWEEN HGFS
2.3.1. HGF Receptor Signaling HGF action on target cells is mediated by high affinity cell-surface receptors. These receptors transduce the binding of their cognate ligands to signals for survival, proliferation and differentiation. Binding of the HGF to their receptors, or to ligand binding subunits, results in extracellular cross-linking. This in turn leads to dimerization of the signaling subunit and tyrosine phosphorylation of its intracellular domain. This tyrosine phosphorylation may be mediated, in the case of receptor tyrosine kinases, by the intrinsic tyrosine kinase of the receptor itself or, in the case of other receptors, by tyrosine kinases they are pre-associated with. The receptor intracellular domain tyrosine residues so phosphorylated create binding sites for signaling molecules possessing phosphotyrosine binding domains. Aspects of the intracellular signaling pathways downstream of different receptors can be similar, because different activated receptor cytoplasmic domains often bind a common signaling molecule or family of signaling molecules10. 2.3.2. Requirement of Multiple HGFs for the Proliferation and Differentiation of Multipotent Cells Late-acting HGFs, like CSF-1 or EPO, are sufficient for the proliferation and differentiation of cells that are committed to the lineage they regulate and which selectively express their receptors. However, immature multipotent hematopoietic cells have been shown to coexpress different lineage-specific as well as
66
E. RICHARD STANLEY
multilineage HGF receptors at low levels11 and the in vitro proliferation and differentiation of these cells requires a combination of HGFs (e.g. SCF, IL-1, IL-3, IL-6, GM-CSF and CSF-1)12,13. As these cells differentiate, they lose the receptors for some HGFs (e.g. SCF or IL-3), while retaining receptors for particular lateacting HGFs (e.g. CSF-1 or EPO). Eventually they reach the stage of a committed progenitor cell, where their further proliferation and differentiation along one particular lineage is primarily regulated by one late-acting HGF. Commitment to a lineage is associated with increased expression of the lineage specific receptor14,15. 2.3.3. Mechanisms of HGF Synergism The synergism between late-acting, lineage-restricted HGFs, such as CSF-1 and EPO, with HGFs like SCF and IL-3, provides a mechanism for coupling the changes in levels of the late-acting HGF, which are tightly regulated by primary stimuli (e.g. hypoxia in the case of EPO), to the channeling of multipotent cells into a lineage to satisfy the demand for differentiated cells. Possible mechanisms underlying synergism include regulation of expression of the receptor of the synergizing HGF or synergism at the level of post-receptor signaling pathways. There is no strong evidence for direct HGF regulation of increased expression of the receptor for the synergizing HGF15. In contrast, synergism has been reported at the level of receptor signaling. The synergism between SCF and EPO in erythropoiesis appears to be regulated by direct association of the SCF receptor (SCFR) with the EPO receptor (EPOR). In this situation, the activation of the SCFR and its association with the EPOR apparently results in tyrosine phosphorylation of the EPOR at sites that differ from those phosphorylated as a result of EPO-induced EPOR dimerization16,17. Clearly, post-receptor synergism may also occur due to synergism between signaling pathways activated independently by the synergizing growth factors. 2.4. PERMISSIVE VERSUS INSTRUCTIVE MODELS OF HGF ACTION
HGFs regulate survival and proliferation of their target cells. A pertinent question, therefore, is whether their regulation of differentiation is “instructive” or “permissive”. In the permissive model, the growth factor does not have a role in multipotent progenitor commitment, but simply allows the survival and proliferation of committed cells. Support for this model has been provided by hybrid receptor experiments in which in which the mouse TPO receptor (TPOR) gene was replaced with gene encoding a chimeric receptor consisting of the extracellular domain and
REGULATION OF HEMATOPOIESIS BY GROWTH FACTORS
67
transmembrane domain of the TPOR and the cytoplasmic domain of the G-CSFR. The resulting mice had a normal platelet count, indicating that the cytoplasmic domain of the G-CSFR can functionally replace that of the TPOR to support normal megakaryocytopoiesis and platelet formation18. This implies that the cytoplasmic domain of the TPOR does not have an instructive role, or that if it does, it must be shared with the instructive function of the G-CSFR cytoplasmic domain. Indeed, these two very similar receptors quite possibly share a common instructive signaling pathway, as their functions can be largely separated by a) their different patterns of expression on hematopoietic cells and b) in cells in which their expression overlaps, by the differential regulation of their cytokines, TPO being constitutively present in the circulation and G-CSF induced. In support of the instructive model, it has been shown that the common lymphoid progenitor cell can be redirected to the myeloid lineage by stimulation through exogenously expressed IL-2 and GM-CSF receptors and that the granulocyte and monocyte differentiation signals are regulated by different cytoplasmic domains of the IL-2 receptor19. It is therefore likely that both instructive and permissive mechanisms are utilized, their use depending on the receptors and commitment steps involved. 2.5. REMAINING QUESTIONS
While much has been achieved in the last 50 years of intensive research in the area of hematopoiesis, important questions remain unanswered. One question that is not yet clear is whether all the HGFs are known. Interestingly, there appears to be at least one novel HGF for a known receptor. The existence of this HGF, predicted from molecular genetic studies in mice, was recently revealed using a high throughput screening approach (section 3.2). In another important area, we are largely ignorant of the signaling mechanisms underlying cell commitment and HGF synergism. Similarly, we have very little information about HGF expression and function in the stem cell niche. Much remains to be learned. 3. Role of Colony Stimulating Factor-1 in Development and Disease 3.1. CSF-1 AND THE CSF-1 RECEPTOR
CSF-1 (also known as macrophage CSF or M-CSF) locally and humorally regulates the survival, proliferation, differentiation and function of mononuclear phagocytic cells (committed progenitor, monoblast, promonocyte, monocyte, tissue
68
E. RICHARD STANLEY
macrophage), Langerhans cells and osteoclasts, as well as cells of the female reproductive tract20-23. CSF-1 is synthesized in the endoplasmic reticulum to yield a disulfide-linked, homodimeric, membrane-spanning precursor that contains 522 amino acids. In secretory vesicles, the mature forms of CSF-1, either glycoprotein (~100-kDa) or proteoglycan (~120-160-kDa)24, are cleaved from this precursor and secreted. However, a smaller CSF-1 precursor (224 amino acids), encoded by an mRNA in which the proteolytic cleavage sites have been spliced out, is stably expressed on the cell surface when the secretory vesicle fuses with the plasma membrane. All these isoforms contain the amino terminal 150 amino acids of CSF1 that are sufficient for in vitro biological activity and that possess a 4 α-helical bundle/anti-parallel ß-ribbon structure25. The CSF-1R is a tyrosine kinase that is identical to the c-fms proto oncogene product from which the v-fms oncogene is derived26. The mature protein includes an immunoglobulin-like extracellular domain, a single hydrophobic transmembrane domain and an intracellular tyrosine kinase domain that is interrupted by an unrelated sequence of 72 amino acids27. The receptor is expressed on mononuclear phagocytes, osteoclasts, Langerhans cells, as well as cells of the female reproductive tract23. Extracellular ligand binding by the CSF-1R results in the formation or stabilization of a receptor dimer that leads to receptor activation and receptor tyrosine phosphorylation and the consequent tyrosine phosphorylation of many other proteins, some of which have been shown to have an important role in transducing the responses to CSF-1 binding28,29. After activation and signaling, the majority of the receptor-ligand complexes are internalized and destroyed intralysosomally30,31. However, signaling through the down-regulated, cell-surface CSF-1R is maintained as CSF-1 must be present for the 10-12h lag phase following CSF-1 addition for entry of cells of into S phase32. 3.2. CSF-1/CSF-1 RECEPTOR MUTATIONS REVEAL NOVEL ROLES FOR CSF-1 IN DEVELOPMENT
CSF-1 is synthesized by many different cell types including fibroblasts, endothelial cells, bone marrow stromal cells, osteoblasts, keratinocytes, astrocytes, myoblasts and, during pregnancy, under the control of estrogen and progesterone, by uterine epithelial cells24. Circulating CSF-1 (t1/2 = ~10 min) is synthesized by endothelial cells and smooth muscle cells. It is primarily cleared by CSF-1R-mediated internalization and destruction by Kupffer cells. Thus the number of sinusoidally located macrophages actually determines the concentration of the cytokine
REGULATION OF HEMATOPOIESIS BY GROWTH FACTORS
69
responsible for their production, a simple feedback control33. Circulating CSF-1 is elevated in response to bacterial endotoxin and to bacterial, viral and parasitic infections24,34-36. Repeated injections of recombinant CSF-1 in mice elevates the circulating monocyte count ~10-fold and increases macrophage numbers in certain areas of the periphery37. The role of CSF-1 in development has been studied in the osteopetrotic (op/op) mutant mouse38. This mouse possesses an inactivating mutation in the CSF-1 gene and fails to produce CSF-139,40. Compared with control mice, op/op mice exhibit impaired bone resorption associated with a paucity of osteoclasts, have no incisors, poor fertility, a lower body weight, a shorter average life span and deficiencies in macrophages in certain tissues23,41,42. Restoration of circulating CSF-1 in newborn op/op mice by injection cured their osteopetrosis and monocytopenia and some, but not all, of the tissue macrophage populations23,41. These and other studies a) showed that CSF-1 is the primary, but not the only regulator of macrophage and osteoclast production, b) indicated that it regulates both humorally and locally and c) suggested that macrophages and osteoclasts not only have scavenger roles but also play trophic roles that are critical for the development and maintenance of the tissues in which they reside. CSF-1 is expressed as a secreted glycoprotein, a secreted proteoglycan and a membrane-spanning, cell-surface glycoprotein20. Transgenic mice exclusively expressing each isoform or their precursors in a normal tissue-specific and developmental pattern exhibit distinct phenotypic differences, indicating differential effects of each CSF-1 isoform43-45. Evidence indicates that the cell surface form of CSF-1 is involved in local regulation that involves cell-cell interaction44. Compared with either the cell surface or secreted glycoprotein isoforms, the proteoglycan form of CSF-1 most effectively corrects the CSF-1-deficient phenotype, particularly the osteopetrosis, indicating that it is either differentially localized to specific extracellular matrices or signals differently in some cell types45. A recent study indicates that there are opposing roles of CSF-1 isoforms in the regulation of hematopoietic cells. When primary, primitive hematopoietic progenitor cells were cocultured with epithelial cells transduced with genes encoding either secreted- or cellsurface- CSF-1, the cells expressing cell-surface CSF-1 stimulated long-term proliferation and self-renewal, whereas those expressing secreted CSF-1 did not support long-term proliferation of the primitive cells and instead promoted their differentiation to macrophages46. Differential effects of these isoforms have also been observed in inflammation and cancer21.
70
E. RICHARD STANLEY
Targeted inactivation of the CSF-1 receptor (CSF-1R) revealed that the CSF1R-deficient mice possessed all of the defects of the CSF-1-deficient mice47,48. Thus all of the effects of CSF-1 are mediated by the CSF-1R encoded by the c-fms protooncogene. However, the phenotype of the CSF-1R-deficient mice is more severe than the phenotype of the CSF-1-deficient mice, indicating that there are CSF-1-independent effects of the CSF-1R. This raised the possibility that either a) there was another, as yet undiscovered, ligand, b) there was CSF-1-independent trans-receptor signaling by another receptor/ligand pair as reported for the EPOR16,17, or that another kind of ligand-independent signaling was possible in some cell types. A recent report indicates that a second ligand for the CSF-1R does exist49 and our current studies are aimed at determining whether regulation by this ligand and CSF-1 is sufficient to account for the CSF-1R deficient phenotype. Detailed analysis of the CSF-1/CSF-1R-deficient phenotypes is far from complete. Apart from the recent description of their involvement in the generation of Langerhans cells47,50, current studies indicate additional roles in the gut and brain. 3.3. CSF-1 IN DISEASE
Studies on the role of CSF-1 in development demonstrate that there is a variable requirement for CSF-1 in the development of individual mononuclear phagocyte populations, the development of macrophages in some tissues being independent of CSF-141. However, these macrophages uniformly express the CSF-1 receptor, and their morphology, phagocytosis and responsiveness to infectious and non-infectious stimuli is regulated by CSF-1. CSF-1 plays important roles in innate immunity and inflammatory diseases, including systemic lupus erythematosus, arthritis, atherosclerosis and obesity. In several inflammatory conditions, activation of macrophages involves a CSF-1 autocrine loop. The reader is referred to a recent review21 where these roles of CSF-1 have been discussed. CSF-1 also plays an important role in cancer. Earlier studies in tumors of the female reproductive tract demonstrated elevated circulating CSF-1, a high incidence of tumor expression of both CSF-1 and the CSF-1R and high levels of tumor-associated macrophages in patients with a poor survival24,51-53. In addition, mouse mammary tumor virus-driven polyoma middle-T transgenic tumors developing in CSF-1-deficient mice display decreased recruitment of macrophages, slowed tumor progression and almost complete suppression of metastasis54. In mice bearing human malignant tumor xenografts, 14 days of mouse CSF-1 blockade with
REGULATION OF HEMATOPOIESIS BY GROWTH FACTORS
71
antisense oligonucleotides, siRNA or anti-CSF-1 antibody suppressed tumor growth, decreased the expression of matrix metalloproteinase-2 and angiogenic factors, reduced tumor vascularity, reversed the chemo-resistance and improved survival of mice55-57. These studies indicate that host CSF-1 production plays an important role in the late stages of tumor growth, metastasis and angiogenesis and that CSF-1 blockade could be efficacious in treatment. In investigations of the interaction between CSF-1 regulated macrophages and tumor cells, it was shown that both mammary carcinoma cells and macrophages comigrate and depend upon each other to be invasive in vivo and in vitro58,59. Macrophages express EGF, which promotes both carcinoma cell invasion and carcinoma cell production of CSF-1, which in turn promotes the expression of EGF by macrophages. Disruption of this loop by blockade of either EGF receptor or CSF-1 receptor signaling is sufficient to inhibit both macrophage and tumor cell migration and invasion. These studies emphasize the importance of interactions between tumor cells and the tumor microenvironment in tumor progression and metastasis. The involvement of CSF-1 in innate immunity, cancer and a variety of inflammatory diseases renders CSF-1 signaling as an attractive therapeutic target. In specific disease situations, such as cancer and atherosclerosis21, individual isoforms of CSF-1 might have opposing effects and studies with mice that exclusively express each CSF-1 isoform43-45 will be useful in dissecting their roles in immunity and disease. Autocrine regulation by CSF-1 is also relevant and has been shown in mononuclear phagocyte activation leading to immunity (e.g. microglia or allograft rejection) or disease (e.g. LC histiocytosis) 21. Disease model studies involving CSF-1- and CSF-1R-deficient mice that have defects in both mononuclear phagocyte development and function complicate our understanding of regulation by CSF-1 in the adult. An accurate understanding of regulation by CSF1 in disease will depend upon the use of conditional ablation of CSF-1 and CSF-1R genes or antibodies to CSF-1 and the CSF-1R, or CSF-1R inhibitors, in fully developed adult mice. Acknowledgements
This work was supported by National Institutes of Health grants, CA32551, CA26504 and P01 100324.
72
E. RICHARD STANLEY
References 1. J. E. Till and E. A. McCulloch, A direct measurement of the radiation sensitivity of normal mouse bone marrow cells, Radiat.Res. 14, 213-222 (1961). 2. A. M. Wu, J. E. Till, L. Siminovitch, and E. A. McCulloch, A cytological study of the capacity for differentiation of normal hematopoietic colony-forming cells, J.Cell.Physiol. 69, 177-184 (1967). 3. M. C. Magli, N. N. Iscove, and N. Odartchenko, Transient nature of early haematopoietic spleen colonies, Nature 295(5849), 527-529 (1982). 4. E. A. Ross, N. Anderson, and H. S. Micklem, Serial depletion and regeneration of the murine hematopoietic system. Implications for hematopoietic organization and the study of cellular aging, J.Exp.Med. 155(2), 432-444 (1982). 5. G. S. Hodgson and T. R. Bradley, Properties of haematopoietic stem cells surviving 5-fluorouracil treatment: evidence for a pre-CFU-S cell?, Nature 281(5730), 381-382 (1979). 6. D. E. Harrison, C. M. Astle, and C. Lerner, Number and continuous proliferative pattern of transplanted primitive immunohematopoietic stem cells, Proc.Natl.Acad.Sci.USA 85, 822-826 (1988). 7. P. Carnot and C. Deflandre, Sur l’activite hematopoietique des serum au cours de la regeneration du sang, Acad. Sci. 3, 384 (1906). 8. D. H. Pluznik and L. Sachs, The cloning of normal “mast” cells in tissue culture, J.Cell.Comp.Physiol. 66, 319-324 (1965). 9. T. R. Bradley and D. Metcalf, The growth of mouse bone marrow cells in vitro, Australian Journal of Experimental Biology and Medical Science 44, 287-299 (1966). 10. E. R. Stanley, in: Samter’s Immunological Diseases, edited by K. F. Austen, M. M. Frank, J. P. Atkinson, H. Cantor (Lippincott Williams and Wilkins, Philadelphia, 2001), pp. 175-193. 11. M. A. Cross and T. Enver, The lineage commitment of haemopoietic progenitor cells, Current Opinion in Genetics and Development 7, 609-613 (1997). 12. T. R. Bradley and G. S. Hodgson, Detection of primitive macrophage progenitor cells in mouse bone marrow, Blood 54, 1446-1450 (1979). 13. E. R. Stanley, A. Bartocci, D. Patinkin, M. Rosendaal, and T. R. Bradley, Regulation of very primitive multipotent hematopoietic cells by hemopoietin-1, Cell 45, 667-674 (1986). 14. R. J. Tushinski, I. T.Oliver, L. J. Guilbert, P. W. Tynan, J. R. Warner, and E. R. Stanley, Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy, Cell 28, 71-81 (1982). 15. S. H. Bartelmez and E. R. Stanley, Synergism between hemopoietic growth factors (HGFs) detected by their effects on cells bearing receptors for a lineage specific HGF: assay of hemopoietin-1, J.Cell.Physiol. 122, 370-378 (1985). 16. H. Wu, U. Klingmüller, P. Besmer, and H. F. Lodish, Interaction of the erythropoietin and stemcell-factor receptors, Nature 377, 242-246 (1995). 17. H. Wu, U. Klingmüller, A. Acurio, J. G. Hsiao, and H. F. Lodish, Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation, Proc.Natl.Acad.Sci.USA 94, 1806-1810 (1997). 18. R. Stoffel, S. Ziegler, N. Ghilardi, B. Ledermann, F. J. de Suvage, and R. C. Skoda, Permissive role of thrombopoeitin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo, Proc.Natl.Acad.Sci.USA 96, 698-702 (1999).
REGULATION OF HEMATOPOIESIS BY GROWTH FACTORS
73
19. M. Kondo, D. C. Scherer, T. Miyamoto, A. G. King, K. Akashi, K. Sugamura, and I. L. Weissman, Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines, Nature 407, 383-386 (2000). 20. F. J. Pixley and E. R. Stanley, CSF-1 regulation of the wandering macrophage: complexity in action, Trends Cell. Biol. 14(11), 628-638 (2004). 21. V. Chitu and E. R. Stanley, Colony-stimulating factor-1 in immunity and inflammation, Curr. Opin. Immunol. 18(1), 39-48 (2006). 22. P. E. Cohen, K. Nishimura, L. Zhu, and J. W. Pollard, Macrophages: important accessory cells for reproductive function, J. Leuk. Biol. 66(5), 765-772 (1999). 23. J. W. Pollard and E. R. Stanley, Pleiotropic roles for CSF-1 in development defined by the mouse mutation osteopetrotic, Advances in Developmental Biochemistry 4, 153-193 (1996). 24. E. R. Stanley, in: Cytokine Reference: A compendium of cytokines and other mediators of host defence, edited by J. J. Oppenheim, M. Feldmann (Academic Press, London, 2000), pp. 911-934. 25. J. Pandit, A. Bohm, J. Jancarik, R. Halenbeck, K. Koths, and S. H. Kim, Three-dimensional structure of dimeric human recombinant macrophage colony-stimulating factor, Science 258, 1358-1362 (1992). 26. C. J. Sherr, C. W. Rettenmier, R. Sacca, M. F. Roussel, A. T. Look, and E.R. Stanley, The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1, Cell 41, 665-676 (1985). 27. L. Coussens, C. Van Beveren, D. Smith, E. Chen, R. L. Mitchell, C. M. Isacke, I. M. Verma, and A. Ullrich, Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyterminus, Nature 32, 277-280 (1986). 28. Y. G. Yeung, Y. Wang, D. B. Einstein, P. S. W. Lee, and E. R. Stanley, Colony-stimulating factor-1 stimulates the formation of multimeric cytosolic complexes of signaling proteins and cytoskeletal components in macrophages, J.Biol.Chem. 273, 17128-17137 (1998). 29. Y. G. Yeung and E. R. Stanley, Proteomic approaches to the analysis of early events in CSF-1 signal transduction, Mol. Cell. Proteomics 2, 1143-1155 (2003). 30. L. J. Guilbert and E. R. Stanley, The interaction of 125I-colony stimulating factor-1 with bone marrow-derived macrophages, J.Biol.Chem. 261, 4024-4032 (1986). 31. P. S. W. Lee, Y. Yang, M. G. Dominguez, Y. G. Yeung, M. A. Murphy, D. D. Bowtell, and E.R. Stanley, The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation, EMBO J. 18, 3616-3628 (1999). 32. R. J. Tushinski and E. R. Stanley, The regulation of mononuclear phagocyte entry into S phase by the colony stimulating factor CSF-1, J.Cell.Physiol. 122, 221-228 (1985). 33. A. Bartocci, D. S. Mastrogiannis, G. Migliorati, R. J. Stockert, A. W. Wolkoff, and E. R. Stanley, Macrophages specifically regulate the concentration of their own growth factor in the circulation, Proc.Natl.Acad.Sci.USA 84, 6179-6183 (1987). 34. P. Roth and E. R. Stanley, The biology of CSF-1 and its receptor, Curr.Top.Microbiol.Immunol. 181, 141-167 (1992). 35. E. R. Stanley, K. L Berg, D. B.Einstein, P. S. W. Lee, F. J. Pixley, Y. Wang, and Y. G.Yeung, Biology and Action of CSF-1, Molecular Reproduction and Development 46, 4-10 (1997). 36. E. R. Stanley, in: The Cytokine Handbook, edited by A. W. Thomson (Academic Press, San Diego, 1994), pp. 387-418.
74
E. RICHARD STANLEY
37. D. A. Hume, P. Pavli, R. E. Donahue, and I. J. Fidler, The effect of human recombinant macrophage colony-stimulating factor (CSF-1) on the murine mononuclear phagocyte system in vivo, J.Immunol. 141, 3405-3409 (1988). 38. S. C. Marks, Jr. and P. W. Lane, Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse., J.Hered. 67, 11-18 (1976). 39. H. Yoshida, S-I. Hayashi, T. Kunisada, M. Ogawa, S. Nishikawa, H. Okamura, T. Sudo, L. D. Shultz and S-I. Nishikawa, The murine mutation “osteopetrosis” (op) is a mutation in the coding region of the macrophage colony stimulating factor (Csfm) gene, Nature 345, 442-444 (1990). 40. W. Wiktor-Jedrzejczak, A. Bartocci, A. W. Ferrante, Jr., A. Ahmed-Ansari, K. W. Sell, J. W. Pollard, and E.R. Stanley, Total absence of colony-stimulating factor 1 in the macrophagedeficient osteopetrotic (op/op) mouse, Proc.Natl.Acad.Sci.USA 87, 4828-4832 (1990). 41. M. G. Cecchini, M. G. Dominguez, S. Mocci, A. Wetterwald, R. Felix, H. Fleisch, O. Chisholm, W. Hoffstetter, J. W. Pollard, and E. R. Stanley, Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse, Development 120, 1357-1372 (1994). 42. R. Felix, W. Hofstetter, A. Wetterwald, M. G. Cecchini, and H. Fleisch, Role of colonystimulating factor-1 in bone metabolism, J.Cell.Biochem. 55, 340-349 (1994). 43. G. R. Ryan, X. M. Dai, M. G. Dominguez, W. Tong, F. Chaun, O. Chisholm, R. G. Russell, J. Pollard, and E. R. Stanley, Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse (Csf1(op)/Csf1(op)) phenotype with a CSF-1 transgene and identification of sites of local CSF-1 synthesis, Blood 98(1), 74-84 (2001). 44. X. M. Dai, X. H. Zong, V. Sylvestre, and E. R. Stanley, Incomplete restoration of colonystimulating factor 1 (CSF-1) function in CSF-1-deficient Csf1op/Csf1op mice by transgenic expression of cell surface CSF-1, Blood 103(3), 1114-1123 (2004). 45. S. Nandi, M. P. Akhter, M. F. Seifert, X. M. Dai, and E. R. Stanley, Developmental and functional significance of the CSF-1 proteoglycan chondroitin sulfate chain, Blood 107(2), 786-795 (2006). 46. J. Friel, C. Heberlein, M. Geldmacher, and W. Ostertag, Diverse isoforms of colony-stimulating factor-1 have different effects on the development of stroma-dependent hematopoietic cells, J.Cell.Physiol. 204(1), 247-259 (2005). 47. X. M. Dai, G. R. Ryan, A. J. Hapel, M. G. Dominguez, R. G. Russell, S. Kapp, V. Sylvestre, and E. R. Stanley, Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects, Blood 99(1), 111-120 (2002). 48. X. M. Dai, X. H. Zong, M. P. Akhter, and E. R. Stanley, Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone, J. Bone Miner. Res 19(9), 1441-1451 (2004). 49. H. Lin, M. M. Huang, C. Leo, M. Ji, G. Wu, A. Zhou, R. Halenbeck, M. Qin, T. Linnemann, D. Behrens, S. Giese, E. Bosch, K. Justin, A. Pham, E. Lee, K. Hestir, H. Zhang, J. Wong, Y. Wang, K. Chu, S. Doberstein, L. T. Williams, and D. Hollenbaugh, A novel cytokine, FTP025, regulates myeloid growth and differentiation via the M-CSF receptor, Blood 108, 191a (2006). 50. F. Ginhoux, F. Thacke, V. Angeli, M. Bogunovic, M. Loubeau, X. M. Dai, E. R. Stanley, G. J. Randolph, and M. Merad, Langerhans cells arise from monocytes in vivo, Nat. Immunol. 7(3), 265-273 (2006).
REGULATION OF HEMATOPOIESIS BY GROWTH FACTORS
75
51. B. M. Kacinski, CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract, Mol. Reprod. Dev. 46(1), 71-74 (1997). 52. S. M. Scholl, C. Pallud, F. Beuvon, K. Hacene, E. R. Stanley, L. Rohrschneider, R. Tang, P. Pouillart, and R. Lidereau, Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis, J.Natl. Cancer Inst. 86(2), 120-126 (1994). 53. L. Bingle, N. J. Brown, and C. E. Lewis, The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies, J.Pathol. 196(3), 254-265 (2002). 54. E. Y. Lin, A. V. Nguyen, R. G. Russell, and J. W. Pollard, Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy, J.Exp.Med. 193(6), 727-740 (2001). 55. S. Aharinejad, D. Abraham, P. Paulus, H. Abri, M. Hoffmann, K. Grossschmidt, R. Schaefer, E. R. Stanley, and R. Hofbauer, Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice, Cancer Res. 62(18), 5317-5324 (2002). 56. S. Aharinejad, P. Paulus, M. Sioud, M. Hoffmann, K. Zins, R. Schaefer, E. R. Stanley, and D. Abraham, Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice, Cancer Res. 64(15), 5378-5384 (2004). 57. P. Paulus, E. R. Stanley, R. Schafer, D. Abraham, and S. Aharinejad, Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts, Cancer Res. 66(8), 4349-4356 (2006). 58. J. Wyckoff, W. Wang, E. Y. Lin, Y. Wang, F. Pixley, E. R. Stanley, T. Graf, J. W. Pollard, J. Segall, and J. Condeelis, A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors, Cancer Res. 64(19), 7022-7029 (2004). 59. S. Goswami, E. Sahai, J. B. Wyckoff, M. Cammer, D. Cox, F. J. Pixley, E. R. Stanley, J. E. Segall, and J. S. Condeelis, Macrophages promote the invasion of breast carcinoma cells via a colonystimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 65(12), 5278-5283 (2005).
II BIOLOGY OF NON-HAEMATOPOIETIC STEM CELLS
STEM CELL TECHNOLOGIES IN GERONTOLOGICAL RESEARCH G.M. BUTENKO* Institute of Gerontology AMS of Ukraine, Kyiv, Ukraine
Keywords: stem cells; aging, gerontology
Abstract. When getting old, a lot of unpleasant events are developing in our organism. Here, we should mention the decline or gradual loss of function and potential and, ultimately, death of cells of different types. Many data exist about age-dependent deterioration of nervous and muscle cells as well as about many proliferating cell populations, such as epithelial, osteogenic, hemopoietic and others. These changes manifest themselves in a number of old age diseases like the Alzheimer’s disease, Parkinsonism, heart and brain infarction, osteoporosis, diabetes, immune deficiency, malignancies and others. So, it takes to elaborate some technologies and methods for improving the situation by stimulation or replacement of the impaired organs and tissues. The dream is to launch a medical revolution, in which failing organs and tissues might be repaired not with crude mechanical devices like insulin pumps or titanium joints, but with the living homegrown replacement. And great promises here make now the use of stem cell technologies. 1. Introduction An emerging body of evidence suggests that many tissues retain minor population of tissue- specific stem cells capable of replenishing cells that are lost through wear and tear, aging, injury and disease. Data exist indicating that even in the adult organism it is possible to restore many terminally differentiated postmitotic effector cells, such as hepatocytes, muscle cells, glial and nerve cells, and even so specialized as the Purkinje cells, by means of hemopoietic stem cells (HSC) (Bjorklund, Svendsen, 1999; Cossu, Mavilio,
______ *
To whom correspondence should be addressed. G.M. Butenko, Institute of Gerontology AMS of
Ukraine, Kyiv, Ukraine; Email:
[email protected]
77 N. M. Bilko et al. (eds.), Stem Cells and their Potential for Clinical Application, 77–82. © 2008 Springer.
78
G.M. BUTENKO
2001; Weimann et al., 2003). Hence, it is reasonable to argue that the sole function of adult stem cells is to rejuvenate the aging tissues. This idea fueled enthusiasm for use of stem cells in strategies aimed at repairing or replacing the damaged, diseased or aged tissues and organs. However, one of the greatest challenges in stem cell work is to harness and direct cell differentiation. Complex combination of intrinsinc factors, microenvironmental and systemic signals drive the process, which researchers are only beginning to pin down. From this viewpoint the hemopoietic stem cells, having been experimentally and clinically studied for more than 50 years, attract the attention of investigators as thoroughly characterized tissue specific stem cell model to estimate its potential application in regenerative medicine. Moreover, a large number of reports have entertained the idea that HSCs have the potential to transdifferentiate into a range of non-hematopoietic cell types, including hepatocytes, skeletal muscle fibers, cardiomyocytes, neuronal and epithelial cells (Wagers, Weissman, 2004; Grove et al., 2004). An important function of HSCs is the maintenance of the body defense mechanisms. In the same time the significant signs of aging process is the decline of organism’s defense capacities. So far as the adaptive immune system is concerned, the principal occurring during life span in the experimental animals and the human being are very similar. They manifest themselves in the specific dynamics of immune response to foreign antigens, namely: an increase of immune reactions at the time of development followed by a gradual decrease after or close to the period of puberty until very low values, often less than one per cent of maximal level in ultimate ages. In parallel, the immune reactivity to self-antigens (immune tolerance) has the opposite dynamics. This is accompanied with changes in the phenotypical characteristics of the immunocompetent cells, a shift of the T- and B- lymphocytes subpopulations, with accumulation of the cells having memory-cell surface markers, with decreased proliferative and functional activity, significant disturbances in regulatory network. On the other hand, the increased susceptibility to myeloand lymphoproliferative diseases is observed. These changes are mirrored in the very typical dynamic of age-dependent curves of population survival/mortality (Makinodan, 1978). In the attempt to explain the events observed, it was supposed that the reason for above has been the exhaustion of proliferative potential of hemopoietic stem cells, so called the Hayflick’s limit, observed previously for the cells, proliferating in vitro (Hayflick and Moorhead, 1961; Hayflick, 1965). However, approximately at the same time it was shown, that due to successive transfers of bone marrow stem cells to lethally irradiated young recipients (mice) the proper life span of bone marrow derived stem cells exceeds at least 3 to 4 times the maximal life span of their hosts. It seems that extinction of these
STEM CELL TECHNOLOGIES IN GERONTOLOGICAL RESEARCH
79
cells did not result from the exhaustion of proliferative capacity, but rather occurred because of cell damages or dilution by transfer procedure (Harrison, 1979; Harrison, Astle, Stone, 1989; Micklem, Ross, 1978). As we now know, the Hayflick’s limit depends on the loss of telomeres which accompanies each chromosome replication , and is observed at cell division in cell cultures or in the terminally differentiated cell population in vivo. The stem cells escape the clonal exhaustion , they differ from above cells by special enzyme, telomerase, which restores the loss of chromosome ends, thus making stem cells practically immortal (Hornsby, 2001). The above-said suggests that there may exists some other cause(s) of age-dependent immune decline. There arises the question whether the above mentioned age specific properties belong to the whole hematopoietic cell line of old body, from stem cells and early precursors to mature lymphocytes, or whether they are acquired at a certain stage of lymphoid cell differentiation. For this purpose, we grafted the bone marrow cells of young and old CBA mice reciprocally to lethally irradiated syngeneic animals of opposite ages: young to old and vice versa. The results obtained was shown out that the young recipients, which had received the young or old bone marrow stem cells, demonstrate that the CD4+ lymphocytes, judging by their phenotypic markers, are very similar to those in young intact animals, irrespective of the age of bone marrow cell donor. On the other hand, the lymphocytes from old recipients, grafted both by young or old donor’s bone marrow cells, demonstrated the features, which are akin to the cells from intact old animals. While comparing the primary immune response to standard T- dependent antigen, SRBC, we may notice that immune reactivity in such long-term (3 months) heterochronic bone marrow chimeras is determined not by the proper age of the cells, involved in the immune response, but by the properties of the environment, both micro- or macro-environment, in which these cells underwent the morphogenesis. Given that the grafted cells were preliminary depleted from mature T cells and under effects of three-month stay in the recipient’s organism we assumed that all other mature immunocompetent cells disappeared in the natural manner. Following from this assumption, we showed, that these cells were progenies of hemopoietic stem cells, which matured in the organism of appropriate age and obtained the specific characteristics of the given age (Butenko, Andrianova, 1985). They maintained these properties even in the artificial conditions in vitro. So, considering the above mentioned facts, we may conclude that the main regulatory and morphogenetic signals originate from micro- environment, into which the stem cells were placed, or/and that they are systemic. In other words, the potential extrinsic modulation of a stem cell senescence program is an exiting field of research, warranting further study.
80
G.M. BUTENKO
We began this work with elaborating the experimental models, called heterochronic chimeras. That is the construction of living systems consisting of elements of opposite ages. One of such models is the heterochronic parabiosis. For this purpose we had sewn together, surgically, two CBA female mice 2-3 (young) and 22-23 (old) months according the method of Bunster and Meyer (1933). The common circulation of fluids had formed as early as 18 hours after joint operation. Two months later, the cross-circulation between partners was determined as 1% of the total blood content of one animal per minute with halflife blood exchange in about 140 min. The mutual population in bone marrow, thymus and spleen by partner’s cells, using T6T6 chromosome markers was observed. It was seen, that repopulation of old bone marrow (homing) with young-derived cells is remarkably less, than in young animal. That has been confirmed recently (Wright et al., 2001; Liang et al., 2005). The primary immune response in old separate mice is considerably lower as compared with young adults. The operation by itself did not influence either the serum antibody level or the antibody producing cells (so called plaque forming cells – PFC) number in the spleen in young and in old mice. But in the young adult mouse stitched with an old animal, the number of PFC in spleen as well as the serum antibody level were considerably lower, approaching to the level of old animal. At the same time, the spleen PFC in old animal was affected very little. A direct correlation was established between the immune response of old animals and the immune response of their young partners (r=0,82, p< 0,001). It means that old animals in the heterochronic pairs determined the immune reactivity of their young partners. We suppose that active inhibition of the immune response in the young parabionts by some factors of the old organism’s underlies the events observed. This inhibitory activity could be mediated by humoral or/and cellular factors and extend on many other cells apart from lymphoid cells, for instance, on the stromal cells of lymphoid organs. Having in mind the intensive cellular exchange between both partners, we could not exclude the short-distance effects of intercellular interactions. That is why, in the new series of the experiments we have irradiated the old parabiotic partner by the bone marrow lethal dose (9Gy) 4 days after joint operation, because since the fourth day cell exchange taking place. Two months later we could observe an essential elevation of the immune response in old partners and its relatively small decrease in young animals. These facts may suggest that irradiation removed at least some part of this unknown inhibitory mechanism. When both of the partners in parabiosis were young, the pair survived 2 years or more. If one mouse was 3 months old and the second was 22 months old, their joint life span was restricted maximum to 9 months. The death of one animal, as a rule old one, led inevitably to the death of a second partner. When the parabiotic pairs were separated from each other after 3 month of joint life,
STEM CELL TECHNOLOGIES IN GERONTOLOGICAL RESEARCH
81
the young mice, which had been in parabiosis with old partners before separation, revealed the high rate of mortality and their life-span did not exceed the life-span of their former old partners. Whereas the young animals which had been in parabiosis with young partners and then separated, survived the normal murine life-span. No doubt, the immune system provides very much for the organism survival. It was shown that the immune response of the young partners that dropped during parabiosis with the old ones did not recover during 7 months of the following independent life (Butenko, 1986). The changes in young parabiotic partners were not restricted by the immune system alone. We observed the pronounced changes in structure and function of ovaries of young animals connected with the old, in particular, in the blood progesterone level, which were accompanied with permanent estrus in young animals and anestrus in old partners. Further, there are evidences shown that with advancing age one can observe an increase in the collagen glycation. In our experiments made on heterochronically parabiosed mice and rats (in collaboration with prof. Z. Deyl) we demonstrated that both, aortal and skin collagen of young animals was rapidly non-enzymatically glycosilated and the proportion of incorporated glucose approached in the young counterparts to the level found in old individuals (Deyl et al., 1990). H. Tauchi and coworkers (1977, 1995) described the changes in the hepatic cells in young heterochronically parabiosed rats similar to those observed in old animals, although the liver cells of old partners had no signs of rejuvenation. Recently the article of Conboy et al. (2005) was published, where the authors have shown that hepatic and muscle stem cells in heterochronically parabiosed mice reveald some signs of rejuvenation, but only after 5 weeks of parabiosis. It is interesting whether that effect will be long-lasting. Based on our own data and the literature data we can rather draw the conclusion that in long-term heterochronic systems the mature elements, originated from the old organism, dominate and their influences were found to be active. But even in old organism, the stem cells do preserve their restorative potential and become capable of generating cells with young characteristics under appropriate conditions. And the question about reverse impacts of stem cells on old organism (so called rejuvenation effect) remains uncertain and till now unresolved and needs further research.
82
G.M. BUTENKO
References Bjorklund A., Svendsen C. (1999). Breaking the brain-blood barrier, Nature, 397, 569-570. Bunster I., Meyer R. K. (1933). Improved method of parabiosis,Anat. Res., 57, 339. Butenko G. M. (1986). Ageing of the immune system and diseases, In: Age-related factors in cancerogenesis. IARC scientific publication No 58, Lyon, 71-83. Butenko G. M., Andrianova L. F. (1985). Functional properties of hemopoietic stem cells in aging, Arch. Biol. (Bruxelles), 96, 246-251. Conboy I. M., Conboy M. J., Wagers A. J. et al. (2005). Rejuvenation of aged progenitor cells by exposure to a young systemic environment, Nature, 433, 760-764. Cossu G., Mavilio F. (2001). Bone marrow-derived myogenic stem cells: a therapeutic alternative for muscular dystrophy? In: Pluripotent stem cells. Eds B. Dodet, M. Vicari. John Libbey Eurotext, 39-44. Deyl Z., Butenko G.M., Hausmann J. et al. (1990). Increased glycation and pigmentation of collagen in aged and young parabiotic rats and mice, Mech. Ageing Dev., 55, 39-47. Grove J. E., Bruscia E., Krause D. S. (2004). Plasticity of bone marrow-derived stem cells, Stem Cells, 22, 487-500. Harrison D. E. (1979). Mouse erythropoietic stem cell lines function normally 100 months: loss related to number of transplantations, Mech. Ageing Dev., 9, 427-433. Harrison D. E., Astle C. M., Stone M. (1989). Numbers and functions of transplantable primitive immunohemopoietic stem cells. Effects of age, J. Immunol., 142, 3833-3840. Hayflick L., Moorhead P. S. (1961). The cerial cultivation of human diploid cell strains, Exp. Cell Res., 25, 582-621. Hayflick L. (1965) .The limited in vitro lifetime of human diploid cell strains, Exp. Cell Res., 37, 614-636. Hornsby P. J. (2001). Cell proliferation in mammalian aging, Handbook of the biology of aging. Eds. E. G. Masoro, S. N. Austad, Acad. Press, NY, 207-245. Ito Y., Sato T., Tauchi H. (1995). On the hepatocytes in parabiosis between young and old mice, Abstr. 6 th Congr.Internatl. Assoc. Biomed. Gerontology, Tokyo, part 1, 51. Makinodan T. (1978). Mechanism of senescence of immune response. Federation Proc., 37, 1239-1240. Liang Y., Van Zant G., Szilvassy S. J. (2005). Effect of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells, Blood, 106, 1479-1487. Micklem H. S., Ross E. (1978). Heterogenity and ageing of haematopoietic stem cells, Ann.Immunol. (Inst. Pasteur), 129C, 367-376. Tauchi H., Hasegawa K. (1977). Change of the hepatic cells in parabiosis between old and young rats, Mech. Ageing Dev., 6, 333-339. Wagers A. J., Wessman I. L. (2004). Plasticity of adult stem cells. Cell, 116, 639-648. Weimann J. M., Charlton C. A., Brazelton T. R. et al. (2003). Contribution of transplanted bone marrow cells to Purkinje neurons in human adult brain, PNAS, 100, 2088-2093. Wright D. E., Wagers A. J., Gulati A. P. et al. (2001) Physiological migration of hematopoietic stem and progenitor cells, Science, 294, 1933-1936.
OSTEOPETROTIC MODELS FOR IDENTIFYING GENES THAT CONTROL BONE RESORPTION WIESLAW WIKTOR-JEDRZEJCZAK* Department of Hematology, Oncology, and Internal Diseases, Medical University of Warsaw, Warsaw, Poland
Keywords: osteopetrosis; osteoclast; bone resorption
Abstract. Hematopoietic system in vertebrates hinges on the development of novel organ not present in other organisms and called bone marrow that is located within bones. In order for this organ to develop, first bones have to develop that occurs in bony fish and then cellular mechanism of creating the space inside them. This cellular mechanism is dependent on a single new type of cell called the osteoclast that is resorbing bone. Identification of genes whose products are critical for that process should be helped by the analysis of a disorder that is due to its disturbance. Such disorder called marble bone disease or osteopetrosis was first discovered in man about one hundred years ago and since then identified in many vertebrate species. It is rare and sometimes fatal disease that is due to smaller or absent bone marrow cavities and disturbed development of bone marrow, In extreme cases, there is no bone marrow. Therefore, it is of crucial importance from the point of view of understanding vertebrate hematopoiesis to investigate which genes when intercepted produce osteopetrosis because these would be the genes that are controlling the process of formation of bone marrow as an organ,. These genes through their products have to affect osteoclasts directly or indirectly either abrogating their formation or function. While for many other cell classes within hematopoiesis, there are only one or two known genetic defects that lead to their inherited deficiency, there is a plethora of osteopetroses with similar final clinical picture but different exact cellular problem and different genetic origin. Some of them have occurred spontaneously, and gene mutations causing them have been later identified, others have been unexpected products of gene targeting. While osteopetroses produced by gene targeting such as c-src, c-fos knockouts from
______ * To whom correspondence should be addressed. Department of Hematology, Oncology, and Internal Diseases, Medical University of Warsaw, Warsaw, Poland, Email:
[email protected]
83 N. M. Bilko et al. (eds.), Stem Cells and their Potential for Clinical Application, 83–104. © 2008 Springer.
84
W. WIKTOR-JEDRZEJCZAK
the beginning possessed known responsible gene, whose interception was producing given defect, naturally occurred osteopetroses still have unresolved affected gene identity in some cases. In resolved cases, the genes whose mutations produce osteopetrosis have very different functions from coding growth factors, and their receptors, transcription factors, and genes coding enzymes critical to bone resorbing function of osteoclasts. The fact, that mutations of so many different genes may produce osteopetrosis is probably due to the relative evolutionary novelty of this cell lineage what did not allow time for the development of alternative regulatory pathways active for other “older” types of cells.Such alternative pathways can take over function of blocked main pathway and assure for continuation of production of given cell type preventing the clinical disease. 1. Introduction Hematopoietic tissue is unique in vertebrate organism in these terms that it does not develop originally in its final location i.e. in the bone marrow. In early vertebrates, that is in cartilaginous fish there are even no bones. First hematopoietic stem cells for definitive hematopoiesis appear in mammals in AGM (aortha, gonads, mesonephros) region and later they colonize liver and spleen, where they function in fetal life, and finally they settle in the bone marrow. In adult mammals there is no hematopoiesis in the liver, but in smaller mammals spleen remains as hematopoietic organ for the lifespan in addition to the bone marrow. Development of the bone marrow has to occur after development of bones and development of mechanism that would create space within bone. Development of bones originally takes place in the so called bony fish, whose bones are acellular and kidneys are the main hematopietic organ in adult animals. It has been found many years ago that bony fish (in contrast to cartilaginous fish such as sharks), while having acellular bone already have mechanism to create space within bones. It has been shown, that when bony fish are implanted with exogenous bone particles they colonize these particles with cells possessing ruffled border overlying the areas of bone matrix that undergoes dissolution, cells that closely resembled osteoclasts (Glowacki et al., 1986). Later it was found that osteoclasts are really present in zebrafish and assist there in tooth eruption (Witten et al., 2001). On the other hand, frogs already have fully developed bone marrow. Therefore, this development has to occur somewhere between bony fish and frogs. This development has to hinge on the appearance in the vertebrates of a new cell type called the osteoclast. There are many lines of evidence that suggest
OSTEOPETROSIS
85
that this cell belongs to monocyte/macrophage lineage but it is quite unusual within this lineage because it is exerting its primary activity i.e. bone resorption through acidic and enzymatic bone dissolution and not through the main mechanism of action of macrophages that is phagocytosis (Figure 1).
Figure 1. Schematic representation of osteoclast function in bone resorption.
The osteoclast is a polarized multinucleated cell attached to the bone surface that has at its bone approaching side the so called ruffled border termed so because of characteristic ruffled appearance. Ruffled border is approaching resorption lacunae lying between osteoclast cell surface and bone surface. Resorption lacunae is the space where bone dissolution takes place. Bone dissolution products are transported out of the resorption lacunae through the osteoclast cytoplasm and are released to the ouside on the other side of the osteoclast called basolateral membrane. Osteoclast is attached to the bone on the borders of resorption lacunae with a region of cytoplasm called clear zone and devoid of organelles. It is sealed in this region to the bone with the aid of αvβ3 integrin interacting with vitronectin. Bone dissolution is composed of two major processes: mineral dissolution and protein degradation. Bone mineral is hydroxyapatite i.e. (Ca3(PO4)2)3 x Ca(OH)2. It is dissolved into Ca2+, HPO42-, and H2O with the help of hydrochloric acid. For this, independently protons (H+) and chloride (Cl-) are
86
W. WIKTOR-JEDRZEJCZAK
released from the ruffled border into clear zone. Protons are originally generated in the cytoplasm by dissociation of carbonic acid made by carbonic anhydrase II. Protons are then transported and released into clear zone by enzyme H+ATPase, while bicarbonate is exchanged for chloride at the basolateral membrane with the help of Cl-/HCO2- exchanger. Chloride is then transported and released into clear zone by chloride channel 7 (Clcn7). The main bone protein is collagen I and it is originally degraded by the enzyme cathepsin K released through ruffled border into the resorption lacunae. Protein degradation products are then endocytosed by ruffled border and transported via cytoplasm to basolateral membrane. On their way they are further degraded by free radicals produced by tartrate-resistant acid phosphatase, which is an osteoclast specific enzyme. From this description it is clear that this new cell is a highly specialized feature and this rises an interesting question of what was the primary reason for development of such a cell in the fish, where bones are not resorbed and colonized by the hematopoiesis. There is no experimental answer to this question yet, but speculation on that subject should concentrate on other requirements for bone resorption that would be of an immediate necessity for the fish. Such other requirement is tooth eruption. Without teeth fish would be unable to eat most of the food available, and to defend itself, so their eruption is of critical importance for survival. With emergence of calcification of bones during their development teeth had it increasingly more difficult to erupt and this required development of mechanism to assist in this process. So the hypothesis based on this speculation is, that the osteoclasts emerged primarily to assist tooth eruption. Bone resorption and remodelling of other bones became important when first amphibians started to leave water, which has essentially changed mechanical requirements for the bones. Bones have to become much more resistant to fractures and also lighter in air conditions than in the water. It is known that the resistance to fractures is not so much dependent of width of the bone as on the number of surfaces that have to be broken. In other words, solid stick (having two surfaces on both sides) is more vulnerable to fracture than tube of the same diameter (having altogether four surfaces). Mouse bones are in fact simple tubes, while bones of larger mammals are composed of many parallel tubes and this makes them capable to resist heavy mechanical stress. It was probably so, that in the first animals leaving water, some osteoclasts began to accidentally appear and act in other bones than the jaws and this made such bones mechanically more resistant. Such animals then gained the evolutionary advantage, because their bones became more resistant to fractures and lighter. Subsequently, hematopoietic stem cells circulating in the peripheral blood
OSTEOPETROSIS
87
discovered new opportunity and begin to settle there creating bone marrow. This way the bone marrow might have developed as an organ. The classical experimental approach to study the mechanisms that govern the development of such a system is to explore naturally occurring disorders, the so called “experiments of nature”, in which there was an interception of such development. In the case of the particular subject of this chapter these would be the disorders in which there was either no formation of the bone marrow cavities and consequently bone marrow or this process was significantly impaired. This has brought me a quarter of century ago to osteopetrosis (Wiktor-Jedrzejczak et al., 1981). At that time already several genes whose mutations produced osteopetrosis have been provisionally identified both in the mouse and the rat as well as in man. At this moment it is necessary to make two important cautions. First, both naturally occurring and artificially produced gene knockouts do not identify the entire spectrum of physiological activity of missed gene product but only those parts of that spectrum that are not duplicated by activity of products of other genes. Secondly, only such naturally occurring knockouts could be identified that are not lethal early in development. In other words, these mutations must affect genes whose knockout is not lethal or such mutations have to only partially abrogate gene function. Osteopetrosis is a disease first described in man in 1904 by German radiologist H. Albers-Schoenberg and called after him Albers-Schoenberg disease (Figure 2). Because of characteristic radiologic appearance it is also called marble bone disease. It is a disease in which bone formation exceeds bone resorption. In vast majority of situations it is the bone resorption that fails but it has to be remembered that the disease could also be produced by overactivity of osteoblasts i.e. bone producing cells. The disease was later identified also in animals including mice and rats and this has allowed various experimental approaches. Four natural mutants originally identified in mice were: microphthalmic or mi/mi, grey-lethal or gl/gl, osteopetrotic or op/op, and osteosclerotic or oc/oc. Four natural mutants identified in rat included again microphthalmic or mib/mib, osteopetrotic or op/op (this is different disease than in the op/op mouse), toothless or tl/tl, and incisor-absent or ia/ia (WiktorJedrzejczak et al., 1981).
88
W. WIKTOR-JEDRZEJCZAK
Figure 2. X-ray of osteopetrotic bone (left) in man.
The most remarkable experiment crucial to the understanding of the disease and of the osteoclast as such was published in 1972 by Donald Walker who has found that osteopetrosis in one of the mouse mutants with that disease: microphthalmic could be cured by parabiosis with normal littermate. Later he has also found that this disease as well as disease in another mouse mutant grey-lethal could be cured by transplantation of hematopoietic cells from normal littermate and transferred to such littermate by transplantation of hematopoietic cells from mutant animals (Walker, 1975a,b). This finding was soon confirmed (Loutit and Sansom, 1976) and has led to the successful application of this treatment modality to human patients (Coccia et al., 1980). From scientific point of view, it has established that the bone resorption is carried out by the progeny of the hematopoietic stem cells, and therefore, that the osteoclast is the progeny of the hematopoietic stem cell. Approach taken to further understanding osteopetrosis was based on knowledge concerning two phenotypically similar murine mutants with macrocytic anemia (Wiktor-Jedrzejczak et al., 1981). These two anemias: one secondary to mutation of the W locus (now known as c-kit) and the other secondary to the mutation of Steel locus (now known as gene for Kit Ligand or Steel Factor) are reciprocally sensitive/resistant to bone marrow transplantation
OSTEOPETROSIS
89
(Russell and Bernstein, 1966). W mutant mice could be cured by transfusion of even single hematopoietic stem cell (Wiktor-Jedrzejczak et al., 1979), while Steel mutant mice are resistant to transplantation of hematopoietic stem cells (McCulloch et al., 1965). Hence, the disease in W mutant mice has served as paradigm of stem cell disorder (McCulloch et al., 1964, Russell and Bernstein, 1968), while the disease in Steel mutant mice has served as paradigm of disorder of hematopoietic microenvironment. Consequently, it has been postulated that osteopetroses could be similarly divided (Wiktor-Jedrzejczak et al., 1981) into those in which the defect is intrinsic to the affected lineage and therefore curable by the infusion of stem cells for that lineage. This would include aforementioned osteopetroses in microphthalmic and grey-lethal mice. Another type would represent osteopetroses in which defect is extrinsic to the affected lineage and resistant to such transplantation. Such osteopetrosis was soon identified in the tl/tl rat (Marks, 1977) and in the op/op mouse (Wiktor-Jedrzejczak et al., 1982). Another possible classification of osteopetroses would include those due to deficient production of osteoclasts related to either intrinsic or extrinsic mechanisms and those, where osteoclasts formed are functionally deficient. According to this classification the osteopetrosis in the op/op mouse would belong to the first category as bones of these mice are devoid of osteoclasts, while osteopetroses in mi/mi and gl/gl mice would belong to the second category as these mice possess osteoclasts that, however, are functionally deficient. From these considerations the osteopetrosis has emerged as extremely interesting model disease. Below, naturally occurring (Table 1) and produced by gene targeting (Table 2) diseases with the common denominator of osteopetrosis would be reviewed in view of their contribution to the understanding the physiology of bone resorption. TABLE 1. Naturally occurring osteopetroses and their genetic background Gene
Protein
Lesion
Rodent disease
Human disease
Other features
Csf1
CSF-1
op allele in the mouse, tl allele in the rat
Osteopetrosis with osteoclast deficiency, failure of tooth eruption,
None known
macrophage deficiencies, fertility defect
Mitf
Microphthalmiaassociated transcription
Mi allele in the
Osteopetrosis with inactive osteoclasts,
Waardenburg syndrome, type 2a, Tietz
microphthalmia albino
W. WIKTOR-JEDRZEJCZAK
90 factor
mouse, Mib allele in the rat
failure of tooth eruption,
syndrome
Ostm 1
Osteopetrosisassociated transmembrane protein 1
gl allele in the mouse,
Osteopetrosis with inactive osteoclasts, failure of tooth eruption
infantile malignant osteopetrosis – rare cases
Chondrodysplasia, abnormal coat color in the mouse, thymic atrophy
Tcirg1 (ATP6i)
A3 subunit of the vacuolar proton ATPase
oc allele in the mouse
Osteopetrosis with increased number of inactive osteoclasts, failure of tooth eruption
Majority of cases of malignant infantile osteopetrosis
Chondrodysplasia, small size, premature death
Tnfrsf11
RANK
Deletion in exon 8
Osteopetrosis without osteoclasts
unknown
Deficiency of lymph nodes, T and B cell deficiency
No osteopetrosis in the mouse Osteopetrosis, failure of tooth eruption
Osteopetrosis
Renal tubular acidosis
Ia allele in the rat Car2
Carbonic anhydrase 2
Clcn7
Chloride channel 7
LDL RP5 gene
LDL RP5
No osteopetrosis in the mouse
Autosomal dominant type 2 osteopetrosis, autosomal recessive osteopetrosis Autosomal dominant type 1 osteopetrosis
OSTEOPETROSIS
91
TABLE 2. Targeted disruption of genes in the mouse producing osteopetrosis Gene
Protein
Bone phenotype
Other features
PU.1
PU.1 transcription factor
Osteopetrosis without osteoclasts
Macrophage deficiency
Csf1r
M-CSF receptor
Osteopetrosis without osteoclasts
Macrophage deficiency, fertility defect
Tnfsf11
RANKL
Osteopetrosis without osteoclasts
Deficiency of lymph nodes, T and B cell deficiency
Tnfrsf11
RANK
Osteopetrosis without osteoclasts
Deficiency of lymph nodes, T and B cell deficiency
Transgene of osteoprotegerin gene
Overexpressed Osteoprotegerin
Osteopetrosis without osteoclasts
Deficiency of lymph nodes, T and B cell deficiency
Traf6
TNF-receptorassociated factor 6
Osteopetrosis with reduced osteoclasts
c-jun
JunB
Osteopetrosis when JunB inactivated selectively in macrophage lineage
Deficiency of lymph nodes, Hipohidrotic ectodermal dysplasia Osteopenia and chronic myeloid leukemia-like disease in totally JunB inactivated mouse
c-fos
c-fos transcription factor
Osteopetrosis with absent osteoclasts
Disturbed B lymphopoiesis
NF-κB 1 and 2 c-src
Src tyrosine kinase
Osteopetrosis Osteopetrosis with defective osteoclasts
β3
β3 integrin
Osteopetrosis developing in adult animals
Disturbed Peyer’s patches Abnormal mammary gland, uterine and ovarian development Glanzmann’s thrombasthenia
Clcn7
Clcn7 chloride channel
Osteopetrosis with impaired osteoclast function
Lysosomal starage disease and neurodegeneration
Cathepsin K
Cathepsin K
Osteopetrosis with morphologically normal osteoclasts that fail to degrade matrix
Abnormal joint morphology
TRAP gene
TRAP
Mild osteopetrosis with dysfunctional osteoclasts
Deficient macrophage function
W. WIKTOR-JEDRZEJCZAK
92 Dap12 gene
DAP12
Mild osteopetrosis with dysfunctional osteoclasts developing in elderly mouse More severe osteopetrosis with earlier development than in DAP12 knockout mouse, tooth eruption
Dap 12 and FcRγ-chain genes
DAP12 and FcRγchain
DC-STAMP
DC-STAMP
Osteopetrosis with inactive mononuclear osteoclasts
LTBP-3
LTBP-3
Osteopetrosis with inactive osteoclasts
Rab3D
Rab3D
Osteopetrosis with inactive osteoclasts
Thalamic hypomyelinosis with synaptic degeneration and immune deficiencies Not characterized
Failure of foreign body giant cell formation
2. Naturally Occurred Osteopetroses and their Genetic Background The elaboration of the sequence of the first gene causing osteopetrosis was made possible after finding that the op/op mouse (Marks and Lane, 1976) has a total deficiency of macrophage growth factor, subsequently identified as CSF-1 or M-CSF (Wiktor-Jedrzejczak et al., 1982, 1990). Then simple sequencing of the CSF-1 gene revealed that in the op/op mouse there is a point mutation shifting the reading frame and producing stop codon further downstream (Yoshida et al., 1990). Since it was found that in the rat toothless mutation produces extremely similar phenotype to the op/op mouse, the tl/tl rat was treated with exogenous CSF-1 and responded extremely well (Marks et al., 1992) similarly as the op/op mouse (Wiktor-Jedrzejczak et al., 1991) it was speculated that it has also a mutation of CSF-1 gene later renamed as Csfm gene. It was later confirmed and it was found that in this rat there is an insertion in the gene also shifting reading frame and producing stop codon (Dobbins et al., 2002, VanWesenbeeck et al., 2002). In both cases, the result of mutation is production of truncated functionally inactive protein product. The hunt for the gene of microphthalmic mouse ended unexpectedly, when the mutant phenotype appeared during experiments concerning vasopressin promoter in transgenic mice (Hodgkinson et al., 1993). Sequencing of the
OSTEOPETROSIS
93
interrupted gene has revealed that it is coding for novel earlier unknown transcription factor helix-loop-helix zipper protein later renamed Mitf (Weilbaecher et al., 2001). Obviously, mutation of the same gene is responsible for osteopetrosis in mib/mib rat (Wojtowicz et al., 1990), although to the best knowledge no sequence of mutated gene for this particular allele was published. The approach to osteosclerotic (Dicke, 1967) mutation was yet different. The location of the gene was originally mapped to chromosome 19 (Marks et al., 1985) and later to a region on that chromosome called pericentromeric region or MMU19. Subsequently, starting from that information it was possible to define the smallest candidate region in area between D19\mit32 and 93 using crosses with Mus spretus. Then a sequence-ready bacterial artificial chromosome contig map of that region was constructed, and best BAC was selected using FISH. Later on, the chosen BAC of the candidate region of the oc/oc was sequenced, and it was found that sequences correspond to the known human osteoclast-specific enzyme. This has allowed to identify 1.6 kb deletion at the translation start site in the gene coding vacuolar proton ATPase subunit. Subsequently, the absence of the enzyme in the apical membranes of osteoclasts, which prevented their bone resorbing function was proven in the oc/oc mouse (Scimeca et al., 2000). The equivalent mutations were at the same time identified in some human cases of osteopetrosis (Frattini et al., 2000, Kornak et al., 2000). This gene (also called TCIRG1 from T-cell immuneregulator-1, OC116 and ATP6i) was later found to be responsible for about 50% of cases of osteopetrosis in man (Balemans et al., 2005). The fourth naturally occurring murine osteopetrosis in grey-lethal mouse (Gruneberg, 1938) was also elaborated using BAC technology (Chalhoub et al., 2003) and it was found that it is produced by a deletion in a gene for newly described 338-amino acid protein named osteopetrosis associated transmembrane protein 1 (Ostm1). Mutations in the same gene have been also identified in some cases of human osteopetrosis (Ramirez et al., 2004, Quarello et al., 2004, Pangrazio et al., 2006). Recently, it was found that Ostm1 serves as a beta-subunit for ClC-7 chloride channel (Lange et al., 2006). Chloride channel itself was earlier found to be necessary for bone resorption and in fact mutations of ClC-7 gene have been found to be responsible for some human cases of osteopetrosis (Kornak et al., 2001, Cleiren et al., 2001). At this time there are still two rodent naturally occurring osteopetroses without defined gene: the one termed ostepetrotic or op/op that is distinct from the mouse op/op, associated with premature thymic atrophy and curable by bone marrow transplantation (Milhaud et al., 1977) and the one produced by mutation of incisor-absent gene also curable by bone marrow transplantation (Marks, 1976). The latter was, however, was recently mapped to chromosome 10q32.1 (VanWesenbeeck et al., 2004), which should help its identification. On
94
W. WIKTOR-JEDRZEJCZAK
the other hand, the op/op rat is in some respect similar to the gl/gl mouse that also develops premature thymic atrophy (Wiktor-Jedrzejczak et al., 1983). Moreover, recently also a natural mutation concerning RANK was identified (Kapur et al., 2004) and was associated with similar phenotype as earlier described osteopetrosis produced by targeted RANK disruption (Li et al., 2000) and discussed later. In man, naturally occurring osteopetroses are classified based on severity and presence of other abnormalities (Balemans et al., 2005). Osteopetroses associated with other severe abnormalities include osteopetrosis associated with renal tubular acidosis which is due to the mutation of gene for carbonic anhydrase type II (Sly et al., 1991), osteopetrosis with infantile neuroaxonal dystrophy, gene for which was not yet identified (Ambler et al., 1983), and osteopetrosis associated with anhydrotic actodermal dysplasia, immunodeficiency and lymphedema, which is secondary to NEMO gene mutation (Smashi et al., 2002, Dupuis-Girod et al., 2002). Osteopetroses being dominant or sole abnormality are classified based on their severity into malignant (lethal in childhood), intermediate, and benign. Malignant osteopetrosis is inherited with at least four different mutant autosomal genes, and it is termed autosomal recessive osteopetrosis or ARO. Three genes have been identified and they include ClC7, OSTM1 and TCIRG1 (Balemans et al., 2005) as already mentioned. In intermediate type osteopetrosis, which is not lethal but associated with spontaneous fractures and short stature a mutation of ClC7 was implicated (Campos-Xavier et al., 2003). This is different mutation that the one causing ARO. Finally, there are at least three types of benign osteopetrosis in man. These disorders are frequently asymptomatic, diagnosed by X-ray performed because of other reasons and are inherited with dominant mutations of autosomal genes. Two such genes have been so far identified. One is again ClC7 (Cleiren et al., 2001), the other being LRP5 (Little et al., 2002). This latter disease is a completely different disease of all others as it is not a disease of osteoclast but rather disease of hyperactive osteoblast. Moreover, the mutation is not producing loss of function as majority of previously mentioned mutations but it is gain of function mutation (VanWesenbeck et al., 2003). However, more recent studies (Glass et al., 2005) may suggest that this overexpressed molecule may promote ability of differentiated osteoblasts to inhibit osteoclast differentiation, inducing osteopetrosis primarily not by stimulating bone formation by inhibiting bone resorption. 3. Osteopetroses Induced by Gene Targeting The first gene whose targeted disruption unexpectedly produced osteopetrosis was c-src (Soriano et al., 1991). c-src codes for cytoplasmic tyrosine kinase
OSTEOPETROSIS
95
important in signal transduction from cell surface to the nucleus. The next one was c-fos (Grigoriadis et al., 1994). c-fos codes for transcription factor implicated in transcription of many genes controlling cell proliferation. Moreover, there is another transcription factor closely related to c-fos, namely c-jun. Targeted disruption of that factor gene leads to osteopetrosis only, when it is limited to the macrophage lineage (Clausen et al., 1999). Mice with c-jun knockout in germ line (and subsequently in other derived lineages) die in utero and cannot be evaluated for osteopetrosis. Other transcription factor genes whose disruption resulted in osteopetrosis included PU.1 and NF-κB 1 and 2 (Tondravi et al., 1997, Iotsova et al., 1997). As mentioned in the introduction disruption of c-kit (or Steel Factor receptor) in W mutant mouse and disruption of gene for Steel Factor in Steel mutant mouse produce very similar phenotype of macrocytic anemia. Since in the op/op mouse the osteopetrosis is due to the naturally occurring disruption of a gene for CSF-1 one would speculate that targeted disruption of the receptor for CSF-1 i.e. c-fms would also produce osteopetrosis. This in fact is the case (Dai et al., 2003, Li et al., 2006). Spontaneous knockouts of CSF-1 gene, Mitf gene and targeted disruption of PU.1 and CSF-1R genes could be grouped together as they most probably affect the same regulatory pathway of osteoclasts i.e. the CSF-1 pathway. This pathway begins with CSF-1 and goes through its receptor and then through both PU.1 and Mitf transcription factors (Weilbaecher et al., 2001). Another cytokine pathways besides CSF-1 seem also to control the osteoclast development. This is receptor activating NF-κB (RANK) and its ligand RANKL. In that axis there is also another receptor called osteoprotegerin, which is a soluble decoy receptor that competes with RANK for RANKL (Kong et al., 2003). Both targeted disruption of RANK and RANKL produce osteopetrosis (Li et al., 2000, Ongren et al., 2003). With osteoprotegerin the situation is different. It is not the gene knockout but overexpression due to transgene that produces osteopetrosis (Simonet et al., 1997). This is because overexpressed osteoprotegerin binds RANKL and prevents its binding to RANK. The RANKL/RANK axis transduces its signal through tumor necrosis associated factor 6 or TRAF-6 and knockout of this gene as expected is producing osteopetrosis (Naito et al., 1999). TRAF-6 is an adapter protein and intermediates between several cytokine receptors and transcription factors. These transcription factors include AP-1 transcription factors such as c-fos and c-jun and both NF-κB subunits. As it was already mentioned, knockouts of these genes produce osteopetrosis (Grigoriadis et al., 1994, Iotsova et al., 1997). However, it is important to mention that disruption of a single NF-κB subunit is not sufficient to induce ostepetrosis and in other words it is not sufficient to critically compromise the osteoclast formation. For this effect simultaneous
96
W. WIKTOR-JEDRZEJCZAK
knockout of both subunits is required (Iotsova et al., 1997). Furthermore, c-src product is a protein downstream of TRAF-6 in the same pathway. The fact that both interception of AP-1 factors and NF-κB factors produces osteopetrosis suggests that they control transcription of different genes critical for bone resorption.. Moreover, there is a possibility, that formation of osteoclasts is regulated by yet another cytokine axis. There was a suggestion that adapter protein DAP12 may affect osteoclast differentiation (Paloneva et al., 2000). DAP12 is adapter protein playing a role in immunoreceptor tyrosine-based activation motif (ITAM) mediated signaling. But DAP12 knockout mice develop mild osteopetrosis only when becoming older and possess normal number of osteoclasts with reduced function (Kaifu et al., 2003). There is one more adapter protein playing similar role: Fc receptor γ-chain (FcRγ). Mice that have double knockout DAP12 and FcRγ are osteopetrotic and are devoid of multinucleated osteoclasts (Mocsai et al., 2004). Interestingly, these mice demonstrate tooth eruption in contrast to majority of other osteopetrotic mutants. There are also some clues regarding the intermediary of DAP12/FcRγ regulation. They seem to act through Syk tyrosine kinase and later on by modulating integrin expression (Mocsai et al., 2004). For the formation of osteoclast from precursor circulating in the peripheral blood it is necessary to attach to the bone, and then to fuse with other similarly attached precursors to form multinucleated cell. As it has been mentioned, the primary adhesion molecule of osteoclasts is αvβ3 integrin. In confirmation of that concept, the interception of a gene for β3 integrin leads to osteopetrosis (McHugh et al., 2000). Then molecule was identified by DNA subtraction screen between multinuclear osteoclasts and mononuclear macrophages. This molecule was called dendritic cell specific transmembrane protein (DCSTAMP) appeared to control formation of multinuclear cells. Again, DCSTAMP deficient mice have completely abrogated osteoclast cell fusion and develop osteopetrosis (Yagi et al., 2005) . Moreover, as expected disruption of genes coding for enzymes critical to the function of osteoclast such as tartrate-resistant acid phosphatase (Hayman et al., 1996) and cathepsin K (Gowen et al., 1999) also produced osteopetrosis. This complements earlier discussed spontaneous osteopetrotic phenotypes produced by interception of pathways generating either protons or chloride necessary for mineral dissolution. Consequently, it is possible to draw on the basis of analysis of osteopetrotic models mentioned so far a scheme of genetic regulation of osteoclast formation, activation, and final function (Figure 3). Still relatively less is known how various intercepted genes interact with each other, in other words, how CSF-1 pathway interacts with RANKL pathway and with regulation of
OSTEOPETROSIS
97
osteoclast function. However, PU.1 regulates transcription of both CSF-1R and RANK (Kwon et al., 2005). Another example of such approach is a study showing that CSF-1 induce osteoclast spreading through αvβ3 integrin and c-src product (Teti et al., 1998). RANK RANKL NF-κB TRAF-6 c-fos
CSF-1 CSF-1R PU.1
Macrophage and osteoclast progenitor
Osteoclast precursor
CAII TCIRG1 CLCN7 OSTM1 c-src
Osteoclast
Bone resorption
Figure 3. Location of action of some genes that when intercepted cause osteopetrosis.
While the role of each of these aforementioned genes appears so important that disruption is producing osteopetrotic phenotype it is also necessary to mention that in majority of situations the defect is not complete and some function is present. This could either happen because the particular mutation only partially abrogates the function of given gene or because its function could be substituted for by some other gene product. While osteopetrotic phenotype is present because the alternative mechanism even if present is not efficient enough it has to be mentioned that these alternative mechanisms seem to develop and are present. Moreover, they may have practical usefulness as their upregulation through therapeutic intervention may reduce severity of osteopetrotic disease. However, there are osteopetrotic phenotypes produced by targeted disrupttion of genes that are yet not completely understood in terms of what is the physiological role of missed gene product in osteoclast function. Moreover, these genes could not be yet easily incorporated into the scheme of osteoclast formation and function. They include disease produced by knockout of latent TGF-beta binding protein (LTBP) 3 in mice (Dabovic et al., 2005). LTBPs are proteins of extracellular matrix that are responsible for binding latent TGF-beta and modulate tissue levels of this cytokine. LTBP 3 knockout mice possess normal numbers of osteoclasts, so this defect affect rather function than formation of this cells. Another novel osteopetrotic phenotype is the one produced by targeted disruption of Rab3 gene (Pavlos et al., 2005). Rab3 proteins belong to the family of GTPases, participating in exocytosis and Rab3D is expressed in osteoclasts. Finding that Rab3D knockout produces osteopetrosis suggests that formation of lysosomal vesicles is also critical in
98
W. WIKTOR-JEDRZEJCZAK
bone resorption. Furthermore, knockout of RAGE (receptor for advanced glycation end products), which is a member of immunoglobulin family also produces osteopetrosis by compromising osteoclast function (Zhou et al., 2006). The physiological role for RAGE is still obscure, so it is impossible to associate this defect with earlier identified function. Completely different mechanism has osteopetrosis induced by neonatal injection of some viruses belonging to murine leukemia virus category. One such virus termed SL3-3 of the Akv family is carrying transcriptional enhancer of sites for nuclear factor 1 and this virus has strong osteopetrosis inducing capacity in addition to ability to induce lymphoma (Ethelberg et al., 1999). This osteopetrosis is thought to be due to increased activity of osteoblasts, but in fact the original publication does not include evaluation of osteoclasts in infected mice. Therefore, it is possible that it also affects these latter cells. 4. Concluding Remarks
Studies of osteopetrotic models have helped so far to identify more than 30 genes that are so important for bone resorption that their disruption produces diseased phenotype. This makes the genetic regulation of osteoclast formation and function probably the best understood of all hematopoietic lineages. Furthermore, there are genes whose knockout produce phenotype lethal in fetal life, but which may also compromise the osteoclast and bone resorption. Moreover, to these genes probably some other could be added including genes that code for proteins used in some therapeutic approaches. The products of these genes clearly influence the bone resorption even if their abrogation does not produce osteopetrosis. Acknowledgements
This work was supported by a grant from Foundation for Polish Medicine and Pharmacy to W. W-J.
References Ambler, M.W., Trice, J., Grauerholz, J., and O’Shea, P.A. (1983) The Association of Infantile Osteopetrosis and Neuronal Storage Disease. Neurology 33, 437-441. Balemans, W., Van Wesenbeeck, L., and VanHul, W. (2005) A Clinical and Molecular Overview of the Human Osteopetroses. Calcified Tissue International 77, 263-274. Campos-Xavier, A.B., Saraiva, J.M., Ribeiro, L.M., Munnich, A., and Cormier-Daire, V. (2003) Chloride Channel 7 (ClCN7) Gene Mutations in Intermediate Autosomal Recessive Osteopetrosis. Human Genetics 112, 186-189.
OSTEOPETROSIS
99
Chalhoub, N., Benachenhou, N., Rajapurohitam, V., Pata, M., Ferron, M., Frattini, A., Villa, A., and Vacher, J. (2003) Grey-lethal Mutation Induces Severe Malignant Autosomal Recessive Osteopetrosis in Mouse and Human. Nature Medicine 9, 399-406. Cleiren, E., Benichou, O., VanHul, E., Gram, J., Bollerslev, J., Singer, F.R., Beaverson, K., Aledo, A., Whyte, M.P., Yoneyama, T., deVernejoul, M.C., and VanHul, W. (2001) AlbersSchonberg Disease (Autosomal Dominant Osteopetrosis type II) Results from Mutations in the ClCN7 Chloride Channel Gene. Human and Molecular Genetics 10, 2861-2867. Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., and Forster, I. (1999) Conditional Gene Targeting in Macrophages and Granulocytes using LysMcre Mice. Transgenic Research 8, 265-277. Coccia, P.F., Krivit, W., Cervenka, J., Clawson, C., Kersey, J.H., Kim, T.H., Nesbit, M.E., Ramsay, N.K., Warkentin, P.I., Teitelbaum, S.L., Kahn, A.J., and Brown, D.M. (1980) Successful Bone Marrow Transplantation for Infantile Malignant Osteopetrosis. New England Journal of Medicine 302, 701-8. Dabovic, B., Levasseur, R., Zambuto, L., Chen, Y., Karsenty, G., and Rifkin, D.B. (2005) Osteopetrosis-like Phenotype in Latent TGF-beta Binding Protein 3 Deficient Mice. Bone 37, 25-31. Dai, X.M., Ryan, G.R., Hapel, A.J., Dominguez, M.G., Russell, R.G., Kapp, S., Sylvestre, V., and Stanley, E.R. (2002) Targeted Disruption of the Mouse Colony-Stimulating Factor 1 Receptor Gene Results in Osteopetrosis, Mononuclear Phagocyte Deficiency, Increased Primitive Progenitor Cell Frequencies, and Reproductive Defects. Blood 99, 111-20. Dicke, M.M. (1967) Mouse News Letter 36, 39. Dobbins, D.E., Sood, R., Hashiramoto, A., Hansen, C.T., Wilder, R.L., and Remmers E.F. (2002) Mutation of Macrophage Colony Stimulating Factor (Csf1) Causes Osteopetrosis in the tl Rat. Biochemical Biophysical Research Communications 294, 1114-20. Dupuis-Girod, S., Corradini, N., Hadj-Rabia, S., Fournet, J.C., Faivre, L., LeDeist, F., Durnad, P., Doffinger, R., Snahi, A., Israel, A., Courtois, G., Brousse, N., Blanche, S., Munnich, A., Fischer, A., Casanova, J.L., and Bodemer, C. (2002) Osteopetrosis, Lymphedema, Anhidrotic Dysplasia and Immunodeficiency in a Boy and Incontinentia Pigmenti in his Mother. Pediatrics 109: e97. Ethelberg, S., Tzchaschel, B.D., Luz, A., Diaz-Cano, S.J., Pedersen, F.S., and Schmidt, J. (1999) Increased Induction of Osteopetrosis, but Unaltered Lymphomagenicity, by Murine Leukemia Virus SL3-3 after Mutation of a Nuclear Factor 1 Site in the Enhancer. Journal of Virology 73, 10406-10415. Frattini, A., Orchard, P.J., Sobacchi, C., Giliani, S., Abinun, M., Mattsson, J.P., Keeling, D.J., Andrsson, A.K., Wallbrandt, P., Zecca, L., Notarangelo, L.D., Vezzoni, P., and Villa, A. (2000) Defects of TCIRG1 Subunit of the Vacuolar Proton Pump are Responsible for a Subset of Human Autosomal Recessive Osteopetrosis. Nature Genetics 25, 343-346. Glass, D.A. 2nd, Bialek, P., Ahn, J.D., Starbuck, M., Patel, M.S., Clevers, H., Taketo, M.M., Long, F., McMahon, A.P., Lang, R.A., and Karsenty, G. (2005) Canonical Wnt Signaling in Differentiated Osteoblasts Controls Osteoclast Differentiation. Development and Cell 8, 751764. Glowacki, J., Cox, K.A., O’Sullivan, J., Wilkie, D., and Deftos, L.J. (1986) Osteoclasts can be Induced in Fish Having an Acellular Bony Skeleton. Proceedings of the National Academy of Sciences of the USA 83, 4104-4107. Gowen, M., Lazner, F., Dodds, R., Kapadia, R., Felid, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tillis, I., Hertzog, P., Debouck, C., and Kola, I. (1999) Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but not Demineralization. Journal of Bone and Mineral Research 14, 1654-63.
100
W. WIKTOR-JEDRZEJCZAK
Gruneberg, H. (1938) Some new data on the grey-lethal mouse. Journal of Genetics 36, 153-173. Hayman, A.R., and Cox, T.M. (2003) Tartrate-Resistant Acid Phosphatase Knockout Mice. Journal of Bone and Mineral Research 18, 1905-1907. Hodgkinson, C.A., Moore, K.J., Nakayama, A., Steingrimsson, E., Copeland, N.G., Jenkins, N.A., and Arnheiter, H. (1993) Mutations at the Mouse Microphthalmia Locus Are Associated with Defects in a Gene Encoding a Novel Basic-Helix-Loop-Helix-Zipper Protein. Cell 74, 395-404. Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A., and Bravo, R. (1997) Osteopetrosis in Mice Lacking NF-kappaB1 and NF-kappaB2. Nature Medicine 3, 1285-9. Kaifu, T., Nakahara, J., Inui, M., Mishima, K., Momiyama, T., Kaji, M., Sugahara, A., Koito, H., Ujike-Asai, A., Nakamura, A., Kanazawa, K., Tan-Takeuchi, K., Iwaszki, K., Yokoyama, W.M., Kudo, A., Fujiwara, M., Asou, H., and Takai, T. (2003) Osteopetrosis and Thalamic Hypomyelinosis with Synaptic Degeneration in DAP12-Deficient Mice. Journal of Clinical Investigation 111, 323-332. Kapur, R.P., Yao, Z., Iida, M.H., Clarke, C.M., Doggett, B., Xing, L., and Boyce, B.F. (2004) Malignant Autosomal Recessive Osteopetrosis Caused by Spontaneous Mutation of Murine Rank. Journal of Bone and Mineral Research 19, 1689-97. Kasper, D., Planells-Cases, R., Fuhrmann, J.C., Scheel, O., Zeitz, O., Ruether, K., Schmitt, A., Poet, M., Steinfeld, R., Schweizer, M., Kornak, U., and Jentsch, T.J. (2005) Loss of the Cloride Channel ClC-7 Leads to Lysosomal Storage Disease and Neurodegeneration. EMBO Journal 24, 1079-1091. Kenner, L., Hoebertz, A., Beil, T., Keon, N., Karreth, F., Eferl, R., Scheuch, H., Szremska, A., Amling, M., Schorpp-Kistner, M., Angel, P., and Wagner, E.F. (2004) Mice Lacking JunB Are Osteopenic Due to Cell-Autonomous Osteoblast and Osteoclast Defects. Journal of Cell Biology 164, 613-623. Kim, N., Odgren, P.R., Kim, D-K., Marks, S.C. Jr, and Choi, Y. (2000) Diverse Roles of the Tumor Necrosis Factor Family Member TRANCE in Skeletal Physiology Revealed by TRANCE Deficiency and Partial Rescue by a Lymphocyte-Expressed TRANCE Transgene. Proceedings of the National Academy of Sciences of the USA 97, 10905-10910. Kong, Y.Y., Yoshida, H., Sarosi, I., Tan, H.L., Timms, E., Capparelli, C., Morony, S., Oliveirados-Santos, A.J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C.R., Lacey, D.L., Mak, T.W., Boyle, W.J., and Penninger, J.M. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323. Kornak, U., Kasper, D., Bosl, M.R., Kaiser, E., Schweizer, M., Schulz, A., Friedrich, W., Delling, G., and Jentsch, T.J. (2001) Loss of the ClC-7 Chloride Channel Leads to Osteopetrosis in Mice and Man. Cell 104, 205-215. Kwon, O.H., Lee, C.K., Lee, Y.I., Paik, S.G., and Lee, H.J. (2005) The Hematopietic Transcription Factor PU.1 Regulates RANK Gene Expression in Myeloid Progenitors. Biochememical and Biophysical Research Communications 335, 437-446. Lange, P.F., Wartosch, L., Jentsch, T.J., and Fuhrmann, J.C. (2006) ClC-7 Requires Ostm1 as a β-Subunit to Support Bone Resorption and Lysosomal Function. Nature 440, 220-223. Li, J., Chen, K., Zhu, L., and Pollard, J.W. (2006) Conditional Deletion of the Colony Stimulating Factor-1 Receptor (c-fms Protooncogene) in Mice. Genesis 44, 328-335. Li, J., Sarosi, I., Yan, X.Q., Morony, S., Capparelli, C., Tan, H.L., McCabe, S., Elliott, R., Scully, S., Van, G., Kaufman, S., Juan, S.C., Sun, Y., Tarpley, J., Martin, L., Christensen, K., McCabe, J., Kostenuik, P., Hsu, H., Fletcher, F., Dunstan, C.R., Lacey, D.L., and Boyle, W.J. (2000) RANK is the Intrinsic Hematopoietic Cell Surface Receptor that Controls
OSTEOPETROSIS
101
Osteoclastogenesis and Regulation of Bone Mass and Calcium Metabolism. Proceedings of the National Academy of Sciences of the USA 97, 1566-71. Little, R.D., Carulli, J.P., DelMastro, R.G., Dupuis, J., Osborne, M., Folz, C., Manning, S.P., Swain, P.M., Zhao, S.C., Eustace, B., Lappe, M.M., Spitzer, L., Zweier, S., Braunschweiger, K., Benchekroun, Y., Hu, X., Adair, R., Chee, L., Fitzgerald, M.G., Tulig, C., Caruso, A., Tzellas, N., Bawa, A., Frankin, B., McGuire, S., Nogues, X., Gong, G., Allen, K.M., Anisowicz, A., Morales, A.J., Lomedico, P.T., Recker, S.M., VanEerdewegh, P., Recker, R.R., and Johnson, M.L. (2002) A Mutation in the LDL Receptor-Related Protein 5 Gene Results in the Autosomal Dominant High-Bone-Mass Trait. American Journal of Human Genetics 70, 11-19. Loutit, J.F., and Sansom, J.M. (1976) Osteopetrosis in microphthalmic mice. A defect of the hematopoietic stem cell. Calcified Tissue Research 20, 251-259. Marks, S.C. Jr. (1976) Osteopetrosis in the ia rat cured by spleen cells from a normal littermate. American Journal of Anatomy 146, 331-338 Marks, S.C. Jr. (1977) Osteopetrosis in the toothless (tl) rat: Presence of osteoclasts but failure to respond to parathyroid extract or to be cured by infusion of spleen or bone marrow cells from normal littermates. American Journal of Anatomy 149, 289-297. Marks S.C. Jr., and Lane, P.W. (1976) Osteopetrosis, a new recessive skeletal mutation on chromosome 12 in the mouse. Journal of Heredity 67, 11-18. Marks, S.C. Jr., Wojtowicz, A., Szperl, M., Urbanowska, E., Mackay, C.A., Wiktor-Jedrzejczak, W., Stanley, E.R., and Aukerman, S.L.: (1992) Administration of Colony Stimulating Factor1 Corrects Some Macrophage, Dental, and Skeletal Defects in an Osteopetrotic Mutation (toothless, tl) in the Rat. Bone 13, 89-93. Marks, S.C. Jr., Seifert, M.F., and Lane, P.W. (1985) Osteosclerosis, a Recessive Skeletal Mutation on Chromosome 19 in the Mouse. Journal of Heredity 76, 171-176. McCulloch, E.A., Siminovitch, L., and Till, J.E. (1964) Spleen-colony formation in anemic mice of genotype W/Wv. Science 144, 844-846. McCulloch, E.A., Siminovitch, L., Till, J.E., Russell, E.S., and Bernstein, S.E. (1965) The cellular basis of the genetically determined Hemopoietic defect in anemic mice of genotype Sl/Sld. Blood 26, 399-410. McHugh, K.P., Hodivala-Dilke, K., Zheng, M-H., Namba, N., Lam, J., Novack, D., Feng, X., Ross, F.P., Hynes, R.O., and Teitelbaum, S.L. (2000) Mice Lacking β3 Integrins Are Osteosclerotic because of Dysfunctional Osteoclasts. Journal of Clinical Investigation 105, 433-440. Milhaud, G., Labat, N.L., Parant, M., Damais, C., and Chedid, L. (1977) Immunological defect and its correction in the osteopetrotic mutant rat. Proceedings of the National Academy of Sciences of the USA 74, 339-342. Mocsai, A., Humphrey, M.B., VanZiffle, J.A.G., Hu, Y., Burghardt, A., Spusta, S.C., Majudmar, S., Lanier, L.L., Lowell, C.A., and Nakamura, M.C. (2004) The Immunomodulatory Adapter Proteins DAP12 and Fc Receptor γ-Chain (FcRγ) Regulate Development of Functional Osteoclasts through the Syk Tyrosine Kinase. Proceedings of the National Academy of Sciences of the USA 101, 6158-6163. Naito, A., Azuma, S., Tanaka, S., Miyazaki, T., Takaki, S., Takatsu, K., Nakao, K., Nakamura, K., Katsuki, M., Yamamoto, T., and Inoue, J. (1999) Severe Osteopetrosis, Defective Interleukin-1 Signalling and Lymph Node Organogenesis in TRAF6-Deficient Mice. Genes and Cells 4, 353-362. Naito, A., Yoshida, H., Nishioka, E., Satoh, M., Azuma, S., Yamamoto, T., Nishikawa, S-I., and Inoue, J-I. (2002) TRAF6-Deficient Mice Display Hypohidrotic Ectodermal Dysplasia. Proceedings of the National Academy of Sciences of the USA 99, 8766-8771.
102
W. WIKTOR-JEDRZEJCZAK
Odgren, P.R., Kim, N., McKay, C.A., Mason-Savas, A., Choi, Y., Marks, S.C. Jr. (2003) The Role of RANKL (TRANCE/TNFSF11), a Tumor Necrosis Factor Family Member, in Skeletal Development: Effects of Gene Knockout and Transgenic Rescue. Connective Tissue Research 44 Suppl 1, 264-271. Paloneva, J., Kestila, M., Wu, J., Salminen, A., Bohling, T., Ruotsalainen, V., Hakola, P., Bakker, A.B., Phillips, J.H., Pekkarinen, P., Lanier, L.L., Timonen, T., and Peltonen, L. (2000) Lossof-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nature Genetics 25, 357-361. Pangrazio, A., Poliani, P.L., Megarbane, A., Lefranc, G., Lanino, E., DiRocco, M., Rucci, F., Lucchini, F., Ravanini, M., Facchetti, F., Abinum, M., Vezzoni, P., Villa, A., and Frattini, A. (2006) Mutations in OSTM1 (grey-lethal) Define a Particularly Severe Form of Autosomal Recessive Osteopetrosis with Neural Involvement. Journal of Bone and Mineral Research 21, 1098-1105. Pavlov, N.J., Xu, J., Riedel, D., Yeoh, J.S., Teitelbaum, S.L., Papadimitriou, J.M., Jahn, R., Ross, F.P., and Zheng, M.H. (2005) Rab3D Regulates a Novel Vesicular Trafficking Pathway That Is Required for Osteoclastic Bone Resorption. Molecular Cell Biology 25, 5253-5269. Quarello, P., Forni, M., Barberis, L., Defilippi, C., Campagnolo, M.F., Silvestro, L., Frattini, A., Chalhoub, N., Vacher, J., and Ramenghi, U. (2004) Severe Malignant Osteopetrosis Caused by a GL Gene Mutation. Journal of Bone and Mineral Research 14, 2107-2117. Ramirez, A., Faupel, J., Goebel, I., Stiller, A., Beyer, S., Stockle, C., Hasan, C., Bode, U., Kornak, U., and Kubisch, C. (2004) Identification of a Novel Mutation in the Coding Region of the Grey-Lethal Gene OSTM1 in Human Malignant Infantile Osteopetrosis. Human Mutations 23, 471-476. Scimeca, J.C., Franchi, A., Trojani, C., Parrinello, H., Grosgeorge, J., Robert, C., Jaillon, O., Poirier, C., Gaudray, P., and Carle, G.F. (2000) The Gene Encoding the Mouse Homologue of the Specific 116-kDa V-ATPase Subunit Bears a Deletion in Osteosclerotic (oc/oc) Mutants. Bone 26, 207-13. Simonet, W.S., Lacey, D.I., Dunstan, C.R., Kelley, M., Chang, M.S., Luthy, R., Nguyen, H.Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H.L., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T.M., Hill, D., Pattison, W., Cambell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R., and Boyle, W.J. (1997) Osteoprotegerin: a Novel Secreted Protein Involved in the Regulation of Bone Density. Cell 89, 309-319. Sly, W.S., Sato, S., and Zhu, X.L. (1991) Evaluation of Carbonic Anhydrase Isoenzymes in Disorders Involving Osteopetrosis and/or Renal Tubular Acidosis. Clinical Biochemistry 24, 311-318. Smashi, A., Courtois, G., Rabia, S.H., Doffinger, R., Bodemer, C., Munnich, A., Casanova, J.L., and Israel, A. (2002) The NF-kappaB Signaling Pathway in Human Diseases: from Incontinentia Pigmenti to Ectodermal Dysplasias and Immune-Deficiency Syndromes. Human and Molecular Genetics 11, 2371-2375. Soriano, P., Montgomery, C., Geske, R., and Bradley, A. (1991) Targeted Disruption of the s-src Proto-Oncogene Produces Osteopetrosis in Mice. Cell 64, 693-702. Teti, A., Taranta, A., Migliaccio, S., Degiorgi, A., Santandrea, E., Vilanova, I., Faraggiana, T., Chellaiah M., and Hruska, K.A. (1998) Colony Stimulating Factor-1-Induced Osteoclast Spreading Depends on Substrate and Requires the Vitronectin Receptor and the c-src ProtoOncogene. Journal of Bone and Mineral Research 13, 50-58. Tondravi, M.M., McKercher, S.R., Anderson, K., Erdmann, J.M., Quiroz, M., Maki, R., and Teitelbaum, S.L. (1997) Osteopetrosis in Mice Lacking Haematopoietic Transcription Factor PU.1. Nature 386, 81-4.
OSTEOPETROSIS
103
VanWesenbeeck, L., Cleiren, E., Gram, J., Beals, R.K., Benichou, O., Scopelliti, D., Key, L., Renton, T., Bartels, C., Gong, Y., Warman, M.L., DeVernejoul, M-C., Bollerslev, J., and VanHul, W. (2003) Six Novel Missense Mutations in the LDL Receptor-Related Protein 5 (LRP5) Gene in Different Conditions with an Increased Bone Density. American Journal of Human Genetics 72, 763-771. VanWesenbeeck, L., Odgren, P.R., MacKay, C.A., D’Angelo, M., Safadi, F.F., Popoff, S.N., VanHul, W., and Marks, S.C. Jr (2002) The Osteopetrotic Mutation Toothless (tl) is a Lossof-Function Frameshift Mutation in the Rat Csf1 Gene: Evidence for Crucial Role for CSF-1 in Osteoclastogenesis and Endochondral Ossification. Proceedings of the National Academy of Sciences of the USA 99, 14303-14308. VanWesenbeeck, L., Odgren, P.R., MacKay, C.A., and VanHul, W. (2004) Localization of the Gene Causing the Osteopetrotic Phenotype in the Incisors Absent (ia) Rat on Chromosome 10q32.1. Journal of Bone and Mineral Research 19, 183-189. Walker, D.G. (1972) Congenital Osteopetrosis in Mice Cured by Parabiotic Union with Normal Siblings. Endocrinology 91, 916-20. Walker, D.G. (1975) Bone Resorption Restored in Osteopetrotic Mice by Transplants of Normal Bone Marrow and Spleen Cells. Science 190, 784-785. Walker, D.G. (1975) Spleen Cells Transmit Osteopetrosis in Mice. Science 190, 785-7. Wiktor-Jedrzejczak, W., Ahmed, A., Szczylik, C., and Skelly R.R. (1982) Hematological Characterization of Congenital Osteopetrosis in op/op Mouse. Possible Mechanism for Abnormal Macrophage Differentiation. Journal of Experimental Medicine 156, 1516-1527. Wiktor-Jedrzejczak, W., Bartocci, A., Ferrante, A.W. Jr, Ahmed-Ansari, A., Sell, K.W., Pollard, J.W., Stanley, E.R. (1990) Total Absence of Colony Stimulating Factor-1 in the MacrophageDeficient Osteopetrotic (op/op) Mouse. Proceedings of the National Academy of Sciences of the USA 87, 4828-4832. Wiktor-Jedrzejczak, W., Grzybowski, J., Ahmed, A., and Kaczmarek, L. (1983) Osteopetrosis associated with premature thymic involu